

CITATION REPORT

List of articles citing

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Womens Health Initiative randomized controlled trial

DOI: 10.1001/jama.291.14.1701

JAMA - Journal of the American Medical Association, 2004, 291, 1701-12.

Source: <https://exaly.com/paper-pdf/36519946/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2305	Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. 2000 , CD001018		27
2304	Hormone replacement therapy and the women's health initiative: the emperor has no clothes. 2004 , 10, 448-9		1
2303	Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. 2004 , 145, 5745-56		113
2302	Tibolone activates nitric oxide synthesis in human endothelial cells. 2004 , 89, 4594-600		30
2301	Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. 2004 , 89, 4879-85		66
2300	Postmenopausal hormone use in women with acute coronary syndromes. 2004 , 13, 863-71		2
2299	The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. 2004 , 1, 440-50		88
2298	Hormone replacement therapy and peripheral vascular disease in women. 2004 , 38, 547-56		21
2297	A Commentary on Treatment at Random: The Ultimate Science or the Betrayal of Hippocrates?. 2004 , 22, 5009-5011		10
2296	Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. 2004 , 160, 1152-8		211
2295	Targeting of the renin-Angiotensin system as an adjunct to estrogen replacement therapy. 2004 , 44, 390-1		3
2294	Hormone replacement therapy and stroke: clinical trials review. 2004 , 35, 2644-7		44
2293	Estrogens, migraine, and stroke. 2004 , 35, 2652-6		63
2292	17Beta-estradiol/levonorgestrel transdermal system for the management of the symptomatic menopausal woman. 2004 , 5, 2559-66		1
2291	Hormone replacement and breast cancer. 2004 , 15 Suppl 4, iv275-7		1
2290	Hormone therapy: physiological complexity belies therapeutic simplicity. 2004 , 304, 1269-73		252
2289	Can hypnosis reduce hot flashes in breast cancer survivors? A literature review. 2004 , 47, 29-42		20

2288	Risk factors for osteoporosis in postmenopausal African-American women. 2004 , 20, 1681-7	6
2287	Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here?. 2004 , 44, 789-95	65
2286	Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials?. 2004 , 24, 1171-9	41
2285	Estrogen and HDL: all that glitters is not gold. 2004 , 24, 1741-2	7
2284	Hormones and pregnancy: thromboembolic risks for women. 2004 , 126, 443-54	56
2283	Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. 2004 , 61, 760-7	18
2282	Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. 2004 , 256, 361-74	43
2281	The continuing evolution of women's health. 2004 , 19, 810-1	1
2280	The implications of body fat mass and fat distribution for cognitive function in elderly women. 2004 , 12, 1519-26	56
2279	Le traitement hormonal substitutif de la mēopause diminue le risquē de cancer colo-rectal. 2004 , 28, 1193-1194	
2278	Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer. 2004 , 13, 515-8	17
2277	Osteoporosis guidelines. 2004 , 2, 315-324	1
2276	The million women study: a critique. 2004 , 24, 187-93	35
2275	Is the WHI relevant to HRT started in the perimenopause?. 2004 , 24, 195-202	48
2274	Adverse neoplastic and cardiovascular outcomes of HRT: the validity of the evidence. 2004 , 24, 203-10	7
2273	Postmenopausal hormone therapy and breast cancer: a clinician's message for patients. 2004 , 24, 211-6	3
2272	Hormones and bone health in postmenopausal women. 2004 , 24, 223-30	42
2271	The metabolic basis for the effects of HRT on coronary heart disease. 2004 , 24, 239-44	11

2270	Estrogen depletion differentially affects blood pressure depending on age in Long-Evans rats. 2004 , 25, 173-86	18
2269	Prävention der Atherosklerose bei gefäßchirurgischen Patienten. 2004 , 9, 172	
2268	Einfluss von Tibolon auf das Brustdrüsenewebe. 2004 , 2, 153	
2267	Evidenzbasierte Entscheidungsgrundlagen für oder gegen eine postmenopausale Hormonbehandlung. 2004 , 116, 504-504	
2266	Lead identification of a potent benzopyranone selective estrogen receptor modulator. 2004 , 14, 3407-10	33
2265	[Cardiovascular risks under hormone replacement therapy]. 2004 , 45, 826-34	
2264	[Cardiovascular risk in the "Women's Health Initiative". Much ado about nothing?]. 2004 , 45, 1315-7	
2263	Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. 2004 , 47, 1175-1187	424
2262	Does WHI tell us how to prevent diabetes?. 2004 , 47, 1133-1134	1
2261	Hormonersatztherapie. 2004 , 37, 860-862	
2260	Postmenopausal osteoporosis. 2004 , 2, 101-6	9
2259	Estrogens and Stroke: Use of Oral Contraceptives and Postmenopausal Use of Estrogen: Current Recommendations. 2004 , 6, 459-467	7
2258	Management of osteoporosis. 2004 , 2, 9	17
2257	Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. 2004 , 101, 1490-500	103
2256	Second thoughts on the women's health initiative study: the effect of age on the safety of HRT. 2004 , 7, 412-4	11
2255	Estro-progestinici in menopausa: benefici e rischi. 2004 , 5, 104-110	
2254	Risk factors for vascular dementia and Alzheimer disease. 2004 , 35, 2620-2	262
2253	Osteoporosis screening of postmenopausal women in the primary care setting: a case-based approach. 2004 , 1, 70-85	14

2252 Areas for future inquiry. **2004**, 33, 761-9

2251 Menopause and hot flashes: no easy answers to a complex problem. **2004**, 79, 735-7

2

2250 Indications for hormone therapy: the post-Women's Health Initiative era. **2004**, 33, 691-715

5

2249 Endocrine treatment and prevention of breast and gynaecological cancers. **2004**, 2, 1-14

2248 Assessment of oral bisphosphonate use in elderly patients with varying degrees of kidney function. **2004**, 2, 213-8

10

2247 Future antidepressants: what is in the pipeline and what is missing?. **2004**, 18, 705-32

36

2246 Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flashes. **2004**, CD002978

182

2245 The aging man and woman: are the differences important?. **2004**, 1, 224-226

2244 Should tamoxifen be used in breast cancer prevention?. **2004**, 27, 979-89

8

2243 Long-cycle treatment with oral contraceptives. **2004**, 64, 2447-62

46

2242 The Role of Hormone Replacement Therapy and Alternative Treatments. **2004**, 3, 67-78

0

2241 Mini-review: estrogen action in the uterus and insulin-like growth factor-I. **2004**, 14, 431-5

23

2240 Medroxyprogesterone acetate attenuates estrogen-induced nitric oxide production in human umbilical vein endothelial cells. **2004**, 324, 193-8

22

2239 Women's cognitive health: postmenopausal dementia and the women's health initiative memory study. **2004**, 14, 71-4

2

2238 Hormones, menopause, and heart disease: making sense of the Women's Health Initiative. **2004**, 14, 212-9

18

2237 Ovariectomy and estradiol replacement therapy alters the adenine nucleotide hydrolysis in rat blood serum. **2004**, 114, 275-81

14

2236 Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. **2004**, 49, 44-50

11

2235 Postmenopausal hormone therapy and the risk of breast cancer. A clinician's view. **2004**, 49, 51-7

9

2234	Exogenous progestagens and the human breast. 2004 , 49, 58-66	20
2233	Lessons to be learned from clinical studies on hormones and the breast. 2004 , 49, 90-6	5
2232	Steroidal hormones and proliferation, differentiation and apoptosis in breast cells. 2004 , 49, 16-24	20
2231	Breast cancer and HRT use. 2004 , 49, S3-4	4
2230	Postmenopausal hormone therapy before and after breast cancer: clinical experiences. 2004 , 49, S22-31	7
2229	Tissue-selective effects of tibolone on the breast. 2004 , 49, S5-S15	32
2228	Drug delivery systems for oestrogenic hormones and antagonists: the need for selective targeting in estradiol-dependent cancers. 2004 , 92, 1-18	19
2227	Coronary artery bypass graft surgery in women. 2004 , 18, 344-52	4
2226	[New treatments in osteoporosis]. 2004 , 25 Suppl 5, S573-9	4
2225	[Current role of hormone replacement therapy in the prevention of postmenopausal osteoporosis: gynecologic point of view]. 2004 , 25 Suppl 5, S580-7	
2224	Phytoestrogens for treatment of menopausal symptoms: a systematic review. 2004 , 104, 824-36	162
2223	Estrogens, lipoproteins, and cardiovascular risk factors: an update following the randomized placebo-controlled trials of hormone-replacement therapy. 2004 , 15, 459-67	27
2222	Association of breast cancer and its therapy with menopause-related symptoms. 2004 , 11, 502-4	1
2221	Hormone therapy prescribing patterns in the United States. 2004 , 104, 1042-50	166
2220	Neuroendocrine changes in sleep apnea. 2004 , 10, 475-81	22
2219	Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care. 2004 , 170, 1535-7	19
2218	Double jeopardy: hormone therapy on trial again. 2004 , 26, 541-7	1
2217	Non bis in idem : Lâhormonothâpapie est ^ nouveau mise au banc des accusâs. 2004 , 26, 544-547	

2216	Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: results of the AWARE survey. 2004 , 26, 967-73	12
2215	Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy. 2004 , 26, 1059-66	8
2214	Vaginal ring an HT alternative. 2004 , 29, 54-5	1
2213	Menopause and Hot Flashes: No Easy Answers to a Complex Problem. 2004 , 79, 735-737	3
2212	Estrogen in cardiovascular disease. 2004 , 15, 589-93	8
2211	Hormone replacement therapy after prophylactic adnexectomy. 2005 , 3, 181-2	2
2210	Attitudes toward hormone replacement therapy in the new millennium: university physicians' and patients' perspectives. 2005 , 53, 305-11	1
2209	Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. 2005 , 105, 1063-73	204
2208	Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy. 2005 , 12, 699-707	5
2207	Menopausal hormone therapy. 2005 , 27, 137-62	23
2206	Activation of nitric oxide synthesis in human endothelial cells by red clover extracts. 2005 , 12, 69-77	35
2205	Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial. 2005 , 12, 366-73	39
2204	Does osteopenia warrant treatment?. 2005 , 12, 639-48	9
2203	Estrogen replacement, muscle composition, and physical function: The Health ABC Study. 2005 , 37, 1741-7	56
2202	Breast cancer risk: is postmenopausal hormone therapy ever safe?. 2005 , 12, 653-5	1
2201	Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist. 2005 , 105, 953-61	22
2200	Ovarian Conservation at the Time of Hysterectomy for Benign Disease. 2005 , 106, 1107	1
2199	Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women. 2005 , 12, 526-35	19

2198	Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate. 2005 , 12, 331-9	14
2197	Hormonal environment in the induction of breast cancer in castrated rats using dimethylbenzanthracene: influence of the presence or absence of ovarian activity and of treatment with estradiol, tibolone, and raloxifene. 2005 , 12, 601-8	3
2196	Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. 2005 , 12, 668-78	59
2195	Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: the Estrogen in the Prevention of Atherosclerosis Trial. 2005 , 12, 728-33	30
2194	17beta-estradiol exerts a beneficial effect on coronary vascular remodeling in the early stages of hypertension in spontaneously hypertensive rats. 2005 , 12, 453-9	10
2193	Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms. 2005 , 12, 708-15	9
2192	The new hormone therapy problem: do we solve it with long-cycle progesterone therapy?. 2005 , 12, 664-7	
2191	The impact of the Women's Health Initiative Randomized Controlled Trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany. 2005 , 12, 405-11	24
2190	Effects of tibolone on bone quality in ovariectomized monkeys. 2005 , 12, 613-8	4
2189	Treatment of menopause-related mood disturbances. 2005 , 10, 489-97	16
2188	Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. 2005 , 105, 779-87	40
2187	Postmenopausal hormone replacement therapy after the Women's Health Initiative. 2005 , 18, 30-7; quiz 39-40	
2186	Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine. 2005 , 12, 92-8	14
2185	The case for less-than-monthly progestogen in women on HT: is transvaginal ultrasound the key?. 2005 , 12, 110-3	5
2184	Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial. 2005 , 21, 433-41	23
2183	Prevention: the key to reducing cardiovascular disease risk in women. 2005 , 20, 433-41	1
2182	Hormone replacement therapy after cancers. 2005 , 17, 493-9	6
2181	Hormone replacement therapy and risk for venous thromboembolism: what's new and how do these findings influence clinical practice?. 2005 , 12, 395-400	3

2180	Low-dose hormone therapy and bone metabolism in the context of pharmacotherapy for the postmenopausal woman. 2005 , 4, 60-66	
2179	Pharmaceuticals for Bone Disease Targeting the Osteoclast. 2005 , 128-150	
2178	HRT and breast cancer: Is there an association?. 2005 , 16, 128-132	1
2177	Molecular mechanism of action of selective estrogen receptor modulator in target tissues. 2005 , 52, 161-7	19
2176	Complex and simple. 2005 , 29, 601-2	4
2175	Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study. 2005 , 17, 217-8	3
2174	Actualit� sur la m�opause. Donn�es de la m�decine factuelle (« evidence based medicine »). 2005 , 2, 90-101	
2173	Is the estrogen controversy over? Deconstructing the Women’s Health Initiative study: a critical evaluation of the evidence. 2005 , 1052, 43-56	76
2172	Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. 2005 , 20, 1525-32	65
2171	Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. 2005 , 28, 579-84	36
2170	Estrogen action in mood and neurodegenerative disorders: estrogenic compounds with selective properties-the next generation of therapeutics. 2005 , 28, 235-42	51
2169	Ultrafiltration tandem mass spectrometry of estrogens for characterization of structure and affinity for human estrogen receptors. 2005 , 16, 271-9	74
2168	Hormone replacement therapy and cardiovascular disease. 2005 , 7, 1-4	1
2167	Safety of vaginal oestrogen in postmenopausal women. 2005 , 7, 241-244	6
2166	The effect of total hysterectomy on specific sexual sensations. 2005 , 192, 1922-7	37
2165	Brief report: attitudes toward hormone therapy after the Women’s Health Initiative: a comparison of internists and gynecologists. 2005 , 20, 416-8	11
2164	The impact of clinical trials on the use of hormone replacement therapy. A population-based study. 2005 , 20, 1026-31	43
2163	The impact of comorbidities on hormone use. After the 2000 release of the Women’s Health Initiative. 2005 , 20, 350-6	13

2162	Management of dyslipidemia in women in the post-hormone therapy era. 2005 , 20, 297-305	7
2161	Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. 2005 , 112, 692-5	22
2160	The hormone replacement therapy controversy. 2005 , 112, 689-91	1
2159	The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. 2005 , 112, 1455-6	2
2158	The association of hysterectomy and menopause: a prospective cohort study. 2005 , 112, 956-62	145
2157	Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. 2006 , 113, 5-14	49
2156	Cardiovascular consequences of hormone therapy in postmenopausal women: Messages to clinicians. 2005 , 4, 1-6	
2155	Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oophorectomized women with hot flashes and depressive tendencies. 2005 , 31, 107-14	27
2154	Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study. 2005 , 60, 641-7	49
2153	Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. 2005 , 92, 1293-7	66
2152	The effects of aromatase inhibitors on lipids and thrombosis. 2005 , 93 Suppl 1, S23-7	49
2151	A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. 2005 , 5, 977-85	142
2150	Effects of combined oral conjugated estrogens and medroxyprogesterone acetate on brain infarction size after experimental stroke in rat. 2005 , 25, 421-6	39
2149	Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. 2005 , 96, 15-25	42
2148	Ostéoporose post-ménopausique : traiter aujourd'hui et demain. 2005 , 72, S10-S15	
2147	Statistical issues arising in the Women's Health Initiative. 2005 , 61, 899-911; discussion 911-41	49
2146	Discussion on "Statistical Issues Arising in the Women's Health Initiative". 2005 , 61, 914-918	1
2145	When practices, promises, profits, and policies outpace hard evidence: the post-menopausal hormone debate. 2005 , 61, 159-79	9

2144	Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. 2005 , 86, 173-85	41
2143	Risk assessment: controversies and management of moderate- to high-risk individuals. 2005 , 11 Suppl 1, S11-9	8
2142	Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. 2005 , 29, 124-32	21
2141	Chronic treatment with 17beta-estradiol increases susceptibility of smooth muscle cells to nitric oxide. 2005 , 520, 142-9	13
2140	Aging, traumatic injury, and estrogen treatment. 2005 , 40, 549-55	64
2139	Common orthopaedic problems in the elderly patient. 2005 , 200, 774-83	3
2138	Bone densitometry and bone biopsy. 2005 , 19, 487-501	11
2137	How to manage osteoporosis after the menopause. 2005 , 19, 1007-19	18
2136	Effects of 17beta-oestradiol on cerebral ischaemic damage and lipid peroxidation. 2005 , 1036, 155-62	61
2135	Neuroprotective effects of an estratriene analog are estrogen receptor independent in vitro and in vivo. 2005 , 1038, 216-22	74
2134	Breast cancer survival and the use of HRT. 2005 , 14, 178-80	1
2133	La terapia hormonal sustitutiva: mandan las evidencias. 2005 , 14, 46-51	
2132	Oestrogen and stroke in women: assessment of risk. 2005 , 4, 743-51	37
2131	Bone health in women with early-stage breast cancer. 2005 , 5 Suppl, S35-40	19
2130	Treatment of postmenopausal osteoporosis. 2005 , 25, 574-84	9
2129	Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. 2005 , 42, 762-71	117
2128	Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. 2005 , 114, 448-54	269
2127	Association of estrogen receptor alpha polymorphisms with breast cancer risk in older Caucasian women. 2005 , 116, 984-91	25

2126	Clinical management of osteoporosis in women with a history of breast carcinoma. 2005 , 104, 443-56	35
2125	Alzheimer's disease, estrogens, and clinical trials: a case study in drug development for complex disorders. 2005 , 66, 53-77	5
2124	Endogene und exogene Östrogene. 2005 , 38, 1065-1073	4
2123	Women's Health Initiative data--what were the real conclusions and how will these studies impact the pelvic floor?. 2005 , 16, 1-2	3
2122	Determinants of changes in bone mass and femoral neck structure, and physical performance after menopause: a 9-year follow-up of initially peri-menopausal women. 2005 , 16, 616-22	21
2121	[Role of hormone-replacement therapy for prevention of coronary artery disease in women]. 2005 , 94 Suppl 3, III/74-8	1
2120	A practical guide to the management of menopausal symptoms in breast cancer patients. 2005 , 13, 573-8	14
2119	Quantitative histomorphometric analysis of gonadal steroid receptor distribution in the normal human endometrium through the menstrual cycle. 2005 , 123, 463-74	28
2118	Möglichkeiten der hormonellen Substitution bei gynäkologischen Malignomen. 2005 , 3, 97-106	
2117	Endogenous sex steroids and bone mineral density in healthy Greek postmenopausal women. 2006 , 24, 65-71	20
2116	Cardiovascular consequences of hormone therapy in postmenopausal women: Messages to clinicians. 2005 , 4, 1-6	
2115	Randomized clinical stroke trials in 2004. 2005 , 7, 319-25	1
2114	Environmental risk factors and colorectal neoplasia: Recent developments. 2005 , 1, 67-72	
2113	The epidemiology of breast cancer. 2005 , 1, 24-28	4
2112	Osteoporosis medications used by older African-American women: effects of socioeconomic status and psychosocial factors. 2005 , 30, 281-97	12
2111	Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States). 2005 , 16, 965-73	30
2110	The Women's Health Initiative study: perspectives and implications for clinical practice. 2005 , 6, 93-9	5
2109	Changes in elderly women's health-related quality of life following discontinuation of hormone replacement therapy. 2005 , 5, 7	5

2108	Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women. 2005 , 5, 2	40
2107	Large mobile thrombus in non-atherosclerotic thoracic aorta as the source of peripheral arterial embolism. 2005 , 3, 19	23
2106	Menopausal hormone therapy: currently no evidence for cardiac protection. 2005 , 44, 625-9	7
2105	Use of postmenopausal hormone therapy since the Women's Health Initiative findings. 2005 , 14, 837-42	40
2104	Soy diet worsens heart disease in mice. 2006 , 116, 209-16	69
2103	Menopause, micronutrients, and hormone therapy. 2005 , 81, 1223S-1231S	11
2102	Hormone replacement therapy and breast cancer: estimate of risk. 2005 , 331, 347-9	9
2101	Naloxone does not influence cardiovascular responses to mild mental stress in postmenopausal women. 2005 , 289, H2120-5	7
2100	The Clinical Potential of Estrogen for the Prevention of Osteoarthritis: What is Known and What Needs to be Done?. 2005 , 1, 125-132	3
2099	Helping women make the right HRT choice. 2005 , 16, 73-78	2
2098	Cooperative Heart Disease Trials. 2005 ,	
2097	Breast Cancer Prevention. 2005 , 255-276	4
2096	Women's Health Initiative Hormone Therapy Trials. 2005 , 1-10	
2095	Cohort Studies. 2005 ,	
2094	Differential regulation of insulin resistance and hypertension by sex hormones in fructose-fed male rats. 2005 , 289, H1335-42	53
2093	Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. 2005 , 23, 5126-37	244
2092	Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). 2005 , 97, 755-65	355
2091	Differential effects of 17beta-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets. 2005 , 288, H2355-62	39

2090	17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. 2005 , 288, F399-405	121
2089	High-soy diet decreases infarct size after permanent middle cerebral artery occlusion in female rats. 2005 , 289, R103-8	44
2088	Where are we with postmenopausal hormone therapy in 2005?. 2005 , 21, 248-56	4
2087	TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status. 2005 , 25, 1691-6	26
2086	Tamoxifen stimulates cancellous bone formation in long bones of female mice. 2005 , 146, 1060-5	22
2085	Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. 2005 , 162, 404-14	231
2084	Progestins and recurrence in breast cancer survivors. 2005 , 97, 471-2	10
2083	Pathogenesis of osteoporosis: concepts, conflicts, and prospects. 2005 , 115, 3318-25	1089
2082	Atherosclerotic lesion development in a novel ovary-intact mouse model of perimenopause. 2005 , 25, 1910-6	51
2081	Estradiol regulates angiopoietin-1 mRNA expression through estrogen receptor-alpha in a rodent experimental stroke model. 2005 , 36, 337-41	77
2080	Breast cancer risk with postmenopausal hormonal treatment. 2005 , 11, 545-60	132
2079	Coronary heart disease in women: what do we know now?. 2005 , 1, 617-28	2
2078	Does hormone replacement therapy have a future?. 2005 , 1, 5-8	
2077	Cost implications of new evidence on prevention of cardiovascular disease. 2005 , 5, 183-92	1
2076	The clinical potential of estrogen for the prevention of osteoarthritis: what is known and what needs to be done?. 2005 , 1, 125-32	4
2075	Are estrogens protective or risk factors in brain injury and neurodegeneration? Reevaluation after the Women's health initiative. 2005 , 26, 308-12	125
2074	Postmenopausal hormone therapy and informed consent: a call for common sense. 2005 , 14, 592-4	
2073	Raloxifene and colorectal cancer. 2005 , 14, 299-305	3

2072	Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. 2005 , 21, 135-40	18
2071	Clinical Q & A. 2005 , 1, 160-162	
2070	Effect of a gonadotropin releasing hormone analog on cerebral hemodynamics in premenopausal women. 2005 , 8, 193-7	5
2069	Menstrual and reproductive factors and fracture risk: the Leisure World Cohort Study. 2005 , 14, 808-19	33
2068	Treatment of menopausal symptoms post-Women's Health Initiative: refinement of existing treatments and development of new therapies. 2005 , 10, 619-41	1
2067	What about breast cancer and cardiovascular disease risks with the best treatments during the climacterium and beyond. 2005 , 20, 301-4	1
2066	Ten polymorphisms of estrogen-metabolizing genes and a family history of colon cancer--an association study of multiple gene-gene interactions. 2005 , 12, e51-4	12
2065	The rise and fall of menopausal hormone therapy. 2005 , 26, 115-40	56
2064	Andropause: is androgen replacement therapy indicated for the aging male?. 2005 , 56, 117-37	78
2063	What influence does hormone replacement therapy have on endometrial cancer risk?. 2005 , 2, 546-7	
2062	Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. 2005 , 11, 561-73	66
2061	Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. 2005 , 97, 1046-54	81
2060	Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene. 2005 , 68, 1225-38	24
2059	Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. 2005 , 111, 1462-70	186
2058	Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. 2005 , 97, 595-602	71
2057	17beta-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. 2005 , 288, R759-66	109
2056	Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. 2005 , 23, 7491-6	360
2055	Current patient perceptions on the menopause: a South African perspective. 2005 , 8, 327-32	5

2054	Colorectal cancer prevention. 2005 , 23, 378-91	161
2053	Estrogen treatment abrogates neointima formation in human C-reactive protein transgenic mice. 2005 , 25, 2094-9	28
2052	Prevention of hormone-related cancers: breast cancer. 2005 , 23, 357-67	57
2051	Invited commentary: how far can epidemiologists get with statistical adjustment?. 2005 , 162, 415-8; discussion 419-20	32
2050	Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. 2005 , 97, 533-5	174
2049	Effects of estrogen on platelet reactivity after transient forebrain ischemia in rats. 2005 , 7, 135-45	7
2048	Astrocyte-derived transforming growth factor- β mediates the neuroprotective effects of 17β -estradiol: involvement of nonclassical genomic signaling pathways. 2005 , 146, 2749-59	122
2047	Ovarian conservation at the time of hysterectomy for benign disease. 2005 , 106, 219-26	184
2046	Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. 2005 , 146, 4917-25	69
2045	Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice. 2005 , 82, 111-20	29
2044	William M. Feinberg Lecture: Cognitive vitality and the role of stroke and cardiovascular disease risk factors. 2005 , 36, 875-9	57
2043	Current status of hormone therapy and breast cancer. 2005 , 11, 541-3	10
2042	Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice. 2005 , 98, 403-13	14
2041	Estrogen: a mitochondrial energizer that keeps on going. 2005 , 68, 956-8	10
2040	Long-term safety of bisphosphonates. 2005 , 90, 1897-9	172
2039	The relationship between mammographic density and duration of hormone therapy: effects of estrogen and estrogen-progestin. 2005 , 20, 1741-5	7
2038	Hormones and endometrial cancer--new data from the Million Women Study. 2005 , 365, 1517-8	12
2037	Treatment of menopausal symptoms: what shall we do now?. 2005 , 366, 409-21	98

2036 Los estrógenos y el hueso: revisión de la evidencia. **2005**, 48, 79-90

2035 [Actions of a 19-norprogesterone derivative on mammary gland: nomegestrol acetate]. **2005**, 34, 69-84

5

2034 [Will publication of the French study E3N change prescription practices for hormone replacement therapy in menopausal women?]. **2005**, 34, 101-4

0

2033 [Methodology of the inquiry MISSION (menopause, breast cancer risk, morbidity and prevalence)]. **2005**, 34, 658-65

4

2032 [Osteoporosis and hormone replacement therapy]. **2005**, 34, 379-84

1

2031 Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. **2005**, 6, 687-95

63

2030 Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. **2005**, 83, 558-66

85

2029 Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. **2005**, 83, 1859-63

21

2028 Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. **2005**, 84, 485-91

22

2027 A critique of the Women's Health Initiative hormone therapy study. **2005**, 84, 1589-601

48

2026 Managing menorrhagia: hysterectomy. **2005**, 2, 25-29

2025 The post-hysterectomy patient. **2005**, 2, 30-32

0

2024 Factors associated with potentially inappropriate drug utilization in a sample of rural community-dwelling older adults. **2005**, 3, 168-79

33

2023 [Not Available]. **2005**, 1, 81-3

2022 [Not Available]. **2005**, 1, 84-5

2021 The negative impact of litigation on women's health care. **2005**, 2, 189-96

4

2020 Regulation and disorders of pubertal timing. **2005**, 34, 617-41, ix

45

2019 Postmenopausal hormone replacement therapy and venous thromboembolism. **2005**, 2 Suppl A, S18-27

25

2018	[Update on menopause treatments, after recent controversies]. 2005 , 66, 30-2	
2017	[Discharge prescription for ischemic stroke patients]. 2005 , 161, 738-44	
2016	Racial and ethnic disparities in breast cancer: a multilevel perspective. 2005 , 89, 753-70	24
2015	Effects of hormone replacement on progression of coronary calcium as measured by electron beam tomography. 2005 , 14, 410-7	29
2014	Here's to Your Health. 2005 , 18, 55-58	
2013	Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. 2005 , 23, 7804-10	339
2012	Emerging and potential therapies for osteoporosis. 2005 , 14, 265-78	15
2011	Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer. 2005 , 8, 342-51	12
2010	IARC monographs program on carcinogenicity of combined hormonal contraceptives and menopausal therapy. 2005 , 8, 311-6	15
2009	Abstracts of the 11th World Congress on the Menopause. 2005 , 8 Suppl 2, 1-238	
2008	Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?. 2005 , 8, 307-10	6
2007	Läästeoporosi indotta da corticosteroidi. 2005 , 6, 71-80	
2006	Estrogen replacement therapy increases plasma ghrelin levels. 2005 , 90, 2954-63	58
2005	Polycaprolactone-block-poly(ethylene oxide) micelles: a nanodelivery system for 17beta-estradiol. 2005 , 2, 519-27	43
2004	Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. 2005 , 54, 49-54	40
2003	Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. 2005 , 96, 95-108	111
2002	Vascular effects of aromatase inhibitors: data from clinical trials. 2005 , 95, 143-9	38
2001	Pregnancy, progesterone and progestins in relation to breast cancer risk. 2005 , 97, 441-50	31

2000	Current understanding of gender dimorphism in hepatic pathophysiology. 2005 , 128, 147-56	54
1999	Postmenopausal hormone therapy and cancer risk. 2005 , 1279, 133-140	1
1998	Sex hormones, anti-hormones and adenocarcinoma of the endometrium. 2005 , 1279, 154-157	
1997	Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women. 2005 , 90, 128-33	41
1996	Osteoporosis beliefs and antiresorptive medication use. 2005 , 50, 196-208	32
1995	. 2005 , 50, 66-67	1
1994	Morphometric evaluation of effects of two sex steroids on mammary gland of female rats. 2005 , 51, 370-9	14
1993	Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. 2005 , 51, 397-404	99
1992	Women's views of the climacteric at the time of low menopausal hormone use, Estonia 1998. 2005 , 51, 413-25	6
1991	Two hormone replacement therapy (HRT) regimens for middle-eastern postmenopausal women. 2005 , 52, 52-9	12
1990	Effect of Aerodiol administration on cerebral blood flow volume in postmenopausal women. 2005 , 52, 127-33	6
1989	The Herbal Alternatives for Menopause (HALT) Study: background and study design. 2005 , 52, 134-46	41
1988	Justification for the use of HRT in the long-term prevention of osteoporosis. 2005 , 51, 113-26	42
1987	Women's health after WHI. 2005 , 51, 1-3	6
1986	Guidelines for hormone treatment of women in the menopausal transition and beyond. 2005 , 51, 15-20	11
1985	Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. 2005 , 51, 21-8	102
1984	The woman patient after WHI. 2005 , 51, 29-37	6
1983	Menopause and HRT--the state of the art in Europe. 2005 , 51, 40-7	6

1982	WHI and aftermath: looking beyond the figures. 2005 , 51, 48-50	2
1981	Coronary heart disease in menopausal women: implications of primary and secondary prevention trials of hormones. 2005 , 51, 51-63	25
1980	Controversies about HRT--lessons from monkey models. 2005 , 51, 64-74	81
1979	Postmenopausal hormone therapy and breast cancer: what is the problem?. 2005 , 51, 75-82	7
1978	Breast cancer risk in the WHI study: the problem of obesity. 2005 , 51, 83-97	42
1977	Menopause 2005: transatlantic confrontation of opinions. 2005 , 51, 38-9	2
1976	Gynecologists' attitudes towards hormone therapy in the post "Women's Health Initiative" study era. 2005 , 52, 18-25	22
1975	Use of hormone replacement therapy in the Hong Kong public health sector after the Women's Health Initiative trial. 2005 , 52, 277-85	12
1974	New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. 2005 , 52, 1-10	56
1973	Prevalence and correlates of hormonal therapy among Israeli women in the post-WHI era. 2005 , 52, 364-73	5
1972	Prophylaxis approach to a-symptomatic post-menopausal women: breast cancer. 2005 , 52 Suppl 1, S23-31	12
1971	Available medical choices for the management of menopause. 2005 , 52 Suppl 1, S61-70	11
1970	Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. 2005 , 71, 95-8	30
1969	Evidence-based hormone replacement therapy for the well woman at menopause. 2005 , 15, 244-250	
1968	Chemoprevention: from research to clinical oncology. 2005 , 41, 1833-41	6
1967	Vaginal oestrogen therapy after breast cancer: is it safe?. 2005 , 41, 2673-81	70
1966	Effect of tamoxifen, raloxifen and tibolon on bile components in ovariectomized rats. 2005 , 119, 194-7	1
1965	The influence of hormone replacement therapy on the pathology of breast cancer. 2005 , 31, 467-72	19

1964	Influence of hormone therapy on the cardiovascular responses to stress of postmenopausal women. 2005 , 69, 39-56	13
1963	Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women. 2005 , 36, 562-7	48
1962	Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading. 2005 , 36, 444-53	46
1961	After the Women's Health Initiative: decision making and trust of women taking hormone therapy. 2005 , 15, 187-95	25
1960	Cerebrovascular disease in patients with pituitary tumors. 2005 , 16, 334-42	31
1959	Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. 2005 , 116, 1-13	67
1958	Treatment of vasomotor symptoms: Is there an alternative to hormone replacement therapy?. 2005 , 5, 109-114	1
1957	The effect of hormone replacement on physical performance in community-dwelling elderly women. 2005 , 118, 1232-9	32
1956	Women's health: the struggle to restore hormonal balance. 2005 , 118, 1181-2	5
1955	Estrogen with and without progestin: benefits and risks of short-term use. 2005 , 118 Suppl 12B, 79-87	17
1954	Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. 2005 , 118 Suppl 12B, 136-41	66
1953	The impact of risk status, preexisting morbidity, and polypharmacy on treatment decisions concerning menopausal symptoms. 2005 , 118 Suppl 12B, 155-62	6
1952	Discontinuation of postmenopausal hormone therapy. 2005 , 118 Suppl 12B, 163-5	51
1951	Bilateral oophorectomy and premature menopause. 2005 , 118 Suppl 12B, 131-5	47
1950	Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. 2005 , 118 Suppl 12B, 64-73	138
1949	Research opportunities for reducing the burden of menopause-related symptoms. 2005 , 118 Suppl 12B, 166-71	24
1948	[Clinical guide to the menopause and post-menopause]. 2005 , 36, 269-72	0
1947	[Substitutive hormonal treatment guidelines and risk of endometrial cancer. Data from the Million Women Study]. 2005 , 125, 374-5	

1946	Long term hormone therapy for perimenopausal and postmenopausal women. 2005 , CD004143	57
1945	Hormone replacement therapy and risk of acute myocardial infarction : a review of the literature. 2005 , 28, 473-93	8
1944	Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations. 2005 , 28, 1085-100	25
1943	Oral contraceptives and polyp regression in familial adenomatous polyposis. 2005 , 128, 1077-80	21
1942	Hormone therapy and platelet function. 2005 , 2, 85-91	11
1941	Unravelling the confusion about HRT in women. 2005 , 2, 287-291	2
1940	Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. 2005 , 54, 939-46	13
1939	The role of mammographic density in evaluating changes in breast cancer risk. 2005 , 21 Suppl 1, 1-5	58
1938	Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. 2005 , 19, 1755-7	140
1937	The association between osteoporosis and oral bone loss. 2005 , 76, 2125-32	81
1936	Neuroendocrinology of female aging. 2005 , 2, 41-56	42
1935	Diabetic nephropathy is associated with decreased circulating estradiol levels and imbalance in the expression of renal estrogen receptors. 2005 , 2, 227-37	66
1934	Anti-resorptive therapy for the prevention of postmenopausal osteoporosis : when should treatment begin?. 2005 , 4, 263-77	8
1933	Pharmacology of estrogens and progestogens: influence of different routes of administration. 2005 , 8 Suppl 1, 3-63	544
1932	Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. 2006 , 8, R8	24
1931	The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. 2005 , 7, R1036-50	55
1930	Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. 2006 , 8, R11	81
1929	High prevalence of vitamin D inadequacy and implications for health. 2006 , 81, 353-73	1355

1928	Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. 2006 , 5, 37-51	27
1927	Brain-targeted delivery of estradiol. 2006 , 4, 161-175	8
1926	Estrogen metabolites and systolic blood pressure in a population-based sample of postmenopausal women. 2006 , 91, 1015-20	18
1925	Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS. 2006 , 3, 254-69	59
1924	Hormone replacement therapy in menopausal women: Past problems and future possibilities. 2006 , 22, 564-77	15
1923	The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy. 2006 , 22, 369-75	73
1922	Hormone-related headache: pathophysiology and treatment. 2006 , 20, 125-41	31
1921	Hormone therapy: maximizing the benefits. 2006 , 22, 160-2	4
1920	Why do some breast cancer cells remain dormant?. 2006 , 22, 190-7	2
1919	Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women. 2006 , 22, 179-84	16
1918	Effects of tibolone on blood flow resistance and intima-media thickness of the carotid arteries: effect of time since menopause. 2006 , 9, 59-65	7
1917	More data on hormone therapy and coronary artery disease: comments on recent publications from the WHI and Nurses' Study. 2006 , 9, 75-6	5
1916	How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. 2006 , 40, 1143-50	41
1915	Biochemical markers surrogating on vascular effects of sex steroid hormones. 2006 , 22, 163-73	12
1914	Colorectal cancer in middle-aged women in relation to hormonal status: a report from the Women's Health in the Lund Area (WHILA) study. 2006 , 22, 416-22	7
1913	The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results. 2006 , 22, 303-17	20
1912	Does retention of the ovaries improve long-term survival after hysterectomy? Prophylactic oophorectomy. 2006 , 9, 164-6	8
1911	Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention; the American Academy of Neurology affirms the value of this guideline. 2006 , 37, 577-617	1174

1910	Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. 2006 , 7, 821-8	398
1909	Hormone therapy and cardiovascular disease. 2006 , 45, 287-93	3
1908	[Hormone replacement therapy in the management of postmenopausal osteoporosis and prevention of fracture risk]. 2006 , 35, 1557-63	10
1907	Folate supplementation and cardiovascular disease. 2006 , 367, 1237-8; author reply 1238-9	5
1906	Osteoporosis. 2006 , 367, 2010-8	938
1905	Treatment for menopausal symptoms. 2006 , 34, 31-37	
1904	HRT and breast cancer. 2006 , 3, 15-17	2
1903	Treatment for menopausal symptoms. 2006 , 3, 217-223	
1902	Estrogen carcinogenesis in breast cancer. 2006 , 354, 270-82	1296
1901	Which progestogen is more likely to increase the risk of fatal myocardial infarction: a combination of epidemiological and trial evidence. 2006 , 54, 154-63	6
1900	The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. 2006 , 185, 347-52	58
1899	Menopausal estrogen therapy counteracts normal aging effects on intima thickness, media thickness and intima/media ratio in carotid and femoral arteries. An investigation using noninvasive high-frequency ultrasound. 2006 , 189, 387-92	32
1898	Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. 2006 , 189, 436-42	64
1897	Gender disparities in Parkinson's disease. 2006 , 6, 407-16	70
1896	Hot flash therapies in breast cancer survivors. 2006 , 4, 38-48	3
1895	Does sex matter in musculoskeletal health? A workshop report. 2006 , 37, 523-9	6
1894	Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. 2006 , 81, 1290-302	154
1893	Breast Cancer and Hormones: What Have We Learned from the Women's Health Initiative?. 2006 , 17, 214-217	

1892	Hormone replacement therapy. 2006 , 33, 953-63	5
1891	Diagnosis, screening, prevention, and treatment of osteoporosis. 2006 , 81, 662-72	98
1890	Hormone Replacement Therapy: The Debate over the Risks and Benefits To Women, from Breast Cancer To Quality of Life. 2006 , 37, 24-28	1
1889	Egg harvesting for stem cell research: medical risks and ethical problems. 2006 , 13, 573-9	49
1888	Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. 2006 , 66, 191-221	43
1887	Current pharmacological options for the management of primary hyperparathyroidism. 2006 , 66, 2189-211	15
1886	Current status of combined hormone replacement therapy in clinical practice. 2006 , 6 Suppl 2, S51-7	9
1885	Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. 2006 , 6 Suppl 2, S58-64	23
1884	Assessing drug risks and benefits: lessons from postmenopausal hormone therapy studies. 2006 , 6 Suppl 2, S65-70	1
1883	[Menopausal hormone therapy and cardiovascular disease]. 2006 , 59, 1058-69	2
1882	Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. 2006 , 26, 10332-48	251
1881	Calcium plus vitamin D supplementation and the risk of fractures. 2006 , 354, 669-83	1366
1880	Clinical practice. Management of menopausal symptoms. 2006 , 355, 2338-47	131
1879	Hypertension, menopause, and coronary artery disease risk in the Women's Ischemia Syndrome Evaluation (WISE) Study. 2006 , 47, S50-8	76
1878	Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. 2006 , 47, 1741-53	156
1877	Menopause and cardiovascular risk cause or consequence?. 2006 , 47, 1984-6	23
1876	Osteoporotic compression fractures of the spine; current options and considerations for treatment. 2006 , 6, 479-87	200
1875	Comparison of the effects of a new conjugated oral estrogen, estradiol-3beta-glucoside, with oral micronized 17beta-estradiol in postmenopausal women. 2006 , 148, 164-70	4

1874	Age-related Changes in Hormones and Their Receptors in Animal Models of Female Reproductive Senescence. 2006 , 533-552	24
1873	Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. 2006 , 119, 167.e1-8	17
1872	The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. 2006 , 4, 297-305	121
1871	Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative. 2006 , 152, 170-6	53
1870	A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. 2006 , 85, 155-60	68
1869	Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women. 2006 , 85, 667-73	12
1868	Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study. 2006 , 85, 989-95	25
1867	Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women. 2006 , 85, 979-88	10
1866	Evidence against a role for ovarian hormones in the regulation of blood flow. 2006 , 86, 440-7	8
1865	Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. 2006 , 86, 1235-42	42
1864	Estrogen and progestogen therapy in postmenopausal women. 2006 , 86, S75-88	3
1863	Appropriate use of estrogen replacement therapy in adolescents and young adults with Turner syndrome and hypopituitarism in light of the Women's Health Initiative. 2006 , 16 Suppl A, S98-102	20
1862	Endometriosis as a model for inflammation-hormone interactions in ovarian and breast cancers. 2006 , 42, 691-703	44
1861	Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. 2006 , 42, 2968-75	87
1860	The thoughts of physicians regarding the need to start hormone replacement therapy in breast cancer survivors. 2006 , 124, 207-11	11
1859	The thoughts of breast cancer survivors regarding the need for starting hormone replacement therapy. 2006 , 124, 250-3	10
1858	Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview. 2006 , 125, 9-28	105
1857	The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. 2006 , 129, 77-83	31

1856	Ex vivo measurement of cell apoptosis and proliferation in breast tissue of healthy women: influence of age and steroid status. An exploratory study. 2006 , 129, 96-8	2
1855	Gynaecological oncology perspective on management of the menopause. 2006 , 32, 892-7	14
1854	Different effects of estradiol and various antiestrogens on TNF-alpha-induced changes of biochemical markers for growth and invasion of human breast cancer cells. 2006 , 78, 1464-8	22
1853	Cardiovascular, anthropometric and neurocognitive features of healthy postmenopausal women: effects of hormone replacement therapy. 2006 , 78, 2625-32	7
1852	Dynamics of progestogenic activity in serum following administration of Ligusticum chuanxiong. 2006 , 79, 1274-80	10
1851	Menopausal hormone therapy (HT) in patients with breast cancer. 2006 , 53, 123-32	19
1850	Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women. 2006 , 53, 158-65	5
1849	AT1 receptor antagonism improves endothelial dysfunction in postmenopausal women. 2006 , 53, 176-83	17
1848	Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. 2006 , 53, 191-200	23
1847	The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. 2006 , 53, 226-33	169
1846	Menopausal symptoms after cessation of hormone replacement therapy. 2006 , 53, 356-61	39
1845	Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women. 2006 , 53, 439-46	14
1844	Use of hormones in the menopausal transition period in the Netherlands between 1993 and 1997. 2006 , 53, 462-75	11
1843	Propensity of gynaecologists towards osteoporosis management and treatment. 2006 , 53, 483-8	3
1842	The effect of low dose hormone therapy on mammographic breast density. 2006 , 54, 78-85	16
1841	A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. 2006 , 54, 164-75	110
1840	HRT use in 2001 and 2004 in The Netherlands--a world of difference. 2006 , 54, 193-7	29
1839	Tibolone and its metabolites inhibit invasion of human mammary carcinoma cells in vitro. 2006 , 54, 229-37	6

1838	Fracture reducing potential of hormone replacement therapy on a population level. 2006 , 54, 285-93	13
1837	Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT. 2006 , 55, 69-75	5
1836	Low dose estrogens inhibit coronary artery atherosclerosis in postmenopausal monkeys. 2006 , 55, 187-94	20
1835	Latin American position on the current status of hormone therapy during the menopausal transition and thereafter. 2006 , 55, 5-13	4
1834	Plasma concentrations of levonorgestrel in patients with an intrauterine progestogen delivery system: do they have any significance?. 2006 , 55, 94-5; author reply 96-7	4
1833	Soy protein and bone mineral density in older men and women: a randomized trial. 2006 , 55, 270-7	37
1832	Postmenopausal hormone therapy and cardiovascular disease: an overview of main findings. 2006 , 54, 372-9	12
1831	Estrogen receptors: new players in diabetes mellitus. 2006 , 12, 425-31	130
1830	Estrogen and the skin. 2006 , 55, 1115-6	
1829	Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant. 2006 , 98, 193-8	6
1828	Characterization of the stimulatory effect of medroxyprogesterone acetate and chlormadinone acetate on growth factor treated normal human breast epithelial cells. 2006 , 98, 174-8	11
1827	Antiestrogenic activities of Ginkgo biloba extracts. 2006 , 100, 167-76	42
1826	Acute and chronic estradiol treatments reduce memory deficits induced by transient global ischemia in female rats. 2006 , 49, 246-60	83
1825	Women's use of hormone therapy before and after the Women's Health Initiative: a psychosocial model of stability and change. 2006 , 43, 158-64	10
1824	A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. 2006 , 27, 141-9	91
1823	DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys. 2006 , 27, 1684-93	23
1822	Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. 2006 , 138, 1031-9	163
1821	The role of estrogens in seizures and epilepsy: the bad guys or the good guys?. 2006 , 138, 837-44	81

1820	Hormone therapy and cognitive function: is there a critical period for benefit?. 2006 , 138, 1027-30	139
1819	Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement. 2006 , 17, 101-9	41
1818	Estrogen therapy for postmenopausal osteoporosis. 2006 , 50, 705-19	39
1817	Pharmacological Therapy for Postmenopausal Osteoporosis. 2006 , 49, 30	
1816	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. 2006 , 113,	347
1815	Starting down the right path: nutrition connections with chronic diseases of later life. 2006 , 83, 415S-420S	255
1814	Relationships of age at menarche and menopause, and reproductive year with mortality from cardiovascular disease in Japanese postmenopausal women: the JACC study. 2006 , 16, 177-84	90
1813	Influence of sex steroid hormones on cerebrovascular function. 2006 , 101, 1252-61	254
1812	Oestrogen and stroke: the potential for harm as well as benefit. 2006 , 34, 1362-5	25
1811	Prevention of osteoporotic fractures. 2006 , 2, 649-659	
1810	Nutritional modulators of bone remodeling during aging. 2006 , 83, 427S-430S	43
1809	Genome-based biomarkers for adverse drug effects, patient enrichment and prediction of drug response, and their incorporation into clinical trial design. 2006 , 3, 177-185	11
1808	Folate Intake and the Risk of Incident Hypertension Among US Women. 2006 , 2006, 23-24	
1807	Canadian Consensus Conference on osteoporosis, 2006 update. 2006 , 28, S95-112	49
1806	Menopause and osteoporosis. 2006 , 28, 185-6; 218	1
1805	Hormonal therapy: does it increase or decrease cardiovascular risk?. 2006 , 61, 673-81	17
1804	Evolving approaches in the treatment of menopausal symptoms. 2006 , 108, 4-5	1
1803	Hormone therapy and breast cancer risk: trumping fear with facts. 2006 , 13, 160-3	7

1802	Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003. 2006 , 108, 33-40	49
1801	Breast cancer risk in postmenopausal women using estrogen-only therapy. 2006 , 108, 1354-60	109
1800	Progesterone-only and non-hormonal contraception in the breast cancer survivor: Joint Review and Committee Opinion of the Society of Obstetricians and Gynaecologists of Canada and the Society of Gynecologic Oncologists of Canada. 2006 , 28, 616-626	10
1799	Accidents vasculaires cřbraux chez la femme. 2006 , 3, 1-14	
1798	Women's autonomy and the evaluation of the information available on the Internet on hormone therapy after menopause. 2006 , 24, 226-34	1
1797	Prevalence and causes of persistent use of hormone replacement therapy among postmenopausal women: a follow-up study. 2006 , 13, 109-12	15
1796	Cardiovascular Disease. 2006 , 28, S81-S86	
1795	Mřopause et ostřoporose. 2006 , 28, 186	
1794	Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. 2006 , 13, 340-67; quiz 368-9	159
1793	Estrogen-progestogen replacement therapy and ovarian cancer: an update. 2006 , 15, 490-2	12
1792	Increased longevity in older users of postmenopausal estrogen therapy: the Leisure World Cohort Study. 2006 , 13, 12-8	34
1791	Postmenopausal hormone therapy: new questions and the case for new clinical trials. 2006 , 13, 139-47	64
1790	Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. 2006 , 13, 377-86	87
1789	Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. 2006 , 13, 517-27	18
1788	Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. 2006 , 13, 265-79	483
1787	Estrogen and stroke: a case for low-dose estrogen. 2006 , 13, 719-20	3
1786	Cardiovascular risk and hormone replacement therapy. 2006 , 18, 658-65	7
1785	Hormone therapy and breast cancer: what factors modify the association?. 2006 , 13, 178-84	13

1784	Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. 2006 , 13, 387-96	201
1783	Helping women stop postmenopausal hormone therapy. 2006 , 13, 323-4	1
1782	Polymorphisms in the estrogen synthesis and metabolism pathways and symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study. 2006 , 13, 902-10	38
1781	Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women. 2006 , 13, 651-9	5
1780	Women and hypertension: what did we learn from the Women's Health Initiative?. 2006 , 14, 267-75	38
1779	Hormone replacement therapy in endometrial cancer survivors: new perspectives after the heart and estrogen progestin replacement study and the women's health initiative. 2006 , 10, 92-101	3
1778	Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy. 2006 , 13, 148-55	16
1777	Stroke management in women. 2006 , 2, 597-603	
1776	Hormone therapy and cardiovascular risk markers and disease: focus on progestagens. 2006 , 2, 677-86	
1775	US women desire greater professional guidance on hormone and alternative therapies for menopause symptom management. 2006 , 13, 506-16	41
1774	Skeletal consequences of hormone therapy discontinuance: a systematic review. 2006 , 61, 115-24	13
1773	When is it appropriate to prescribe postmenopausal hormone therapy?. 2006 , 13, 404-10	18
1772	Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years. 2006 , 13, 130-8	22
1771	Observational studies and clinical trials of menopausal hormone therapy: can they both be right?. 2006 , 13, 1-3	10
1770	The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. 2006 , 13, 643-50	65
1769	A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. 2006 , 13, 737-43	108
1768	Hormone therapy and cerebrovascular events: a population-based nested case-control study. 2006 , 13, 730-6	29
1767	Oxidative stress explains differences in large elastic artery compliance between sedentary and habitually exercising postmenopausal women. 2006 , 13, 951-8	39

1766	Effects of soy germ isoflavones and hormone therapy on nitric oxide derivatives, low-density lipoprotein oxidation, and vascular reactivity in hypercholesterolemic postmenopausal women. 2006 , 13, 942-50	9
1765	The neurology of menopause. 2006 , 12, 149-59	19
1764	Fracture prevention in postmenopausal osteoporosis: a review of treatment options. 2006 , 61, 39-50	11
1763	Experimental therapies for hypoxia-induced pulmonary hypertension during acute lung injury. 2006 , 25, 214-26	19
1762	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. 2006 , 12, 315-37	54
1761	Osteoporosis. 2006 ,	
1760	Hormone therapy after the Women's Health Initiative: a qualitative study. 2006 , 7, 61	20
1759	Breast cancer risk associated with different HRT formulations: a register-based case-control study. 2006 , 6, 13	13
1758	Dietary phytoestrogens improve stroke outcome after transient focal cerebral ischemia in rats. 2006 , 23, 703-10	61
1757	Advice has changed for hormone therapy in the WHI era. 2006 , 46, 74-6	2
1756	Skin climacteric aging and hormone replacement therapy. 2006 , 5, 3-8	17
1755	Hormone replacement therapy and risk of venous thromboembolism--still unresolved questions. 2006 , 4, 68-9	1
1754	Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. 2006 , 4, 1259-65	81
1753	The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women. 2006 , 4, 1701-6	11
1752	Bone safety of aromatase inhibitors versus tamoxifen. 2006 , 16 Suppl 2, 518-20	16
1751	Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. 2006 , 21, 363-6	244
1750	Mortality associated with hormone replacement therapy in younger and older women. 2006 , 21, 401	9
1749	Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials. 2006 , 60, 1394-400	36

1748	The risk of breast, endometrial and ovarian cancer in users of hormonal preparations. 2006 , 98, 288-96	34
1747	Chemoprevention in gastrointestinal cancers: current status. 2006 , 98, 281-7	32
1746	Hormone in the hot seat. 2006 , 12, 8-9	9
1745	Therapeutic implications of the gender-specific aspects of cardiovascular disease. 2006 , 5, 425-38	200
1744	Mortality in women given diethylstilbestrol during pregnancy. 2006 , 95, 107-11	10
1743	Japanese Society of Hypertension. 2006 , 29, S1-S105	29
1742	Estradiol increases proteinuria and angiotensin II type 1 receptor in kidneys of rats receiving L-NAME and angiotensin II. 2006 , 70, 1759-68	30
1741	Traitement hormonal et ostéoporose postménopausique. 2006 , 73, 812-816	
1740	Pitfalls of the WHIs: Women's Health Initiative. 2006 , 1092, 331-40	16
1739	Hormone replacement therapy in breast cancer survivors. 2006 , 1092, 349-60	8
1738	Recent results from clinical trials using SERMs to reduce the risk of breast cancer. 2006 , 1089, 127-42	10
1737	Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. 2006 , 21, 817-28	170
1736	Obesity and female hormones. 2006 , 8, 26-31	
1735	Hormone therapy in the WHI era. 2006 , 46, 84-91	13
1734	Multiple pathways transmit neuroprotective effects of gonadal steroids. 2006 , 29, 199-207	82
1733	Mechanisms of neuroprotection by estrogen. 2006 , 29, 209-15	126
1732	Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. 2006 , 30, 45-53	87
1731	Incidence of malignancy in hormone therapy users with indeterminate calcifications on mammogram. 2006 , 194, 82-5	2

1730	Strategies for the prevention and treatment of osteoporosis during early postmenopause. 2006 , 194, S12-23	86
1729	Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. 2006 , 194, 1702-9	83
1728	Fallout from the Women's Health Study: A Short-lived Vindication for Feminists and the Resurrection of Hormone Therapies. 2006 , 54, 401-411	8
1727	Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). 2006 , 17, 695-703	43
1726	Breast cancer risk factors in relation to breast density (United States). 2006 , 17, 1281-90	80
1725	Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment. 2006 , 15, 1035-49	21
1724	p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2. 2006 , 11, 413-25	22
1723	Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms. 2006 , 274, 74-80	7
1722	Klinische Bedeutung von gestagenen Partialwirkungen. 2006 , 4, 52-64	1
1721	Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. 2006 , 17, 29-40	42
1720	Racial variations in antiresorptive medication use: results from the 2000 Medical Expenditure Panel Survey (MEPS). 2006 , 17, 395-404	22
1719	Osteoporosis prevention and therapy: preserving and building strength through bone quality. 2006 , 17, 1707-15	29
1718	The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. 2006 , 49, 459-68	156
1717	Aromatase inhibitors as adjuvant treatment of breast cancer. 2006 , 57, 53-61	17
1716	Endothelial function and cerebrovascular disease: implications for diagnosis and treatment. 2006 , 8, 213-9	2
1715	Osteoporosis and skeletal fractures. 2006 , 2, 62-9	43
1714	Estrogen and hypertension. 2006 , 8, 368-76	102
1713	Menopause hormonal therapy from the urologist's perspective. 2006 , 7, 1-3	5

1712 Opliegers. **2006**, 49, 951-956

1711 Phytoestrogen derivatives differentially inhibit arterial neointimal proliferation in a mouse model. **2006**, 548, 123-8 13

1710 Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. **2006**, 97, 520-7 44

1709 The effect of lifestyle factors on gynaecological cancer. **2006**, 20, 227-51 52

1708 Menopause: evidence-based practice. **2006**, 20, 799-839 44

1707 Effects of continuous and intermittent estrogen treatments on memory in aging female mice. **2006**, 1115, 135-47 51

1706 Pharmacologic and nonpharmacologic management of osteoporosis. **2006**, 8, 40-53 19

1705 The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. **2006**, 36, 10-21 13

1704 Drug delivery systems for hormone therapy. **2006**, 112, 1-14 57

1703 Differences in brain volumes among males and female hormone-therapy users and nonusers. **2006**, 147, 127-34 23

1702 Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. **2006**, 6, 152 93

1701 Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. **2006**, 4, 16 40

1700 Hypnosis in cancer care. **2006**, 23, 47-57 8

1699 Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. **2006**, 54, 3194-204 102

1698 How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. **2006**, 107, 1624-33 158

1697 Epidemiology and the causes of breast cancer. **2006**, 118, 2373-8 87

1696 Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. **2006**, 118, 1292-301 33

1695 Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. **2006**, 119, 2907-15 91

1694	Osteoporosis: how should it be treated?. 2006 , 54, 114-22	4
1693	Estrogen replacement effectively improves the accelerated intimal hyperplasia following balloon injury of carotid artery in the ovariectomized rats. 2006 , 47, 37-45	51
1692	Advancing the study of stroke in women: summary and recommendations for future research from an NINDS-Sponsored Multidisciplinary Working Group. 2006 , 37, 2387-99	87
1691	Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. 2006 , 21, 2715-20	44
1690	Association between alcohol intake and domain-specific cognitive function in older women. 2006 , 27, 1-12	26
1689	[The benefits and risks of hormonal replacement therapy--an update]. 2006 , 46, 166-73	0
1688	[Hormone replacement therapy for internal risk patients]. 2006 , 46, 174-90	5
1687	Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. 2006 , 15, 946-54	69
1686	Clinical management of BRCA1 and BRCA2 mutation carriers. 2006 , 3, 2-3	7
1685	HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?. 2006 , 21, 1668-71	23
1684	Arzoxifene: the development and clinical outcome of an ideal SERM. 2006 , 15, 317-26	26
1683	Current breast cancer risks of hormone replacement therapy in postmenopausal women. 2006 , 7, 2455-63	6
1682	Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. 2006 , 91, 3123-30	39
1681	Impact of combined estradiol and norethindrone therapy on visuospatial working memory assessed by functional magnetic resonance imaging. 2006 , 91, 4476-81	55
1680	Differential modulation of estrogen receptors (ERs) in ischemic brain injury: a role for ERalpha in estradiol-mediated protection against delayed cell death. 2006 , 147, 3076-84	160
1679	Coronary heart disease in women: highlights of the past 2 years--stepping stones, milestones and obstructing boulders. 2006 , 3, 194-202	20
1678	Current state of hormone replacement therapy: the case for using trimegestone. 2006 , 2, 539-50	1
1677	Risk-benefit profiles of raloxifene for women. 2006 , 355, 190-2	32

1676	Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. 2006 , 354, 261-9	618
1675	Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. 2006 , 98, 1275-84	232
1674	Estrogen and progestagens differentially modulate vascular proinflammatory factors. 2006 , 291, E261-7	63
1673	Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. 2006 , 163, 589-99	135
1672	Expression of sex steroid receptor subtypes in normal and malignant breast tissue - a pilot study in postmenopausal women. 2006 , 45, 54-60	7
1671	A tale of three species--rabbits, chickens and humans: an interview with clinical trials pioneer Jeremiah Stamler. Interview by Janet Wittes. 2006 , 3, 320-34	
1670	Testosterone replacement therapy for late-onset hypogonadism. 2006 , 3, 260-7	29
1669	Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. 2006 , 24, 587-92	158
1668	Is HRT justified for symptom management in women at higher risk of developing breast cancer?. 2006 , 9, 404-15	12
1667	Cardiovascular health and the menopause: the gynecologist as the patients' interface. 2006 , 9 Suppl 1, 6-12	6
1666	Menopause in Egypt: past and present perspectives. 2006 , 9, 421-9	18
1665	Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep. 2006 , 291, H1216-25	2
1664	Impact of cyclooxygenase inhibitors in the Women's Health Initiative hormone trials: secondary analysis of a randomized trial. 2006 , 1, e26	2
1663	Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; the American Academy of Neurology affirms the value of this guideline. 2006 , 31, 1369-83	869
1662	Risk of brain tumors associated with exposure to exogenous female sex hormones. 2006 , 164, 629-36	118
1661	Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). 2006 , 98, 920-31	415
1660	Risk factors for cardiovascular disease and hormone therapy in women. 2006 , 92 Suppl 3, iii24-8	10
1659	FIVE AUTHORS REPLY. 2006 , 163, 1068-1069	4

1658	Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. 2006 , 27, 1301-9	135
1657	Hormone replacement therapy and acute myocardial infarction: a large observational study exploring the influence of age. 2006 , 35, 731-8	12
1656	Epidemiology of coronary heart disease in women. 2006 , 92 Suppl 3, iii2-4	9
1655	Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. 2006 , 24, 1409-14	93
1654	Rethinking primary prevention of atherosclerosis-related diseases. 2006 , 114, 2517-27	80
1653	Clinical review: Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. 2006 , 91, 4215-22	140
1652	Hormones and cardiovascular health in women. 2006 , 12, 483-97	72
1651	Benchmarks for designing two-stage studies using modified mini-mental state examinations: experience from the Women's Health Initiative Memory Study. 2006 , 3, 99-106	19
1650	Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women. 2006 , 61, 61-4	6
1649	Commentary: hormones, heart disease, and the definition of hormone 'initiation'. 2006 , 35, 738-9; discussion 740	3
1648	WHI and breast cancer: a response to a recent publication from the WHI. 2006 , 9, 244	3
1647	Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 2006 , 113, e85-151	1994
1646	Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. 2006 , 113, 2425-34	272
1645	The women's health initiative--curse or blessing?. 2006 , 35, 814-6	4
1644	Hormone replacement therapy in women with past history of endometriosis. 2006 , 9, 325-35	56
1643	Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. 2006 , 15, 35-44	314
1642	Are possible risk factors for differentiated thyroid cancer of prognostic importance?. 2006 , 16, 659-66	3
1641	The endogenous estrogen status regulates microglia reactivity in animal models of neuroinflammation. 2006 , 147, 2263-72	125

1640	Breast cancer in postmenopausal women with and without hormone replacement therapy: preliminary results of the MISSION study. 2006 , 22, 423-31	9
1639	Adipose tissue, insulin resistance and low-grade inflammation: implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy. 2006 , 9, 169-80	17
1638	Menopausal hormone therapy in a health maintenance organization before and after women's health initiative hormone trials termination. 2006 , 15, 369-78	18
1637	Algorithm for prescription of HRT or ERT for postmenopausal women. 2006 , 9, 238-9	1
1636	Raloxifene increases proliferation and up-regulates telomerase activity in human umbilical vein endothelial cells. 2006 , 281, 24270-8	24
1635	Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. 2006 , 26, 6823-33	126
1634	Estrogen alters spine number and morphology in prefrontal cortex of aged female rhesus monkeys. 2006 , 26, 2571-8	204
1633	Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women. 2006 , 26, 2807-12	16
1632	Fertility approaches to interim monitoring by data monitoring committees. 2006 , 3, 522-9	36
1631	Drug insight: Existing and emerging therapies for osteoporosis. 2006 , 2, 670-80	38
1630	Is there a link between oestrogen therapy and gallbladder disease?. 2006 , 5, 117-29	23
1629	Coronary heart disease and postmenopausal hormone therapy: conundrum explained by timing?. 2006 , 15, 51-3	12
1628	Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter. 2006 , 9, 146-51	9
1627	Comparison between phytoestrogens and estradiol in the prevention of atheroma in ovariectomized cholesterol-fed rabbits. 2006 , 9, 430-6	12
1626	The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. 2006 , 9, 108-18	38
1625	Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women. 2006 , 26, 385-91	30
1624	Re: "combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the women's health initiative clinical trial". 2006 , 163, 1067-8; author reply 1068-9	12
1623	Have we found the ultimate risk factor for breast cancer?. 2006 , 24, 1791-4	7

1622	Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. 2006 , 15, 961-6	59
1621	Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies. 2006 , 27, 575-605	208
1620	Bioidentical estradiol gel for hormone therapy in menopause. 2007 , 2, 423-430	1
1619	The latest elaboration of the Women's Health Initiative data on hormone replacement therapy and cardiovascular disease in postmenopausal women. 2007 , 23, 183-5	4
1618	The relative contributions of menopause and aging to postmenopausal reduction in intervertebral disk height. 2007 , 10, 298-305	32
1617	Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. 2007 , 115, 840-5	565
1616	Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. 2007 , 25, 5584-90	147
1615	Low-dose tamoxifen for combination hormone replacement therapy users. 2007 , 25, 4162-4	3
1614	Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women. 2007 , 27, 1782-7	71
1613	Hormone replacement therapy, body mass, and the risk of colorectal cancer among postmenopausal women from Germany. 2007 , 97, 1486-92	22
1612	WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. 2007 , 7, 1549-64	70
1611	Drospirenone and estradiol: a new option for the postmenopausal woman. 2007 , 10 Suppl 1, 3-10	24
1610	17beta-Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. 2007 , 292, R769-77	67
1609	Treatment of vasomotor symptoms in the menopausal transition and postmenopausally: psychiatric comorbidity. 2007 , 7, S115-37	5
1608	An Interview with Jeffrey S. Dungan, M.D.. 2007 , 23, 1-6	
1607	Age alters cerebrovascular inflammation and effects of estrogen. 2007 , 292, H2333-40	35
1606	The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women. 2007 , 10, 400-7	7
1605	Reply to 'Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature' by Delea et al. 2007 , 18, 198-199	

1604	Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17beta-estradiol in an in vivo model of myocardial ischemia and reperfusion. 2007 , 293, H1408-15	18
1603	Possible Increase in Liver Enzymes Secondary to Atorvastatin and Black Cohosh Administration. 2007 , 20, 341-346	2
1602	Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. 2007 , 2, e28	29
1601	Nuclear Hormone Receptors. 2007 , 993-1036	
1600	Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. 2007 , 19, 2-24	57
1599	Estrogen-TNF interactions and vascular inflammation. 2007 , 292, H2566-9	11
1598	The weight problem. 2007 , 10, 83-4	7
1597	Number of women needed in a prospective trial to prove potential cardiovascular benefit of hormone replacement therapy. 2007 , 10, 238-43	8
1596	Estrogen deficiency decreases ischemic tolerance in the aged rat heart: Roles of PKCdelta, PKCepsilon, Akt, and GSK3beta. 2007 , 292, R800-9	53
1595	Are some types of hormone therapy safer than others? Lessons from the Estrogen and Thromboembolism Risk study. 2007 , 115, 820-2	12
1594	Cognitive effects of short-term use of raloxifene: a randomized clinical trial. 2007 , 117, 1579-90	12
1593	Epidemiology and Risk Factors of Cardiovascular Disease in Postmenopausal Women. 2007 , 405-452	5
1592	Hormone therapy and breast cancer risk. 2007 , 10 Suppl 2, 54-61	24
1591	Recent epidemiological evidence relevant to the clinical management of the menopause. 2007 , 10 Suppl 2, 2-15	22
1590	Hormone therapy and cardiovascular disease in the early postmenopause: the WHI data revisited. 2007 , 10, 195-6	11
1589	Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. 2007 , 22, 2325-34	42
1588	Managing the menopause. 2007 , 334, 736-41	29
1587	Postmenopausal hormone therapy. 2007 , 334, 860-1	10

1586	Neurocognitive outcomes are not improved by 17beta-estradiol in postmenopausal women undergoing cardiac surgery. 2007 , 38, 2048-54	20
1585	Determinants of serum total and free testosterone levels in women over the age of 65 years. 2007 , 92, 509-16	47
1584	Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. 2007 , 109, 588-96	49
1583	Ineffectiveness of sertraline for treatment of menopausal hot flashes: a randomized controlled trial. 2007 , 109, 823-30	64
1582	The pathway-selective estrogen receptor ligand WAY-169916 reduces infarct size after myocardial ischemia and reperfusion by an estrogen receptor dependent mechanism. 2007 , 49, 401-7	17
1581	Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. 2007 , 29, 45-60	33
1580	The estrogen paradox. 2007 , 3, 496-7	17
1579	Estrogen therapy and coronary-artery calcification. 2007 , 357, 1252-3; author reply 1254	4
1578	HRT and the young at heart. 2007 , 356, 2639-41	95
1577	Estrogen therapy and coronary-artery calcification. 2007 , 356, 2591-602	532
1576	Hormonal and nutritional effects on cardiovascular risk markers in young women. 2007 , 92, 3089-94	17
1575	Lifestyle intervention and postmenopausal bone density. 2007 , 92, 3777-9	3
1574	Emerging pharmacologic therapies for osteoporosis. 2007 , 12, 493-508	23
1573	Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone. 2007 , 148, 2613-21	65
1572	Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. 2007 , 335, 239	157
1571	Hormone-replacement therapy, dementia and stroke. 2007 , 3, 699-710	5
1570	Migraine and cardiocerebrovascular risk in women. 2007 , 3, 369-79	
1569	Chapter 1: Introduction. 2007 , 14, S2-S113	

1568	Breast cancer: are estrogen metabolites carcinogenic?. 2007 , 10 Suppl 2, 62-5	15
1567	Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen. 2007 , 16, 2005-20	11
1566	Effects of dydrogesterone on the vascular system. 2007 , 23 Suppl 1, 2-8	6
1565	Cardiovascular risk in women: the impact of hormone replacement therapy and prospects for new therapeutic approaches. 2007 , 8, 279-88	17
1564	Perceptions of clinical research participation among African American women. 2007 , 16, 423-8	86
1563	Patient selection, statistical presumption, and uncertainty of outcomes. 2007 , 16, 213-5	
1562	1 Statistical Methods and Challenges in Epidemiology and Biomedical Research. 2007 , 1-27	0
1561	Long-term trials of HRT for cardioprotection--is this as good as it gets?. 2007 , 10, 1-4	4
1560	Symptoms during the menopausal transition and early postmenopause and their relation to endocrine levels over time: observations from the Seattle Midlife Women's Health Study. 2007 , 16, 667-77	76
1559	Bone, cartilage and hormone therapy: established concepts and future scenarios. 2007 , 10, 270-2	3
1558	An innovative program to provide adequate women's health education to residents with VA-based ambulatory care experiences. 2007 , 19, 148-53	4
1557	Hysterectomy with preservation of both ovaries does not result in premature ovarian failure. 2007 , 35, 416-21	8
1556	Physical activity and colon cancer risk among women in the California Teachers Study. 2007 , 16, 517-25	55
1555	Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board. 2007 , 4, 218-34	36
1554	The effect of menopause on the metabolic syndrome among Korean women: the Korean National Health and Nutrition Examination Survey, 2001. 2007 , 30, 701-6	139
1553	Rashomon revisited: two views of monitoring the Women's Health Initiative trials. 2007 , 4, 205-6	1
1552	Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. 2007 , 25, 308-12	74
1551	Drospirenone and its antialdosterone properties. 2007 , 10 Suppl 1, 11-8	67

1550	Hormones and breast cancer: what's the story?. 2007 , 16, 1697-9	0
1549	Sex steroid effects at target tissues: mechanisms of action. 2007 , 31, 26-33	108
1548	The effects of short-term hormone replacement therapy on long-term bone mineral density. 2007 , 10, 257-63	13
1547	The position of the Regulatory Authorities. 2007 , 10 Suppl 2, 121-4	
1546	Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists. 2007 , 10, 508-26	47
1545	Hormone replacement therapy and female malignancy: what has the Million Women Study added to our knowledge?. 2007 , 33, 237-43	
1544	Breast cancer trends: a marriage between clinical trial evidence and epidemiology. 2007 , 99, 1139-41	16
1543	Hormone replacement therapy and breast cancer: where are we now?. 2007 , 33, 3-6	
1542	Vascular and metabolic effects of sex steroids: new insights into clinical trials. 2007 , 14, 300-14	12
1541	Osteoimmunology. 2007 , 143, 31-48	108
1540	Loss-of-function deletion of the steroid receptor coactivator-1 gene in mice reduces estrogen effect on the vascular injury response. 2007 , 27, 1521-7	13
1539	Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women. 2007 , 10 Suppl 1, 32-41	18
1538	The role of menopausal hormone therapy in osteoporosis. 2007 , 10 Suppl 2, 71-3	3
1537	Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials. 2007 , 4, 207-17	19
1536	Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. 2007 , 67, 7534-9	105
1535	Estradiol topical emulsion for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. 2007 , 3, 29-37	2
1534	Considerations of study design. 2007 , 22, 593-8	7
1533	Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast. 2007 , 212, 1-12	36

1532	Estradiol action in atherosclerosis and reendothelialization. 2006 , 69-86	3
1531	Pharmacotherapeutic decisions in menopausal women with cardiovascular risk. 2007 , 2, 197-210	1
1530	Biological roles of estrogen and progesterone in human endometrial carcinoma--new developments in potential endocrine therapy for endometrial cancer. 2007 , 54, 667-79	94
1529	Endogenous sex steroids and ischemic stroke risk in older women. 2007 , 3, 201-207	
1528	Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. 2007 , 112, 517-525	52
1527	Flavonoids and heart health: proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC. 2007 , 137, 718S-737S	271
1526	Parenteral versus oral treatment of postmenopausal women with estrogen. 2007 , 14, 968-70	3
1525	Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease. 2007 , 22, 434-42	7
1524	Menopause and determinants of quality of life in women at midlife and beyond: the study of health in pomerania (SHIP). 2007 , 14, 123-34	38
1523	Surgical menopause: effects on psychological well-being and sexuality. 2007 , 14, 586-91	74
1522	Postmenopausal hormone replacement therapy: endometrial and breast effects. 2007 , 14, 17-24	22
1521	Evidence and opinion: closing the gap. 2007 , 14, 3-4	1
1520	Isoflavones and cardiovascular risk in postmenopausal women: no free lunch. 2007 , 14, 606-8	3
1519	Estrogens in vascular biology and disease: where do we stand today?. 2007 , 18, 554-60	55
1518	Fracture risk associated with drugs: a search for candidate drugs in the same way as for candidate genes. 2007 , 4, 407-422	1
1517	Screening and follow-up of the patient at high risk for breast cancer. 2007 , 110, 1404-16	16
1516	Evolving practice patterns and attitudes toward hormone therapy of obstetrician-gynecologists. 2007 , 14, 20-8	25
1515	Hot flashes: what are women's expectations from therapeutic options?. 2007 , 14, 166-7	1

1514	Postmenopausal hormone therapy in clinical perspective. 2007 , 14, 944-57	37
1513	Women's awareness and knowledge of hormone therapy post-Women's Health Initiative. 2007 , 14, 853-8	17
1512	Options for hormone therapy in women who have had a hysterectomy. 2007 , 14, 592-7; quiz 598-9	15
1511	NIH and WHI: time for a mea culpa and steps beyond. 2007 , 14, 1056-9	19
1510	Colorectal cancer incidence, mortality and survival in South-east England between 1972 and 2001. 2007 , 16, 10-6	12
1509	Effects of lasofoxifene on bone in surgically postmenopausal cynomolgus monkeys. 2007 , 14, 97-105	13
1508	Complementary and alternative medicine use among midlife women for reasons including menopause in the United States: 2002. 2007 , 14, 300-7	36
1507	Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women. 2007 , 14, 235-42	4
1506	Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. 2007 , 14, 391-6	15
1505	Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. 2007 , 14, 408-14	27
1504	Raloxifene improves the ovariectomy-induced impairment in endothelium-dependent vasodilation. 2007 , 14, 656-61	11
1503	Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. 2007 , 16, 232-42	12
1502	Update on the cardiovascular risks of hormone replacement therapy. 2007 , 3, 87-97	9
1501	Menopausal hormone therapy: calculating risks and benefits. 2007 , 109, 578-80	1
1500	The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. 2007 , 14, 510-7	69
1499	Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. 2007 , 22, 1769-77	44
1498	Antihypertensive Medications and the Risk of Incident Type 2 Diabetes. 2007 , 2007, 36-38	
1497	The relationship between physical activity and lipoprotein subclasses in postmenopausal women: the influence of hormone therapy. 2007 , 14, 115-22	8

1496	Should testosterone be added to estrogen-progestin therapy for breast protection?. 2007 , 14, 159-62	4
1495	Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. 2007 , 14, 373-84	125
1494	Coadministration of estradiol/drospirenone and indomethacin does not cause hyperkalemia in healthy postmenopausal women: a randomized open-label crossover study. 2007 , 47, 774-81	7
1493	Acupuncture for hot flashes: a randomized, sham-controlled clinical study. 2007 , 14, 45-52	95
1492	Ovarian conservation at the time of hysterectomy for benign disease. 2007 , 50, 354-61	47
1491	Historical Perspectives in Postmenopausal Hormone Therapy: Defining the Right Dose and Duration. 2007 , 82, 219-226	3
1490	Mhopause. 2007 , 2, 1-20	6
1489	Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial. 2007 , 2007, 341-342	
1488	Estrogen Receptor Gene Polymorphisms Are Associated with the Angiographic Extent of Coronary Artery Disease. 2007 , 2007, 400-401	
1487	Virus d'immunodeficiency humaine et gynécologie. 2007 , 2, 1-5	
1486	Unopposed estradiol therapy in postmenopausal women: results from two randomized trials. 2007 , 109, 581-7	18
1485	Acute pretreatment with estradiol protects against CA1 cell loss and spatial learning impairments resulting from transient global ischemia. 2007 , 51, 335-45	19
1484	Pharmacological postconditioning with the phytoestrogen genistein. 2007 , 42, 79-87	75
1483	Cancer genetics. 2007 , 23, 2-9	4
1482	Endocrine effects of breast cancer treatment. 2007 , 23, 55-70	9
1481	Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. 2007 , 72, 381-405	425
1480	Discontinuing hormone replacement therapy: attenuating the effect on CVD risk with lifestyle changes. 2007 , 32, 483-9	14
1479	Isoflavones--safe food additives or dangerous drugs?. 2007 , 6, 150-88	121

1478	Why do women live longer than men?. 2007 , 133, 126-33	69
1477	Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal women. 2007 , 87, 849-57	11
1476	Effects of the components of hormone therapy on matrix metalloproteinases in breast-cancer cells: an in vitro study. 2007 , 87, 978-81	7
1475	Raloxifene increases proliferation of human endothelial cells in association with increased gene expression of cyclins A and B1. 2007 , 88, 326-32	10
1474	Estrogen increases apoptosis in the arterial wall in a murine atherosclerosis model. 2007 , 88, 1190-6	14
1473	The clinical trial of Women On the Move through Activity and Nutrition (WOMAN) study. 2007 , 28, 370-81	29
1472	Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. 2007 , 29, 230-41	85
1471	Role of the oral and maxillofacial surgeon in the diagnosis and treatment of patients with osteoporosis. 2007 , 19, 475-85, v	1
1470	Range of published estimates of venous thromboembolism incidence in young women. 2007 , 75, 328-36	102
1469	Observation versus intervention in the evaluation of drugs: the story of hormone replacement therapy. 2007 , 330, 347-55	2
1468	The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. 2007 , 17, 210-9	5
1467	[Hormone replacement therapy in postmenopausal women: all the treatments are not the same]. 2007 , 35, 388-97	6
1466	Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. 2007 , 28, 387-439	138
1465	The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. 2007 , 21, 359-75	164
1464	Aromatase excess in cancers of breast, endometrium and ovary. 2007 , 106, 81-96	69
1463	Molecular and pharmacodynamic properties of estrogenic extracts from the traditional Chinese medicinal herb, Epimedium. 2007 , 113, 218-24	31
1462	Physicians' views and practices concerning menopausal hormone therapy. 2007 , 56, 30-7	14
1461	The effect of tibolone versus 17beta-estradiol on climacteric symptoms in women with surgical menopause: a randomized, cross-over study. 2007 , 56, 61-8	19

1460	Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells. 2007 , 56, 142-52	23
1459	Menopause characteristics of women with physical disabilities from poliomyelitis. 2007 , 56, 161-72	5
1458	Feasibility and acceptability of restorative yoga for treatment of hot flushes: a pilot trial. 2007 , 56, 198-204	48
1457	Benefits and risks of long-term low-dose oral continuous combined hormone therapy. 2007 , 56, 231-48	26
1456	Why is the RUTH trial so important?. 2007 , 56, 111-2	2
1455	Use of hormone replacement therapy (HRT) among women aged 45-64 years in the German EPIC-cohorts. 2007 , 56, 436-46	8
1454	Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease. 2007 , 57, 239-46	14
1453	WHI risks: any relevance to menopause management?. 2007 , 57, 6-10	7
1452	HRT and the primary prevention of cardiovascular disease. 2007 , 57, 31-4	21
1451	Using Internet technologies to improve and simplify counseling about menopause: the WISDOM website. 2007 , 57, 95-9	6
1450	Endometrial bleeding during hormone therapy: the effect of progestogens. 2007 , 57, 71-6	9
1449	Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study. 2007 , 57, 361-9	18
1448	In vitro effects of tibolone and its metabolites on human vascular coronary cells. 2007 , 58, 42-9	5
1447	A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women. 2007 , 58, 201-7	11
1446	Good agreement between physician and self-reported hormone therapy data in a case-control study. 2007 , 60, 1280-7	17
1445	Acute administration of 17beta-estradiol reduces endothelin-1 release during pacing-induced ischemia. 2007 , 116, 34-9	8
1444	An effective vascular-healing agent after coronary stent implantation: estrogen. 2007 , 118, 116-7	2
1443	Retention of ovaries and oxidative stress of surgery. 2007 , 97, 40-3	7

1442	Ovarian cancer and HRT in the Million Women Study. 2007 , 369, 1667-8	6
1441	La Cimifuga racemosa, administrada como única sustancia o asociada a otros derivados botánicos, tiene poca eficacia en el control de los síntomas vasomotores. 2007 , 14, 434	
1440	Primary systemic chemotherapy of invasive lobular carcinoma of the breast. 2007 , 8, 55-62	77
1439	Gender-specific care of diabetes. 2007 , 3, 735-64	2
1438	Breast cancer from oral and transdermal estradiol: a cohort study of Finnish women. 2007 , 3, 321-4	3
1437	Bioidentical hormone therapy: a review of the evidence. 2007 , 16, 600-31	53
1436	Adjuvant endocrine treatment of early breast cancer. 2007 , 21, 223-38	11
1435	Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation. 2007 , 9, R36	21
1434	The oestrogen paradox: an hypothesis. 2007 , 9,	2
1433	Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women. 2007 , 47, 1292-302	8
1432	Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option?. 2007 , 67, 2311-21	14
1431	Neuroendocrinology of Memory and Cognitive Function. 2007 , 775-800	2
1430	Variations on hormone replacement therapy: an answer to the 'one dose fits all' Women's Health Initiative study. 2007 , 23, 665-71	10
1429	The truth about hormone replacement therapy and breast cancer. 2007 , 2, 25-29	1
1428	Postmenopausal osteoporosis: an update on current and future therapeutic options. 2007 , 2, 79-90	
1427	Estrogen and tibolone metabolite levels in blood and breast tissue of postmenopausal women recently diagnosed with early-stage breast cancer and treated with tibolone or placebo for 14 days. 2007 , 14, 151-9	6
1426	The association between soy nut consumption and decreased menopausal symptoms. 2007 , 16, 361-9	26
1425	The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. 2007 , 25, 913-33	50

1424	The heart of the WHI study: time for hormone therapy policies to be revised. 2007 , 10, 267-9	20
1423	Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. 2007 , 16, 1663-72	23
1422	Timing is everything. 2007 , 23, 1-4	11
1421	Long-term use of progestogens: colon adenoma and colon carcinoma. 2007 , 23 Suppl 1, 42-4	6
1420	Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen. 2007 , 23, 692-9	14
1419	Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. 2007 , 23, 391-7	35
1418	Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels. 2007 , 23 Suppl 1, 9-16	6
1417	The HRT misuse and osteoporosis epidemic: a possible future scenario. 2007 , 10, 273-5	16
1416	Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. 2007 , 23, 436-44	5
1415	Hormone replacement as the first-line prevention for postmenopausal osteoporosis. 2007 , 2, 689-700	1
1414	Downgrading skin climacteric aging by hormone replacement therapy. 2007 , 2, 373-376	12
1413	New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation. 2007 , 10, 358-70	14
1412	Reducing the risk of cardiovascular disease in older women. 2007 , 49, 32-35	
1411	Combination of drospirenone and estradiol: a new hormone therapy in postmenopausal women. 2007 , 3, 409-15	
1410	Estrogen receptor-beta: recent lessons from in vivo studies. 2007 , 21, 1-13	233
1409	[Hormone replacement therapy and vessels: what's the story in 2007?]. 2007 , 32, 190-1	
1408	Hormonal replacement therapy (HRT) in postmenopause: a reappraisal. 2007 , 68, 241-50	13
1407	Sleep Apnea and Neuroendocrine Function. 2007 , 2, 225-236	10

1406 Virus de la inmunodeficiencia humana y ginecologâ. **2007**, 11, 1-5

1405 Historical perspectives in postmenopausal hormone therapy: defining the right dose and duration. **2007**, 82, 219-26 7

1404 [Postmenopausal hormone therapy and vascular risk]. **2007**, 163, 851-6 0

1403 Enrollment in a brain magnetic resonance study: results from the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study (WHIMS-MRI). **2007**, 14, 603-12 35

1402 Management of the BRCA mutation carrier or high-risk patient. **2007**, 34, 15-27; abstract v 6

1401 Teaching evidence-based medicine in otolaryngology. **2007**, 40, 1261-74, vii-viii 12

1400 A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis. **2007**, 82, 999-1012 35

1399 Arterial vascular disease in women. **2007**, 46, 1295-302 57

1398 A decline in breast-cancer incidence. **2007**, 357, 509; author reply 513 37

1397 Clinical trials report. **2007**, 1, 135-136

1396 Clinical guidelines for cardiovascular disease prevention: Should they differ by gender?. **2007**, 1, 148-152

1395 Nuevas estrategias terapûticas en la osteoporosis. **2007**, 54, 420-431 1

1394 Drospirenone, a new progestogen, for postmenopausal women with hypertension. **2007**, 24, 453-66 18

1393 Musings on Guidelines and Evidence: An Opposing View. **2007**, 27, 35-38 14

1392 Raloxifene. **2007**, 103-121 4

1391 [Menopausal hormone therapy]. **2007**, 51, 938-42 5

1390 Preventive Health Care for Women. **2007**, 125-155

1389 Treatment of Osteoporosis. **2007**, 377-392

1388	Use of vascular Doppler ultrasound to detect acute estradiol vascular effect in postmenopausal women. 2007 , 62, 673-8	5
1387	A critique of Women's Health Initiative Studies (2002-2006). 2006 , 4, e023	19
1386	Menopause, estrogens, and endothelial dysfunction: current concepts. 2007 , 62, 77-86	54
1385	Endometrial Hyperplasia, Estrogen Therapy, and the Prevention of Endometrial Cancer. 2007 , 125-146	
1384	Endometrial safety assessment of a specific and standardized soy extract according to international guidelines. 2007 , 14, 1006-11	17
1383	Randomized Controlled Trials and the Effects of Postmenopausal Hormone Therapy on Cardiovascular Disease: Facts, Hypotheses, and Clinical Perspective. 2007 , 529-564	
1382	HRT: a reappraisal of the risks and benefits. 2007 , 186, 643-6	19
1381	Hormone replacement therapy. 2007 , 399-401	
1380	Menopause. 2007 , 383-407	0
1379	Menopausal Hot Flashes. 2007 , 187-198	1
1378	Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. 2007 , 121, 2517-23	28
1377	Synthesis of a selective estrogen receptor β modulator via asymmetric phase-transfer catalysis. 2007 , 63, 4459-4463	17
1376	The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. 2007 , 7, 2	31
1375	Pilot study of fluvoxamine treatment for climacteric symptoms in Japanese women. 2007 , 1, 12	3
1374	The endocrine system and ageing. 2007 , 211, 173-80	186
1373	Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. 2007 , 16, 17-27	51
1372	Medical decisions regarding hormone therapy for menopausal women are significantly influenced by the media. 2007 , 16, 28-31	11
1371	Sex hormones and the cardiovascular system: effects on arterial function in women. 2007 , 34, 672-6	40

1370	The critical period hypothesis: can it explain discrepancies in the oestrogen-cognition literature?. 2007 , 19, 77-81	99
1369	The association between blood pressure and mortality in ESRD-not different from the general population?. 2007 , 20, 510-7	36
1368	The current state of postmenopausal hormone therapy: update for neurologists and epileptologists. 2007 , 7, 119-22	3
1367	Hormone replacement therapy use and variations in the risk of breast cancer. 2008 , 115, 169-75; discussion 175	64
1366	Osteoporosis and periodontal disease. 2007 , 44, 29-43	31
1365	Is treatment of early postmenopausal women with bisphosphonates justified?. 2007 , 61, 963-71	2
1364	The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. 2007 , 61, 2051-63	118
1363	Treating vasomotor symptoms of menopause: the nurse practitioner's perspective. 2007 , 19, 152-63	9
1362	Care of the menopausal patient: a nurse practitioner's view. 2007 , 19, 427-37	6
1361	Colon cancer risk and different HRT formulations: a case-control study. 2007 , 7, 76	10
1360	Pharmacologic interventions for the management of critical bleeding. 2007 , 27, 69S-84S	13
1359	Tamoxifen and estrogen attenuate enhanced vascular reactivity induced by estrogen deficiency in rat carotid arteries. 2007 , 73, 1330-9	7
1358	Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial. 2007 , 16 Suppl 2, S182-9	12
1357	Designing drugs for the treatment of female sexual dysfunction. 2007 , 12, 757-66	19
1356	Role of C-reactive protein in coronary risk reduction: focus on primary prevention. 2007 , 99, 718-25	35
1355	Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. 2007 , 99, 1648-52	23
1354	The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. 2007 , 104, 7-10	116
1353	Hormone replacement therapy. 2007 , 35, 529-532	2

1352	Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. 2008 , 23, 112-20	96
1351	Biostatistics primer: part I. 2007 , 22, 629-35	6
1350	Which gender is better positioned in the process of liver surgery? Male or female?. 2007 , 37, 823-30	29
1349	Combination therapy for treatment of osteoporosis: A review. 2007 , 197, 559-65	21
1348	Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. 2007 , 24, 448-61	45
1347	Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: a framework for personalized risk assessment and counseling. 2007 , 22, 10-4	5
1346	Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. 2007 , 63, 843-9	69
1345	Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. 2007 , 18, 9-23	142
1344	Molecular analysis of human endometrium: short-term tibolone signaling differs significantly from estrogen and estrogen + progestagen signaling. 2007 , 85, 471-80	15
1343	Observational studies, clinical trials, and the women's health initiative. 2007 , 13, 449-62	12
1342	Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. 2007 , 101, 125-34	68
1341	Progesterone, progestins, pregnancy and breast cancer risk. 2007 , 103, 373-4	
1340	Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter. 2007 , 106, 1-9	23
1339	The discovery and mechanism of action of letrozole. 2007 , 105 Suppl 1, 7-17	135
1338	Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer. 2007 , 18, 723-33	35
1337	Kardiovaskuläre Risiken unter HRT in der Postmenopause. 2007 , 5, 120-126	4
1336	Treatment and prevention of osteoporosis. 2007 , 157, 589-92	9
1335	Tibolone and osteoporosis. 2007 , 276, 577-81	5

1334	The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative. 2007 , 5, 153-9	22
1333	Effect of parathyroidectomy on osteoporosis and bone metabolism. 2007 , 5, 115-121	2
1332	Treatment of postmenopausal osteoporosis. 2007 , 33, 114-9	3
1331	Postmenopausal hormone therapy and cardiovascular disease: Making sense of the evidence. 2007 , 1, 138-147	5
1330	Bioidentical hormones for menopausal hormone therapy: variation on a theme. 2007 , 22, 1030-4	28
1329	Vrais et faux bñfices et risques des traitements hormonaux de la mhopause. 2007 , 2, 168-174	
1328	Wichtige Risikofaktoren hñufiger Erkrankungen von Frauen in der 2. Lebenshñfte. 2007 , 2, 26-30	2
1327	Phenolic phytochemicals and bone. 2008 , 7, 313-344	46
1326	Aktuelles zur Hormontherapie in der Peri- und Postmenopause. 2008 , 41, 209-214	
1325	Hormontherapie in den Wechseljahren. 2008 , 41, 858-864	
1324	Differenzierter Einsatz von Gestagenen in der Peri- und Postmenopause. 2008 , 41, 884-893	1
1323	Postmenopausale Hormontherapie und Mammakarzinomrisiko. 2008 , 41, 865-873	1
1322	Wirkungen der postmenopausalen Hormontherapie (HT) auf das Risiko ff gynkologische und kolorektale Karzinome. 2008 , 41, 874-878	
1321	The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden. 2008 , 19, 819-27	11
1320	Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. 2008 , 19, 449-58	317
1319	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. 2008 , 19, 399-428	688
1318	Effect of the women's health initiative on prescription anti-osteoporosis medication utilization. 2008 , 19, 1603-12	6
1317	Sex hormones, their receptors and bone health. 2008 , 19, 1517-25	60

1316	Progesterin and breast cancer. The missing pieces of a puzzle. 2008 , 51, 782-6	8
1315	The clinical management of BRCA1 and BRCA2 mutation carriers. 2008 , 10, 47-53	13
1314	New thoughts about estrogen therapy from the Women's Health Initiative. 2008 , 6, 108-13	
1313	Effects of ginkgo biloba on in vitro osteoblast cells and ovariectomized rat osteoclast cells. 2008 , 31, 216-24	18
1312	Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg. 2008 , 25, 525-51	10
1311	Update in women's health 2006-2007. 2008 , 23, 93-9	
1310	Use of oral contraceptives and postmenopausal hormone replacement: evidence on risk of stroke. 2008 , 10, 468-74	16
1309	Gynecologic cancers associated with Lynch syndrome/HNPCC. 2008 , 10, 313-7	40
1308	Hormonersatztherapie und kardiovaskuläre Erkrankungen. 2008 , 2, 435-448	
1307	Dietary fish oil results in a greater bone mass and bone formation indices in aged ovariectomized rats. 2008 , 26, 241-7	13
1306	Klassische Naturheilverfahren und Lebensführung im Klimakterium. 2008 , 6, 102-108	
1305	Cimicifuga, Johanniskraut und andere Phytotherapeutika im Klimakterium. 2008 , 6, 72-75	2
1304	Long-term impact of the women's health initiative on HRT. 2008 , 277, 219-24	33
1303	Changes in utilisation of hormone replacement therapy in Australia following publication of the findings of the Women's Health Initiative. 2008 , 17, 861-8	11
1302	Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. 2008 , 47, 1049-66	26
1301	Do female hormones affect the onset or severity of rheumatoid arthritis?. 2008 , 59, 299-301	11
1300	Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. 2008 , 59, 302-10	63
1299	Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. 2008 , 58, 1687-95	211

1298	Preventing cardiovascular disease in women: an update. 2008 , 31, 109-13	13
1297	Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. 2008 , 11 Suppl 1, 2-14	36
1296	The medical management of menopause: to treat or not to treat?. 2008 , 1127, 134-9	6
1295	Hormone therapy improves femur geometry among ethnically diverse postmenopausal participants in the Women's Health Initiative hormone intervention trials. 2008 , 23, 1935-45	22
1294	The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women. 2008 , 198, 265.e1-7	14
1293	Molecular markers and targets for colorectal cancer prevention. 2008 , 29, 1-20	83
1292	Hormone therapy, dilemmas, medical decisions. 2008 , 36, 73-88, 4	3
1291	Preventing coronary heart disease in women. 2008 , 62, 1299-300	
1290	Estradiol attenuates neuroprotective benefits of isoflurane preconditioning in ischemic mouse brain. 2008 , 28, 1824-34	17
1289	Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines. 2008 , 27, 2737-45	20
1288	Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. 2008 , 83, 702-10	30
1287	Osteoporosis and inflammation. 2007 , 65, S147-51	220
1286	Effects of long-term transdermal hormone replacement therapy on the renin-angiotensin-aldosterone system, plasma bradykinin levels and blood pressure in normotensive postmenopausal women. 2008 , 8, 259-64	26
1285	Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. 2008 , 10, 1135-56	41
1284	Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats. 2008 , 152, 21-7	27
1283	Primary hyperparathyroidism and the skeleton. 2008 , 69, 1-19	129
1282	The selective oestrogen receptor modulator, LY362321, is not neuroprotective in a rat model of transient focal ischaemia. 2008 , 20, 366-74	5
1281	Roles of oestrogen receptors alpha and beta in behavioural neuroendocrinology: beyond Yin/Yang. 2008 , 20, 873-9	64

1280	Issues concerning the use of hormone replacement therapy and risk of fracture: a population-based, nested case-control study. 2008 , 65, 123-9	4
1279	Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. 2008 , 29, 88-113	226
1278	Progesterone receptors: form and function in brain. 2008 , 29, 313-39	434
1277	Hormone replacement therapy and ovarian cancer risk: a meta-analysis. 2008 , 108, 641-51	91
1276	Experiences of a long-term randomized controlled prevention trial in a maiden environment: Estonian Postmenopausal Hormone Therapy trial. 2008 , 8, 51	
1275	Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials). 2008 , 102, 693-9	41
1274	Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. 2008 , 101, 1599-1605	49
1273	[Hormone replacement therapy and colorectal cancer]. 2008 , 32, 19-28	1
1272	Intravaginal oestrogen and progestin administration: advantages and disadvantages. 2008 , 22, 391-405	28
1271	Cognitive effects of hormonal therapy in older adults. 2008 , 35, 569-81	20
1270	Sex modulates intestinal transformation by the tumor-suppressor GCC. 2008 , 1, 150	
1269	Sex modulates intestinal transformation by the tumor-suppressor GCC. 2008 , 1, 146-50	
1268	Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. 2008 , 57, 1088-92	39
1267	Estrogen replacement therapy decreases plasma adiponectin but not resistin in postmenopausal women. 2008 , 57, 1509-15	25
1266	Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral. 2008 , 208, 1-24	38
1265	Translational approaches to addressing complex genetic pathways in colorectal cancer. 2008 , 151, 10-6	13
1264	Sex- and gender-based differences in healthy and diseased eyes. 2008 , 79, 636-52	21
1263	Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines--2007 Update. 2008 , 68, 339-58	4

1262	Red cardiovascular HERACLES. 2008 , 61, 66-75	6
1261	Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. 2008 , 7, 17	111
1260	Pathways to ischemic neuronal cell death: are sex differences relevant?. 2008 , 6, 33	138
1259	Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux. 2008 , 135, 72-81	18
1258	Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. 2008 , 135, 380-99	98
1257	The HERACLES Cardiovascular Network. 2008 , 61, 66-75	
1256	Exogenous and endogenous hormones and breast cancer. 2008 , 22, 573-85	58
1255	The effects of a web-based tool on patient-provider communication and satisfaction with hormone therapy: a randomized evaluation. 2008 , 17, 147-58	14
1254	Prevention and treatment of postmenopausal osteoporosis. 2008 , 35, 301-15, ix	34
1253	An update review of cellular mechanisms conferring the indirect and direct effects of estrogen on articular cartilage. 2008 , 11, 4-16	43
1252	HDL-C in post-menopausal women: An important therapeutic target. 2008 , 124, 275-82	16
1251	Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers. 2008 , 60, 71-7	2
1250	Hormone therapy use in the South African public and private sectors 2001-2005. 2008 , 60, 182-4	1
1249	Risks of hormone therapy in the 50-59 year age group. 2008 , 60, 59-64	13
1248	beta-Sitosterol modulation of monocyte-endothelial cell interaction: a comparison to female hormones. 2008 , 60, 202-8	16
1247	Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. 2008 , 60, 185-201	76
1246	Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2005. 2008 , 61, 299-304	31
1245	Reprint of The Herbal Alternatives for Menopause (HALT) Study: background and study design. 2008 , 61, 181-93	6

1244	Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. 2008 , 283, 49-57	144
1243	Differing transcriptional responses to pulsed or continuous estradiol exposure in human umbilical vein endothelial cells. 2008 , 111, 41-9	5
1242	[Prevention of coronary heart disease by early postmenopausal hormone therapy: new supporting data]. 2008 , 37, 340-5	
1241	Differential effects on visual and spatial recognition memory of a novel hormone therapy regimen of estrogen alone or combined with progesterone in older surgically menopausal monkeys. 2008 , 154, 1205-17	29
1240	Anti-resorptive therapies for osteoporosis. 2008 , 19, 473-8	62
1239	Molecular characterization of a B-ring unsaturated estrogen: implications for conjugated equine estrogen components of premarin. 2008 , 73, 59-68	26
1238	Challenges to defining a role for progesterone in breast cancer. 2008 , 73, 914-21	47
1237	Can menopausal hormone therapy prevent coronary heart disease?. 2008 , 19, 206-12	11
1236	Progesterone and breast cancer. 2008 , 4, 151-62	49
1235	Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial. 2008 , 42, 294-306	23
1234	Inducible nitric oxide synthase and estradiol exhibit complementary neuroprotective roles after ischemic brain injury. 2008 , 210, 782-7	18
1233	Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. 2008 , 90, 642-72	50
1232	Perspectives on hormone replacement therapy: the Women's Health Initiative and new observational studies sampling the overall population. 2008 , 90, 258-64	19
1231	Estrogen and progestogen therapy in postmenopausal women. 2008 , 90, S88-102	21
1230	Hormone replacement therapy and the risk of breast cancer. 2008 , 44, 2344-9	36
1229	[Hormone replacement therapy: the pros]. 2008 , 36, 98-103	1
1228	[The risk of getting breast cancer after hormonal replacement therapy for menopause is stopped]. 2008 , 36, 1067-9	
1227	[Hormonal carcinogenesis in women: from mechanisms to prevention]. 2008 , 331, 104-13	5

1226	Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. 2008 , 69, 318-33	9
1225	Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. 2008 , 109, 11-5	30
1224	Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. 2008 , 201, 76-84	17
1223	Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). 2008 , 4, S7-S14	25
1222	Menopause. 2008 , 371, 760-70	451
1221	Menopause and the menopausal transition. 2008 , 92, 1253-71, xii	24
1220	Women's perception of the efficacy of a soy extract with probiotic: the M3 study. 2008 , 24, 178-83	14
1219	Joint position statement of the Polish Cardiologic Society, the Polish Gynaecological Society and the Polish Menopause and Andropause Society on the effect of postmenopausal hormone replacement therapy on the cardiovascular system. 2008 , 24, 261-6	
1218	The effect of different preparations of hormone therapy on tumor necrosis factor-alpha levels in women with surgical menopause. 2008 , 24, 79-83	2
1217	Abstracts of the 12th World Congress on the Menopause. 2008 , 11 Suppl 2, 3-304	1
1216	Update on hormones, menopause, and heart disease: evaluating professional responses to the Women's Health Initiative. 2008 , 29, 720-37	8
1215	IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. 2008 , 8, 1377-85	48
1214	Isoflavones and clinical cardiovascular risk factors in obese postmenopausal women: a randomized double-blind placebo-controlled trial. 2008 , 17, 1363-9	20
1213	Prevention of postmenopausal osteoporosis and associated fractures: Clinical evaluation of the choice between estrogen and bisphosphonates. 2008 , 24, 601-9	12
1212	Secular trends in cardiovascular risk factors with a 36-year perspective: observations from 38- and 50-year-olds in the Population Study of Women in Gothenburg. 2008 , 26, 140-6	39
1211	Stroke among women, ethnic groups, young adults, and children. 2009 , 92, 337-53	2
1210	Hormone therapy in postmenopausal osteoporosis: 2008. 2008 , 13, 8-12	1
1209	Stability evaluation of selected polyphenols and triterpene glycosides in black cohosh. 2008 , 56, 9510-9	10

1208	Calcium plus vitamin D supplementation and the risk of breast cancer. 2008 , 100, 1581-91	332
1207	Menopausal women's perceived causes of hot flash. 2008 , 29, 755-65	2
1206	Selective estrogen receptor modulators accelerate cutaneous wound healing in ovariectomized female mice. 2008 , 149, 551-7	86
1205	Commentary: Hormone therapy and breast cancer incidence: did epidemiologists miss an effect on national trends?. 2008 , 37, 638-40	1
1204	17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women. 2008 , 51, 1190-6	9
1203	Obituary: Professor Norman Morris. 2008 , 34, 190-190	
1202	Oral contraceptives, hormone therapy and cardiovascular risk. 2008 , 11, 355-63	12
1201	Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. 2008 , 26, 1650-6	48
1200	Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. 2008 , 17, 3150-60	63
1199	Sex differences in stroke. 2008 , 26, 462-74	114
1198	Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. 2008 , 17, 655-60	59
1197	Osteoporosis primer for the vertebroplasty practitioner: expanding the focus beyond needles and cement. 2008 , 29, 1816-22	9
1196	Time since menopause influences the acute and chronic effect of estrogens on endothelial function. 2008 , 28, 348-52	63
1195	The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. 2008 , 149, 6084-91	109
1194	Is research on hormones and aging finished? No! Just started!. 2008 , 63, 696-7	8
1193	Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate. 2008 , 149, 3952-9	18
1192	The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. 2008 , 22, 2743-50	25
1191	Cancer and cholesterol: understanding the V-shaped association in patients with diabetes. 2008 , 179, 403-4	5

1190	Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. 2008 , 29, 2031-41	134
1189	Hormone therapy and risk of myocardial infarction: a national register study. 2008 , 29, 2660-8	85
1188	Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. 2009 , 30, 866-7	3
1187	Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. 2008 , 74, 370-6	47
1186	Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. 2008 , 168, 2245-53	60
1185	Indications and limitations of third-generation aromatase inhibitors. 2008 , 17, 723-39	15
1184	Toward optimal health: managing women's medical challenges in midlife. 2008 , 17, 1551-4	
1183	Redefining quality--implications of recent clinical trials. 2008 , 358, 2537-9	62
1182	The women's health initiative: lessons learned. 2008 , 29, 131-50	57
1181	Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents. 2008 , 11, 74-83	14
1180	Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats. 2008 , 105, 3527-32	30
1179	Estrogen plus progestin and risk of benign proliferative breast disease. 2008 , 17, 2337-43	29
1178	Menopause and hypertension: an age-old debate. 2008 , 51, 952-9	163
1177	Effect of ovariectomy on cardiac gene expression: inflammation and changes in SOCS gene expression. 2008 , 32, 254-63	31
1176	Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. 2008 , 19, 1669-80	78
1175	Primary prevention of coronary heart disease in women. 2008 , 14, 40-5	20
1174	ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults. 2008 , 65, 343-357	7
1173	Hormones and cardiovascular disease. 2008 , 24, 483-4	2

1172	Coronary heart disease and HRT in France: MISSION study prospective phase results. 2008 , 24, 696-700	2
1171	Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. 2008 , 167, 1207-16	111
1170	Vascular actions of estrogens: functional implications. 2008 , 60, 210-41	368
1169	Hormonal influences in multiple sclerosis. 2008 , 318, 267-311	15
1168	The World Health Organization defines hormone replacement therapy as carcinogenic: is this plausible?. 2008 , 24, 129-32	6
1167	Effects of gender and sex steroids on ischemic injury. 2009 , 92, 149-69	2
1166	Oestrogen plays a permissive role in cardioprotection. 2008 , 79, 353-4	3
1165	Causation, bias and confounding: a hitchhiker's guide to the epidemiological galaxy Part 2. Principles of causality in epidemiological research: confounding, effect modification and strength of association. 2008 , 34, 185-90	21
1164	Epidemiology of cytokines: the Women On the Move through Activity and Nutrition (WOMAN) Study. 2008 , 168, 443-53	26
1163	Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. 2008 , 17, 1082-7	36
1162	Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. 2008 , 117, 3031-8	220
1161	Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. 2008 , 100, 475-82	215
1160	Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. 2008 , 100, 563-71	46
1159	Long-term drug prevention trials. 2008 , 5, 168-76	2
1158	Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. 2008 , 167, 1407-15	111
1157	A Lifestyle Approach for Primary Cardiovascular Disease Prevention in Perimenopausal to Early Postmenopausal Women. 2008 , 2, 421-431	2
1156	Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women. 2008 , 51, 1115-22	42
1155	Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. 2008 , 17, 2609-18	76

1154	Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?. 2008 , 13, 222-31	54
1153	Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. 2008 , 17, 43-50	57
1152	Stroke and the female brain. 2008 , 4, 22-33	67
1151	The effects of tibolone in older postmenopausal women. 2008 , 359, 697-708	308
1150	Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women. 2008 , 93, 3082-7	21
1149	Approach to the patient with menopausal symptoms. 2008 , 93, 4567-75	42
1148	Management of Parkinson's disease in older women. 2008 , 14, 38-9	2
1147	Estrogen agonists/antagonists in combination with estrogen for prevention and treatment of menopause-associated signs and symptoms. 2008 , 4, 257-68	11
1146	Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. 2008 , 100, 1361-7	152
1145	Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials. 2008 , 28, 1666-71	46
1144	Seladin-1 is a fundamental mediator of the neuroprotective effects of estrogen in human neuroblast long-term cell cultures. 2008 , 149, 4256-66	59
1143	A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. 2008 , 93, 1702-10	58
1142	Cardiovascular risk in women with nonspecific chest pain. 2008 , 4, 561-4	2
1141	Premenopausal oophorectomy and the risk for dementia. 2008 , 4, 127-31	4
1140	The Influence of reproductive status and age on women's sleep. 2008 , 17, 1209-14	31
1139	Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. 2008 , 336, 1227-31	346
1138	Hormonal treatment, mild cognitive impairment and Alzheimer's disease. 2008 , 20, 47-56	45
1137	Lifetime hormonal factors may predict late-life depression in women. 2008 , 20, 1203-18	24

1136	Factors Associated With 5-Year Risk of Hip Fracture in Postmenopausal Women. 2008 , 2008, 196-198	
1135	Possible involvement of altered arginase activity, arginase type I and type II expressions, and nitric oxide production in occurrence of intimal hyperplasia in premenopausal human uterine arteries. 2008 , 106, 385-93	15
1134	Hormone replacement therapy: risks and benefits. 2008 , 6, 433-439	3
1133	Estrogens, progestins, and risk of breast cancer. 2007 , 127-50	9
1132	Barriers and motivations for women to participate in cardiovascular trials. 2008 , 30, 332-337	19
1131	When hormone therapy sneaks under your nose. 2008 , 15, 215-6	3
1130	Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. 2008 , 15, 639-47	44
1129	Symptoms of menopause: hot flushes. 2008 , 51, 539-48	41
1128	Postmenopausal hormone therapy and cardiovascular disease in perspective. 2008 , 51, 564-80	31
1127	Low-dose estradiol gel 0.1% for the treatment of vasomotor symptoms associated with menopause. 2008 , 3, 155-162	
1126	Hormone replacement therapy post Women's Health Initiative study: where do we stand?. 2008 , 20, 513-8	13
1125	Perceptions of and attitudes toward estrogen therapy among surgically menopausal women in Taiwan. 2008 , 15, 517-23	9
1124	Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. 2008 , 15, 1145-50	7
1123	Agreement of self-reported estrogen use with prescription data: an analysis of women from the Kuopio Osteoporosis Risk Factor and Prevention Study. 2008 , 15, 282-9	27
1122	Effects of alcohol and cigarette smoking on change in serum estrone levels in postmenopausal women randomly assigned to fixed doses of conjugated equine estrogens with or without a progestin. 2008 , 15, 382-5	6
1121	On redefining the relationship of the hot flash to the health of peri-and postmenopausal women. 2008 , 15, 821-2	
1120	Low-Dose Transdermal Estrogens. 2008 , 111, 209-211	
1119	Medroxyprogesterone acetate inhibits proliferation of colon cancer cell lines by modulating cell cycle-related protein expression. 2008 , 15, 442-53	15

1118	Sex hormones and circulating lipoprotein levels. 2008 , 3, 603-606	3
1117	Data analysis methods and the reliability of analytic epidemiologic research. 2008 , 19, 785-8; discussion 789-93	7
1116	B-type natriuretic peptide after hormone therapy in postmenopausal women with chest pain and normal coronary angiogram. 2008 , 15, 352-6	13
1115	Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. 2008 , 15, 248-55	6
1114	Hormone therapy initiation after the Women's Health Initiative. 2008 , 15, 487-93	12
1113	Progestins oppose the effects of estradiol on the endothelin-1 receptor type B in coronary arteries from ovariectomized hyperlipidemic rabbits. 2008 , 15, 503-10	17
1112	Effects of phytoestrogens derived from red clover on atherogenic adhesion molecules in human endothelial cells. 2008 , 15, 542-50	18
1111	Soy isoflavones in the management of postmenopausal osteoporosis. 2008 , 15, 748-57	60
1110	Beyond frequency: who is most bothered by vasomotor symptoms?. 2008 , 15, 841-7	115
1109	Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease. 2008 , 15, 1060-4	6
1108	Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. 2008 , 15, 584-602	146
1107	Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy. 2008 , 15, 875-84	21
1106	Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence. 2008 , 3, 1-8	16
1105	Clinical Trials. 2008 , 744-754	
1104	Women's Health Initiative Hormone Therapy Trials. 2008 , 1	
1103	Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies. 2009 , 2, 193-202	25
1102	Who Should Be Screened: Who Should Be Treated?. 2008 , 1449-1460	
1101	Raloxifene for older women: a review of the literature. 2008 , 3, 45-50	21

1100	Calcium supplementation and cancer incidence. 2008 , 87, 792-793	10
1099	Hormone-replacement therapy and lobular cancers: new deals and old myths. 2008 , 3, 287-290	1
1098	Hormone-dependent aging problems in women. 2008 , 49, 345-51	11
1097	New Approaches to Osteoporosis Therapeutics. 2008 , 1837-1895	
1096	[Hormone therapy and risk of venous thromboembolism: new insights from the ESTHER study]. 2008 , 24, 228-31	
1095	Proliferation of the superficial epithelium of ovaries in senile female rats following oral administration of conjugated equine estrogens. 2008 , 63, 381-8	7
1094	The Pharmacology of Estrogens in Osteoporosis. 2008 , 1769-1775	
1093	Modulateurs sélectifs du récepteur de la progestérone (SPRMs): perspectives médicales. 2008 , 192, 1159-1173	1
1092	Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. 2010 , 1, 11-20	15
1091	Diagnosis and management of osteoporosis in the older senior. 2009 , 4, 121-36	33
1090	Treating postmenopausal osteoporosis in women at increased risk of fracture - critical appraisal of bazedoxifene: a review. 2010 , 1, 97-103	4
1089	The benefits of oestrogen following menopause: why hormone replacement therapy should be offered to postmenopausal women. 2009 , 190, 321-5	32
1088	Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. 2009 , 5, 817-27	12
1087	Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. 2009 , 338, b81	95
1086	Women's Health Initiative Memory Study (WHIMS) program: emerging findings. 1-10	
1085	Identifying risk factors for cognitive change in the Women's Health Initiative: a neural networks approach. 11-24	1
1084	Estrogen therapy and relationship to longevity and prevalent dementia in the oldest-old: the Leisure World Cohort Study and the 90+ Study. 25-31	
1083	The effect of gonadectomy and estradiol on sensitivity to oxidative stress. 2009 , 34, 43-58	23

1082	Hormone therapy and colorectal cancer. 2009 , 12, 89-90	
1081	Effects of drospirenone on cardiovascular markers in human aortic endothelial cells. 2009 , 12, 80-7	15
1080	Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women. 2009 , 12 Suppl 1, 66-70	9
1079	Flaxseed does not antagonize the effect of ultra-low-dose estrogen therapy on bone mineral density and biomechanical bone strength in ovariectomized rats. 2009 , 72, 1209-16	8
1078	Hormone therapy and risk of venous thromboembolism among postmenopausal women. 2009 , 12 Suppl 1, 76-80	13
1077	Progesterone as a neuroprotective factor in traumatic and ischemic brain injury. 2009 , 175, 219-37	153
1076	Cost-effectiveness of hormone therapy in the United States. 2009 , 18, 1669-77	19
1075	Individualized therapy for osteoporosis prevention and treatment in women under 60. 2009 , 12, 210-2	4
1074	Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk. 2009 , 170, 1241-9	15
1073	Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. 2009 , 119, 922-30	89
1072	Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. 2009 , 170, 24-8	48
1071	Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. 2009 , 23, 74-85	53
1070	Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis. 2009 , 12, 427-30	4
1069	Progestin may modify the effect of low-dose hormone therapy on mammographic breast density. 2009 , 12, 240-7	3
1068	Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. 2009 , 29, 13823-36	209
1067	Heart failure in women: epidemiology, biology and treatment. 2009 , 5, 517-27	20
1066	Delayed wound healing in elderly people. 2009 , 19, 171-184	4
1065	Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. 2009 , 27, 6135-43	52

1064	Mammographic screening and risk factors for breast cancer. 2009 , 170, 1422-32	40
1063	Trends and determinants of prescription medication use for treatment of osteoporosis. 2009 , 66, 1191-201	12
1062	New Therapies for Osteoporosis. 2009 , 22, 53-64	2
1061	Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. 2009 , 18, 3079-85	51
1060	Cardiovascular effects of noncardiovascular drugs. 2009 , 120, 1123-32	17
1059	Hormone replacement therapy and cardiovascular disease revisited. 2009 , 15, 55-7	17
1058	Long-term prevention with hormone-replacement therapy after the menopause: which women should be targeted?. 2009 , 5, 637-47	9
1057	Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen. 2009 , 24, 1739-47	5
1056	Use of hormone replacement therapy and the risk of colorectal cancer. 2009 , 27, 4542-7	64
1055	Postmenopausal hormone therapy and the risk of cardiovascular disease. 2009 , 10, 2041-53	4
1054	Sex differences in caspase activation after stroke. 2009 , 40, 1842-8	124
1053	Long term hormone therapy for perimenopausal and postmenopausal women. 2009 , CD004143	46
1052	Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. 2009 , 113, 65-73	134
1051	Estradiol is a potent protective, restorative, and trophic factor after brain injury. 2009 , 27, 240-9	58
1050	Advances in the treatment of menopausal symptoms. 2009 , 5, 361-384; quiz 383-4	33
1049	Stroke in women: an evolving topic. 2009 , 40, 1027-8	14
1048	References. 2009 , 76, S121-S130	2
1047	Statistical methods in pharmacoepidemiology: advances and challenges. 2009 , 18, 3-6	6

1046	Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. 2009 , 94, 4152-61		83
1045	Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 774-80	27.4	206
1044	The potential for estrogens in preventing Alzheimer's disease and vascular dementia. 2009 , 2, 31-49		52
1043	Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. 2009 , 9, 481-99		95
1042	Does tibolone reduce the risk of fracture in older postmenopausal women with osteoporosis?. 2009 , 5, 128-9		1
1041	Perspectives on the soy-breast cancer relation. 2009 , 89, 1673S-1679S		95
1040	Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. 2009 , 72, 135-42		173
1039	Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK. 2009 , 15, 19-25		8
1038	Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. 2009 , 18, 1531-7		51
1037	Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. 2009 , 72, 125-34		76
1036	Stroke Prevention. 2009 , 581-604		
1035	Smoking may be considered an established risk factor for sporadic ALS. 2009 , 73, 1693-8		117
1034	Postmenopausal levels of endogenous sex hormones and risk of colorectal cancer. 2009 , 18, 275-81		67
1033	Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. 2009 , 18, 2835-41		35
1032	Limited evidence for a protective effect of unopposed oestrogen therapy for osteoarthritis of the hip: a systematic review. 2009 , 48, 104-12		39
1031	Cancer prevention: from 1727 to milestones of the past 100 years. 2009 , 69, 5269-84		94
1030	Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium. 2009 , 76113, S50-99		19
1029	Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. 2009 , 297, H1806-13		179

1028	Estrogen, aging and the cardiovascular system. 2009 , 5, 93-103	45
1027	Why are physicians reluctant to use estrogens for anything--or do they prefer 'PROFOX'?. 2009 , 15, 52-4	6
1026	Interference of progestins with endothelial actions of estrogens: a matter of glucocorticoid action or deprivation?. 2009 , 29, 441-3	4
1025	Steroid sulfatase and estrogen sulfotransferase in colon carcinoma: regulators of intratumoral estrogen concentrations and potent prognostic factors. 2009 , 69, 914-22	44
1024	Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. 2009 , 170, 12-23	165
1023	Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. 2009 , 53, 805-11	123
1022	Estrogen decreases atherosclerosis in part by reducing hepatic acyl-CoA:cholesterol acyltransferase 2 (ACAT2) in monkeys. 2009 , 29, 1471-7	32
1021	Reassessing Benefits and Risks of Hormone Therapy. 2009 , 3, 29-43	3
1020	Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone. 2009 , 15, 341-58	26
1019	Menopausal hormone therapy and risk of colorectal cancer. 2009 , 18, 196-203	79
1018	Low-fat, increased fruit, vegetable, and grain dietary pattern, fractures, and bone mineral density: the Women's Health Initiative Dietary Modification Trial. 2009 , 89, 1864-76	60
1017	Brain volumes, cognitive impairment, and conjugated equine estrogens. 2009 , 64, 1243-50	29
1016	Bioidentical Hormones, Compounding, and Evidence-Based Medicine: What Women's Health Practitioners Need to Know. 2009 , 5, 421-427	5
1015	Preventing and Treating Osteoporosis: Pharmacologic and Nonpharmacologic Approaches. 2009 , 5, S13-S20	2
1014	Novel pathogenic insights in the primary prevention of cardiovascular disease. 2009 , 51, 503-23	19
1013	Use of gabapentin in patients experiencing hot flashes. 2009 , 29, 74-81	21
1012	Prevalence and impact of vaginal symptoms among postmenopausal women. 2009 , 6, 2133-42	227
1011	Estrogens, MSI and Lynch syndrome-associated tumors. 2009 , 1796, 194-200	7

1010	Cancer issues. 2009 , 23, 87-107	9
1009	Menopause and menopause transition. Preface and introduction. 2009 , 23, 1-6	2
1008	HRT and cardiovascular disease. 2009 , 23, 109-20	27
1007	Effects of two years of conjugated equine estrogens on cholinergic neurons in young and middle-aged ovariectomized monkeys. 2009 , 1264, 13-23	9
1006	[Dyslipidemia in women after 50: age, menopause or both?]. 2009 , 58, 159-64	5
1005	[Should we change our attitude on postmenopausal hormone replacement therapy?]. 2009 , 41, 295-7	1
1004	Osteoporosis in males and females: Is there really a difference?. 2009 , 76, 595-601	48
1003	Breast Cancer in Young Women and its Impact on Reproductive Function. 2009 , 6, 200-208	4
1002	Moduladores del receptor de la progesterona. 2009 , 45, 1-12	
1001	Coronary heart disease of females: lessons learned from nonhuman primates. 2009 , 71, 785-93	45
1000	Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. 2009 , 115, 936-45	50
999	Ostôporose de lâhomme et de la femme : est-ce vraiment diffffent ?. 2009 , 76, 952-958	
998	The Women's Health Initiative Randomized Controlled Dietary Modification Trial: a post-mortem. 2009 , 114, 1-6	24
997	Menstrual and reproductive history, postmenopausal hormone use, and risk of benign proliferative epithelial disorders of the breast: a cohort study. 2009 , 114, 113-20	10
996	Hormone therapy in relation to survival from large bowel cancer. 2009 , 20, 409-16	14
995	Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. 2009 , 8, 23-8	33
994	Sporadic breast, ovarian, or uterine cancers as risk factors for colorectal cancer. 2009 , 5, 24-29	0
993	17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice. 2009 , 2, 289-99	39

992	Women and heart disease: neglected directions for future research. 2009 , 2, 256-7	4
991	Menopausal hormone therapy for cardiovascular protection--unfulfilled expectations. 2009 , 2, 286-8	2
990	Different forms of oestrogen rapidly upregulate cell proliferation in the dentate gyrus of adult female rats. 2009 , 21, 155-66	83
989	No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy. 2009 , 86, 416-24	43
988	Dose-related neuroprotective versus neurodamaging effects of estrogens in rat cerebral ischemia: a systematic analysis. 2009 , 29, 1359-72	73
987	Evidence-based review of therapies at the menopause. 2009 , 7, 112-23	28
986	Longitudinal assessment of the effects of oestrogen on blood pressure and cardiovascular autonomic activity in female rats. 2009 , 36, 1002-9	25
985	Differential effects of medroxyprogesterone acetate on thrombosis and atherosclerosis in mice. 2009 , 158, 1951-60	8
984	Women's health in menopause with a focus on hypertension. 2009 , 17, 68-72	66
983	Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study. 2009 , 200, 72.e1-7	35
982	Effects of Sex Steroids on Damaged Neural Systems. 2009 , 2223-2260	6
981	Reproductive Aging of Females: Neural Systems. 2009 , 2199-2224	8
980	Estrogen receptor actions on vascular biology and inflammation: implications in vascular pathophysiology. 2009 , 12 Suppl 1, 12-7	22
979	Targeting the redox sensitive Nrf2-Keap1 defense pathway in cardiovascular disease: protection afforded by dietary isoflavones. 2009 , 9, 139-45	123
978	Discrepancy between results of randomized control studies and retrospective analysis: the case of statin therapy effect on one-year mortality in patients with decompensated heart failure. 2009 , 20, 494-8	4
977	Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial. 2009 , 142, 139-44	13
976	Menopausal estrogen deprivation activates steroid sensitive stem cells (3SC) and local estrogen biosynthesis: A model for breast cancer development. 2009 , 2, 252-256	3
975	Epimedium-derived flavonoids promote osteoblastogenesis and suppress adipogenesis in bone marrow stromal cells while exerting an anabolic effect on osteoporotic bone. 2009 , 45, 534-44	70

974	Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause. 2009 , 92, 605-12	18
973	Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. 2009 , 92, 1045-1052	187
972	Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis. 2009 , 92, 403-12	12
971	Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women's Health Initiative era. 2009 , 92, 1171-1186	104
970	Lípidos y lipoproteínas en pacientes menopáusicas tratadas con diosgenina. 2009 , 36, 82-86	
969	Conservación de los ovarios frente a ooforectomía bilateral en pacientes sometidas a histerectomía por procesos benignos. 2009 , 36, 94-98	
968	Progesterone and medroxyprogesterone acetate differentially regulate alpha4 subunit expression of GABA(A) receptors in the CA1 hippocampus of female rats. 2009 , 97, 58-61	26
967	Estrone and progesterone inhibit the growth of murine MC38 colon cancer line. 2009 , 113, 75-9	10
966	Effects of raloxifene and hormone replacement therapy on forearm skin elasticity in postmenopausal women. 2009 , 62, 53-7	16
965	Progestogens and target tissues: vascular systems. 2009 , 62, 356-61	6
964	Preventive cardiology and cardiac rehabilitation programmes in women. 2009 , 63, 28-33	12
963	Diabetes and the menopause. 2009 , 63, 200-3	22
962	Health correlates and mode of administration of hormones--are there any differences between parenteral and oral estrogen preparations?. 2009 , 64, 228-34	1
961	Use of dydrogesterone in hormone replacement therapy. 2009 , 65 Suppl 1, S51-60	10
960	Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. 2009 , 65 Suppl 1, S3-11	40
959	On the possible role of mammary-derived growth hormone in human breast cancer. 2009 , 65 Suppl 1, S13-6	4
958	Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal. 2009 , 62, 695-702	38
957	Ethics in clinical research. 2009 , 51, 792-7	20

956	Microcirculatory function in postmenopausal women: role of aging, hormonal exposure and metabolic syndrome. 2009 , 78, 405-12	14
955	The cost-effectiveness of hormone therapy in younger and older postmenopausal women. 2009 , 122, 42-52.e2	55
954	Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. 2009 , 122, 1016-1022.e1	117
953	Undertreatment of menopausal symptoms and novel options for comprehensive management. 2009 , 25, 2689-98	38
952	Contraceptive hormone use and cardiovascular disease. 2009 , 53, 221-31	186
951	Hormone replacement therapy: a 2008 perspective. 2009 , 19, 13-18	5
950	Bone signaling pathways and treatment of osteoporosis. 2009 , 4, 639-650	11
949	Gender differences in the cardiovascular effect of sex hormones. 2009 , 6, 532-42	221
948	Androgens and the breast. 2009 , 11, 212	115
947	Postmenopausal estrogen and progestin effects on the serum proteome. 2009 , 1, 121	29
946	Using a global proteomic approach to identify proteins affected by estrogen therapy. 2009 , 1, 58	0
945	Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. 2009 , 1, 47	34
944	Progress in osteoporosis and fracture prevention: focus on postmenopausal women. 2009 , 11, 251	29
943	The Breast. 2009 , 235-248	0
942	Influence of menopause on diabetes and diabetes risk. 2009 , 5, 553-8	104
941	[Review of current treatment for hot flushes induced by androgen deprivation in prostate carcinoma]. 2009 , 33, 337-43	
940	Le traitement hormonal de la mēopause : aprē sept ans de polēmiques. 2009 , 1, 31-37	
939	Breast cancer in young women and its impact on reproductive function. 2009 , 15, 323-39	110

938	Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60. 2009 , 12, 206-9	16
937	Estrogen and mechanisms of vascular protection. 2009 , 29, 289-95	237
936	Estrogen actions in the cardiovascular system. 2009 , 12 Suppl 1, 18-21	35
935	Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. 2009 , 12, 514-24	35
934	Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. 2009 , 94, 3132-54	728
933	Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. 2009 , 25, 807-15	21
932	Is HRT still indicated for the primary prevention of osteoporosis?. 2009 , 25, 629-33	1
931	Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. 2009 , 12, 230-9	44
930	Vaginal estrogen therapy for the treatment of atrophic vaginitis. 2009 , 18, 1595-606	48
929	Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. 2009 , 18, 1615-26	40
928	Emerging drugs for postmenopausal osteoporosis. 2009 , 14, 129-44	20
927	Neither antioxidants nor genistein inhibit the progression of established atherosclerotic lesions in older apoE deficient mice. 2009 , 203, 82-8	18
926	Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women. 2009 , 205, 325-30	19
925	Coronary heart disease and menopause management: the swinging pendulum of HRT. 2009 , 207, 336-40	46
924	Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: Eisen A, Lubinski J, Gronwald J, et al (Sunnybrook Regional Cancer Ctr, Toronto, Ontario, Canada; Pomeranian Med Univ, Szczecin, Poland; et al) J Natl Cancer Inst 100:1361-1367, 2008. 2009 , 20, 101-102	
923	Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626. 2009 , 20, 211-212	
922	Impact of hormone therapy for women aged 35 to 65 years, from contraception to hormone replacement. 2009 , 6 Suppl 1, 37-59	15
921	Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. 2009 , 16, 500-8	16

920	A novel animal model to study hot flashes: no effect of gonadotropin-releasing hormone. 2009 , 16, 1030-6	6
919	The complex interplay of vasomotor symptoms, hormone therapy, and cardiovascular risk. 2009 , 16, 619-20	6
918	Role of ezetimibe in the management of patients with atherosclerosis. 2009 , 20, 169-74	6
917	An update on osteoporosis. 2009 , 16, 437-45	5
916	Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women's Health Across the Nation. 2009 , 16, 257-64	63
915	Type 2 diabetes mellitus and other cardiovascular risk factors are no more common during menopause: longitudinal study. 2009 , 16, 817-21	30
914	Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. 2009 , 16, 132-40	20
913	Provider attributes associated with hormone therapy prescribing frequency. 2009 , 16, 810-16	5
912	Short-term (1-2 mo) hormone therapy cessation before mammography. 2009 , 16, 1125-31	6
911	Postmenopausal hormone therapy and the risk of cardiovascular disease. 2009 , 10, 303-9	8
910	Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer. 2009 , 113, 74-80	50
909	Duration of vasomotor symptoms in middle-aged women: a longitudinal study. 2009 , 16, 453-7	97
908	Hormone replacement therapy: real concerns and false alarms. 2009 , 15, 93-104	22
907	Pharmacotherapeutic management of osteoporosis and osteopenia. 2009 , 34, 30-40; quiz 41	8
906	Bone mineral density, arterial stiffness, and coronary atherosclerosis in healthy postmenopausal women. 2009 , 16, 937-43	45
905	MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flashes: a phase II clinical trial. 2009 , 16, 458-65	46
904	Flaxseed combined with low-dose estrogen therapy preserves bone tissue in ovariectomized rats. 2009 , 16, 545-54	35
903	The need for evidence-based medicine to be integrated into clinical practice: role of the North American Menopause Society. 2009 , 16, 438-41	1

902	A tissue selective estrogen complex: a new horizon for menopausal symptoms. 2009 , 16, 1083-4	3
901	Sexual ramifications of medical illness. 2009 , 52, 691-701	7
900	The role of flow-mediated dilatation in the evaluation and development of antiatherosclerotic drugs. 2009 , 20, 460-6	16
899	Gender considerations in stroke management. 2009 , 15, 132-41	5
898	Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. 2009 , 10, 85-92	23
897	Age at natural menopause and risk of ischemic stroke: the Framingham heart study. 2009 , 40, 1044-9	164
896	Cardiovascular Disease. 2009 , 31, S11-S18	
895	Modulateurs du r�cepteur de la progest�rone. 2009 , 4, 1-11	
894	Bone Health. 2009 , 31, S34-S41	1
893	Delivery may affect arterial elasticity in women. 2009 , 73, 750-4	11
892	[Carcinogenesis theory based on estrogen deficiency]. 2009 , 150, 1155-66	1
891	Bringing the Women's Health Initiative to the Patient Level in the Age of Informed Consent. 2009 , 29, 1-5	
890	Changes in postmenopausal hormone replacement therapy use among women with high cardiovascular risk. 2009 , 99, 2184-7	7
889	Vulvovaginal atrophy: new and upcoming approaches. 2009 , 16, 5-7	8
888	Mood, Memory, and Cognition. 2009 , 31, S31-S33	
887	Research into Specific Modulators of Vascular Sex Hormone Receptors in the Management of Postmenopausal Cardiovascular Disease. 2009 , 5, 283-306	14
886	Association of oral but not transdermal estrogen therapy with enhanced platelet reactivity in a subset of postmenopausal women. 2009 , 16, 407-12	7
885	Association between serum estradiol level and coronary artery calcification in postmenopausal women. 2010 , 17, 902-7	25

884	Dietary vitamin D and calcium intake and mammographic density in postmenopausal women. 2010 , 17, 1152-60	15
883	Rationale for routine and immediate administration of intravenous estrogen for all critically ill and injured patients. 2010 , 38, S620-9	25
882	Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. 2010 , 70, 1722-30	64
881	Mhopause. 2010 , 7, 1-19	1
880	Role of hormone therapy in the management of menopause. 2010 , 115, 839-855	59
879	Benign breast disease. 2010 , 116, 747-758	49
878	Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: a double-blind, placebo-controlled study. 2010 , 17, 303-8	9
877	Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. 2010 , 17, 25-54; quiz 55-6	318
876	Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. 2010 , 17, 1122-7	40
875	Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. 2010 , 17, 457-63	86
874	Efficacy and tolerability of local estrogen therapy for urogenital atrophy. 2010 , 17, 194-203	95
873	Estradiol gel 0.1% relieves vasomotor symptoms independent of age, ovarian status, or uterine status. 2010 , 17, 1167-73	1
872	Vasomotor symptoms and coronary artery calcium in postmenopausal women. 2010 , 17, 1136-45	34
871	Evaluating the safety and effectiveness of new drugs. 2010 , 116, 1405-1409	3
870	Antiaging medicine: what should we tell our patients?. 2010 , 6, 149-154	
869	Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. 2010 , 17, 946-54	47
868	Clinical update on hormone replacement therapy. 2010 , 19, 496, 498-504	1
867	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. 2010 , 16 Suppl 3, 1-37	263

866	In the clinic. Breast cancer screening and prevention. 2010 , 152, ITC41	6
865	Prospective study of endogenous circulating estradiol and risk of stroke in older women. 2010 , 67, 195-201	43
864	Laparoscopic ovarian transposition before pelvic irradiation: a Saudi tertiary center experience. 2010 , 20, 1082-6	27
863	Human breast cancer stem cells and sex hormones-a narrative review. 2010 , 17, 801-810	10
862	Complexities of oestrogen in stroke. 2009 , 118, 375-89	18
861	Progestogens for hot flushes. 2010 ,	
860	Anti-Aging Medicine in Cardiovascular Disease. 2010 , 7, 45-49	
859	Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. 2010 , 170, 1678-85	36
858	The Women's Health Initiative Study: individualisation of hormone replacement therapy in a defined South African population. 2010 , 16, 115-122	
857	Hormone replacement therapy and breast disease. 2010 , 12, 155-163	1
856	Atherosclerosis and sex hormones: current concepts. 2010 , 119, 493-513	74
855	Risikokommunikation. 2010 , 43, 276-281	
854	Stellenwert der Hormontherapie (HT) zum Erhalt der Knochengesundheit postmenopausaler Frauen. 2010 , 43, 294-300	
853	Herz-Kreislauf-Risiko und Hormontherapie in der Postmenopause. 2010 , 43, 301-307	1
852	Hormontherapie (HT) in der Peri- und Postmenopause. 2010 , 43, 839-847	1
851	Baseline serum estradiol and fracture reduction during treatment with hormone therapy: the Women's Health Initiative randomized trial. 2010 , 21, 167-77	15
850	What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?. 2010 , 21, 1793-802	31
849	Proatherogenic effects of estradiol in a model of accelerated atherosclerosis in ovariectomized ApoE-deficient mice. 2010 , 105, 479-86	21

848	Effects of raloxifene treatment on the structural geometry of the proximal femur in Japanese women with osteoporosis. 2010 , 28, 561-7	9
847	Behandlung von klimakterischen Beschwerden bei Patientinnen mit Mammakarzinom. 2010 , 8, 271-282	
846	Gender dimorphisms in progenitor and stem cell function in cardiovascular disease. 2010 , 3, 103-13	29
845	Circulating sex steroids and breast cancer risk in premenopausal women. 2010 , 1, 2-10	30
844	Fracture Risk Assessment in Clinical Practice: T-scores, FRAX, and Beyond. 2010 , 8, 101-112	5
843	Common soil of smoking-associated and hormone-related cancers: estrogen deficiency. 2010 , 4, 73-87	9
842	How to judge the association of postmenopausal hormone therapy and the risk of breast cancer. 2010 , 4, 290-3	2
841	Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women. 2010 , 21, 897-908	14
840	Monitoring pharmacological therapy for osteoporosis. 2010 , 11, 261-73	8
839	The association between a functional CYP1A1 polymorphism and colorectal neoplasia risk in post menopausal women. 2010 , 55, 2965-70	1
838	Management of osteoporosis in CKD Stages 3 to 5. 2010 , 55, 941-56	34
837	Cancer Prevention II: Introduction. 2010 , 37, 321-6	1
836	Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. 2010 , 59, 1794-800	12
835	Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. 2010 , 20, 73-8	112
834	Role of endogenous and exogenous female sex hormones in arthritis and osteoporosis development in B10.Q-ncf1 ^{*/*} mice with collagen-induced chronic arthritis. 2010 , 11, 284	8
833	Inhibitory signaling of 17 β estradiol in platelet activation: the pivotal role of cyclic AMP-mediated nitric oxide synthase activation. 2010 , 649, 140-9	16
832	Menstrual cycle-related exacerbation of disease. 2010 , 202, 221-31	57
831	Z-Bisdehydrodoisynolic acid (Z-BDDA): an estrogenic seco-steroid that enhances behavioral recovery following moderate fluid percussion brain injury in male rats. 2010 , 1362, 93-101	7

830	Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. 2010 , 19, 92-6	28
829	A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. 2010 , 7, 1284-90	54
828	Vulvovaginal atrophy: current and future therapies (CME). 2010 , 7, 1042-50; quiz 1051	29
827	Post-translational regulation of endothelial nitric oxide synthase (eNOS) by estrogens in the rat vagina. 2010 , 7, 1768-77	8
826	A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. 2010 , 126, 483-9	71
825	Sex differences in cerebral ischemia: possible molecular mechanisms. 2010 , 88, 2765-74	59
824	Analysis of soy isoflavone plasma levels using HPLC with coulometric detection in postmenopausal women. 2010 , 53, 682-7	11
823	EVITA: a tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantage. 2010 , 10, 5	10
822	Role of oestrogen replacement therapy in women with diabetes. 2010 , 27, 180-180	
821	A rational guide to reducing fracture risk in dialysis patients. 2010 , 23, 43-54	10
820	Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. 2010 , 58, 1263-71	35
819	Gender differences in the cardiovascular effects of sex hormones. 2010 , 24, 675-85	76
818	Global gene expression profiles in skeletal muscle of monozygotic female twins discordant for hormone replacement therapy. 2010 , 9, 1098-110	29
817	Women's decision making during the menopausal transition. 2010 , 22, 612-21	10
816	Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. 2010 , 18, 604-10	134
815	Reproductive aging, menopause, and health outcomes. 2010 , 1204, 169-78	24
814	Possibility of the regression of atherosclerosis through the prevention of endothelial senescence by the regulation of nitric oxide and free radical scavengers. 2010 , 10, 115-30	13
813	Menopause. 2010 , 449-455	0

812	Community Pharmacists' Therapeutic Recommendations for Heavy Flow, Androgen Excess, Fragility Fractures and Night Sweats in Menstruating Women. 2010 , 143, 88-95.e2	1
811	Osteoporotic Fracture-Medical Treatment. 2010 , 23, 326	4
810	Coronary heart disease in women: a challenge for the 21st century. 2010 , 65, 99-106	33
809	Progesterone and bone: actions promoting bone health in women. 2010 , 2010, 845180	57
808	Free Radicals as Atherosclerotic Risk in Relation to Nitric Oxide. 2010 , 673-703	
807	A longitudinal study of the effect of genistein on bone in two different murine models of diminished estrogen-producing capacity. 2010 , 2010,	10
806	Current and emerging therapies for the treatment of osteoporosis. 2010 , 2, 121-34	19
805	Actividades preventivas en la mujer. Actualizaci3n PAPPs 2018. 2018 , 50 Suppl 1, 125-146	4
804	G-1 exhibit antidepressant effect, increase of hippocampal ERs expression and improve hippocampal redox status in aged female rats. 2019 , 359, 845-852	13
803	27-Hydroxycholesterol, an Endogenous SERM, and Risk of Fracture in Postmenopausal Women: A Nested Case-Cohort Study in the Women's Health Initiative. 2019 , 34, 59-66	5
802	Menopausal hormone therapy and breast cancer risk: effect modification by body mass through life. 2019 , 34, 267-278	3
801	Menopausal Treatment. 2019 , 634-645	1
800	Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates: A Meta-analysis. 2019 , 179, 1491-1500	39
799	[Menopause]. 2019 , 161, 50-57	
798	Hormonersatztherapie und vaskul6res Risiko. 2019 , 22, 10-13	
797	Hormone therapy for first-line management of menopausal symptoms: Practical recommendations. 2019 , 15, 1745506519864009	11
796	Cognitive resilience among APOE ε carriers in the oldest old. 2019 , 34, 1833-1844	5
795	Kontrazeption f6r 40 J6hrige: Was ist zweckm66ig und wie lange ist sie sinnvoll. 2019 , 29, 39-44	

794	Vascular Effects of Progestogens. 2019 , 197-207	
793	Hormonersatztherapie und Brustkrebsrisiko. 2019 , 52, 605-616	3
792	BMS consensus statement for primary prevention of coronary heart disease in women. 2019 , 25, 64-69	1
791	Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer. 2019 , 9, 525	7
790	Advantages of large medical record database for outcomes research: Insights into post-menopausal hormone therapy. 2019 , 3, e10193	1
789	Effects of Estrogens on Platelets and Megakaryocytes. 2019 , 20,	21
788	Position statement on the hormonal management of adult transgender and gender diverse individuals. 2019 , 211, 127-133	26
787	Chapitre 2 : Maladies cardiovasculaires. 2019 , 41 Suppl 1, S49-S57	
786	Endocrine Outcomes After Pituitary Surgery. 2019 , 30, 491-498	2
785	Menopause, cognition and dementia - A review. 2019 , 25, 200-206	8
784	Ischemic Stroke Etiology and Secondary Prevention. 2019 , 119-152	
783	Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. 2019 , 317, R912-R920	5
782	Cardiovascular implications of gender-affirming hormone treatment in the transgender population. 2019 , 129, 45-49	12
781	[Hormone and breast cancer]. 2019 , 48, 1085-1091	7
780	Assessment and hormonal management of osteoporosis. 2019 , 22, 122-126	6
779	Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. 2019 , 394, 1159-1168	234
778	Health considerations for transgender women and remaining unknowns: a narrative review. 2019 , 10, 2042018819871166	19
777	Menopausal hormones: definitive evidence for breast cancer. 2019 , 394, 1116-1118	7

776	Effect of alendronate or 8-prenylnaringenin applied as a single therapy or in combination with vibration on muscle structure and bone healing in ovariectomized rats. 2019 , 11, 100224	6
775	Cardiovascular Risk/Benefit Profile of MHT. 2019 , 55,	5
774	Reply. 2019 , 157, 586	1
773	Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause. 2019 , 14, 301-314	9
772	The Controversial History of Hormone Replacement Therapy. 2019 , 55,	49
771	Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. 2019 , 153, 192-200	51
770	[Menopausal hormone therapy: I am back!]. 2019 , 47, 91-92	
769	Equilin in conjugated equine estrogen increases monocyte-endothelial adhesion via NF- κ B signaling. 2019 , 14, e0211462	1
768	The unintended sexual health consequences of risk-reducing surgery: we must do more!. 2019 , 26, 118-120	1
767	Oral investigational drugs currently in phase I or phase II for the amelioration of menopausal symptoms. 2019 , 28, 235-247	5
766	Cancer genetic counselors' experiences with transgender patients: A qualitative study. 2019 , 28, 641-653	9
765	Reply to: Statins for Primary Prevention in Older Adults. 2019 , 67, 857-858	
764	Challenges in Cardiovascular Risk Prediction and Stratification in Women. 2019 , 3, 329-348	1
763	Multiple Modes of Vitamin K Actions in Aging-Related Musculoskeletal Disorders. 2019 , 20,	18
762	Hepatic steroid sulfatase critically determines estrogenic activities of conjugated equine estrogens in human cells and in mice. 2019 , 294, 12112-12121	3
761	The Role of 17 β Estradiol and Estrogen Receptors in Regulation of Ca Channels and Mitochondrial Function in Cardiomyocytes. 2019 , 10, 310	29
760	The History of Estrogen Therapy. 2019 , 7, 416-421	9
759	Longitudinal impact of the Women's Health Initiative study on hormone therapy use in Australia. 2019 , 22, 489-497	4

758	Estrogen Receptor Signaling and Cardiovascular Function. 2019 , 13-22	1
757	Effects of Hormone Therapy on List and Story Recall in Post-Menopausal Women. 2019 , 45, 199-222	1
756	Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen. 2019 , 104, 1937-1947	36
755	Pharmacotherapy for the treatment of vaginal atrophy. 2019 , 20, 821-835	22
754	Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines. 2019 , 22, 352-360	21
753	Sex Hormones and Anticancer Immunity. 2019 , 25, 4603-4610	44
752	Blood pressure variability and brain morphology in elderly women without cardiovascular disease. 2019 , 92, e1284-e1297	10
751	Impacts of Psychological Stress on Osteoporosis: Clinical Implications and Treatment Interactions. 2019 , 10, 200	32
750	Neuroimmunology of the female brain across the lifespan: Plasticity to psychopathology. 2019 , 79, 39-55	13
749	PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol. 2019 , 22, 483-488	8
748	Progestogens and PGRMC1-dependent breast cancer tumor growth: An in-vitro and xenograft study. 2019 , 123, 1-8	15
747	Sex differences in mechanisms of arterial stiffness. 2019 , 176, 4208-4225	69
746	Pharmaceutical Treatments of Osteoporosis. 2019 , 389-410	2
745	British Menopause Society consensus statement: The risks and benefits of HRT before and after a breast cancer diagnosis. 2019 , 25, 33-37	11
744	Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial. 2019 , 171, 406-414	19
743	Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. 2019 , 171, 37-50	46
742	Comparison of the Efficacy of Tibolone and Transdermal Estrogen in Treating Menopausal Symptoms in Postmenopausal Women. 2019 , 25, 123-129	2
741	Menopausal Hormone Therapy and Risk of Melanoma: A Nationwide Register-Based Study in Finland. 2019 , 28, 1857-1860	8

740	BREAST CANCER. 2019 , 227-243	
739	Update on Menopausal Hormone Therapy for Fracture Prevention. 2019 , 17, 465-473	18
738	[Hypertension and menopausal hormone therapy]. 2019 , 48, 1295-1300	1
737	Sex and Gender Driven Modifiers of Alzheimer's: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks. 2019 , 11, 315	37
736	Difference in carotid intima-media thickness between pre and postmenopausal women. 2019 , 26, 39-44	7
735	Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease. 2019 , 26, 841-849	5
734	Stroke Characteristics, Risk Factors, and Outcomes in Transgender Adults: A Case Series. 2019 , 24, 66-70	5
733	Antidepressive Effects of Kamishoyosan through 5-HT1A Receptor and PKA-CREB-BDNF Signaling in the Hippocampus in Postmenopausal Depression-Model Mice. 2019 , 2019, 9475384	10
732	Stroke in the elderly. 2019 , 167, 393-418	11
731	Hormone therapy is not associated with the risk of sudden sensorineural hearing loss in postmenopausal women: a 10-year nationwide population-based study. 2019 , 26, 892-898	0
730	A call to increase the use of hormone therapy to prevent disease in symptomatic postmenopausal women. 2019 , 26, 573-575	2
729	Veterans Health Administration Primary Care Provider Adherence to Prescribing Guidelines for Systemic Hormone Therapy in Menopausal Women. 2019 , 41, 99-109	1
728	DNA methylation profiling to explore colorectal tumor differences according to menopausal hormone therapy use in women. 2019 , 11, 1765-1778	1
727	Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. 2019 , 1-26	
726	Management of Menopause and the Role For Hormone Therapy. 2019 , 62, 677-686	1
725	Best practices in care for menopausal patients: 16 years after the Women's Health Initiative. 2019 , 31, 420-427	0
724	Cognitive behavior therapy for menopausal symptoms (CBT-Meno): a randomized controlled trial. 2019 , 26, 972-980	23
723	Hormonersatztherapie und Brustkrebsrisiko. 2019 , 14, 570-579	

722	Side effects of drugs for osteoporosis and metastatic bone disease. 2019 , 85, 1063-1071	38
721	Association between age at menopause and fracture risk: a systematic review and meta-analysis. 2019 , 63, 213-224	29
720	Impact of radiotherapy on cardiovascular health of women with breast cancer. 2019 , 63, 250-256	
719	Determinants of hormone therapy uptake and decision-making after bilateral oophorectomy (BO): A narrative review. 2019 , 120, 68-76	6
718	Bone protection for early menopausal women in China: standard or half-dose estrogen with progestin? A one-year prospective randomized trail. 2019 , 35, 165-169	3
717	Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO. 2019 , 42, 609-618	7
716	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. 2019 , 30, 3-44	522
715	Choice of progestogen for endometrial protection in combination with transdermal estradiol in menopausal women. 2018 , 37,	6
714	Human versus non-human sex steroid use in hormone replacement therapies part 1: Preclinical data. 2019 , 480, 12-35	2
713	The relationship between menopausal hormone therapy and keratinocyte carcinoma: A review. 2019 , 5, 8-13	4
712	Aging, the menopausal transition, and hormone replenishment therapy: retrieval of confidence and compliance. 2019 , 1440, 5-22	4
711	Thrombotic Risk of Contraceptives and Other Hormonal Therapies. 2019 , 637-650	
710	Estrogen-induced neuroimmunomodulation as facilitator of and barrier to reproductive aging in brain and lymphoid organs. 2019 , 95, 6-12	10
709	Ovarian Hormones and Bone. 2020 , 583-587	
708	Lifestyle and Cancer Prevention. 2020 , 337-374.e12	0
707	Encapsulation of Mesenchymal Stem Cells in 3D Ovarian Cell Constructs Promotes Stable and Long-Term Hormone Secretion with Improved Physiological Outcomes in a Syngeneic Rat Model. 2020 , 48, 1058-1070	14
706	The Pharmacologic Management of Osteoporosis in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. 2020 , 23, 223-236	4
705	The Influence of Sex on Cardiac Physiology and Cardiovascular Diseases. 2020 , 13, 3-13	10

704	Associations of Hearing Loss and Menopausal Hormone Therapy With Change in Global Cognition and Incident Cognitive Impairment Among Postmenopausal Women. 2020 , 75, 537-544	1
703	Folic acid prevents the progesterone-promoted proliferation and migration in breast cancer cell lines. 2020 , 59, 2333-2344	3
702	Proceedings of the 2019 Santa Fe Bone Symposium: New Concepts in the Care of Osteoporosis and Rare Bone Diseases. 2020 , 23, 1-20	6
701	Intracranial Hemorrhage from Meningioma: 2 Novel Risk Factors. 2020 , 135, 217-221	6
700	S3-Leitlinie: Hormonersatztherapie und Krebsrisiko. 2020 , 53, 29-34	1
699	Menopausal Hormone Therapy and Risks of First Hospitalized Heart Failure and its Subtypes During the Intervention and Extended Postintervention Follow-up of the Women's Health Initiative Randomized Trials. 2020 , 26, 2-12	11
698	Metabolomic profiles associated with all-cause mortality in the Women's Health Initiative. 2020 , 49, 289-300	7
697	Metformin Treatment for Diabetes Mellitus Correlates with Progression and Survival in Colorectal Carcinoma. 2020 , 13, 383-392	12
696	Is there a role for menopausal hormone therapy in a woman with increased lipoprotein (a) concentrations?. 2020 , 14, 155-156	
695	Estrogen receptor- β in female skeletal muscle is not required for regulation of muscle insulin sensitivity and mitochondrial regulation. 2020 , 34, 1-15	8
694	Hormonersatztherapie und vaskuläres Risiko. 2020 , 53, 25-28	
693	Hormone replacement therapy: revisiting the risk of breast cancer. 2020 , 29, 303-305	2
692	Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention. 2020 , 27, 82-87	0
691	Hormone Therapy and Effects on Sporadic Alzheimer's Disease in Postmenopausal Women: Importance of Nomenclature. 2020 , 73, 23-37	2
690	Progestogens are the problem in hormone replacement therapy: Time to reappraise their use. 2020 , 26, 26-31	7
689	Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with breast tumor characteristics and comparison with known tumor markers. 2020 , 27, 183-193	10
688	When Should Prophylactic Oophorectomy Be Recommended at the Time of Elective Hysterectomy?. 2020 , 63, 337-348	0
687	Trends in Prescribing Menopausal Hormone Therapy and Bisphosphonates in Australia and Manitoba, Canada and Adherence to Recommendations. 2020 , 29, 177-186	2

686	Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location. 2020 , 4, pkaa042	2
685	The risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis. 2020 , 26, 126-135	3
684	Peri- and postmenopause-diagnosis and interventions interdisciplinary S3 guideline of the association of the scientific medical societies in Germany (AWMF 015/062): short version. 2020 , 302, 763-777	3
683	The Role of Sex-Specific Risk Factors in the Risk Assessment of Atherosclerotic Cardiovascular Disease for Primary Prevention in Women. 2020 , 22, 46	8
682	Molecular Mechanism for Breast Cancer Incidence in the Women's Health Initiative. 2020 , 13, 807-816	10
681	Research on Aromatherapy Relieving Anxiety of Menopausal Women and Introducing Artificial Intelligence and Robot Arms. 2020 ,	0
680	Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort. 2020 , 22, 129	4
679	Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. 2020 , 142, e506-e532	90
678	Targeting progesterone signaling prevents metastatic ovarian cancer. 2020 , 117, 31993-32004	9
677	The Women's Health Initiative trials of menopausal hormone therapy: lessons learned. 2020 , 27, 918-928	19
676	Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 369-380	27.4 85
675	A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. 2020 , 27, 848-857	15
674	Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer. 2020 , 98, 364-381	12
673	Menopause and Midlife Aging in Cross-Cultural Perspective: Findings from Ethnographic Research in China. 2020 , 35, 367-388	1
672	A current perspective into young female sex hormone replacement: a review. 2020 , 15, 405-414	4
671	Integrative genomic analysis implicates ERCC6 and its interaction with ERCC8 in susceptibility to breast cancer. 2020 , 10, 21276	3
670	Women's reproductive system as balanced estradiol and progesterone actions—a revolutionary, paradigm-shifting concept in women's health. 2020 , 32, 31-40	8
669	Estradiol and mortality in women with end-stage kidney disease. 2020 , 35, 1965-1972	1

668	Metabolomic Effects of Hormone Therapy and Associations With Coronary Heart Disease Among Postmenopausal Women. 2020 , 13, e002977	2
667	Hormonersatztherapie und Krebsrisiko. 2020 , 30, 123-124	
666	The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. 2020 , 98, 24-37	14
665	It is all in the name: The importance of correct terminology in hormone replacement therapy. 2020 , 26, 142-146	3
664	Sequential Tests of Multiple Hypotheses Controlling False Discovery and Nondiscovery Rates. 2020 , 39, 65-91	3
663	Breast imaging in transgender individuals. 2020 , 187-205	
662	Menopausal Hormone Therapy: a Comprehensive Review. 2020 , 22, 33	8
661	The impact of menopausal hormone therapy on overall mortality - a comprehensive review. 2020 , 23, 447-459	4
660	The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groups. 2020 , 27, 632-639	2
659	Effect of a new herbal composition comprised of red clover and hop extract on human endothelial cell damage and vasorelaxant activity. 2020 , 44, e13314	1
658	Ten things to know about ten cardiovascular disease risk factors ("ASPC Top Ten - 2020"). 2020 , 1, 100003	3
657	Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women. 2020 , 126, 2956-2964	7
656	S3-Leitlinie: Hormonersatztherapie und Krebsrisiko. 2020 , 18, 20-25	
655	Perioperative considerations for transgender women undergoing routine surgery: a narrative review. 2020 , 124, 702-711	5
654	Breast cancer risk after hysterectomy with and without salpingo-oophorectomy for benign indications. 2020 , 223, 900.e1-900.e7	2
653	Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches. 2020 , 139, 115516	13
652	Empirical use of causal inference methods to evaluate survival differences in a real-world registry vs those found in randomized clinical trials. 2020 , 39, 3003-3021	0
651	Novel Melatonin, Estrogen, and Progesterone Hormone Therapy Demonstrates Anti-Cancer Actions in MCF-7 and MDA-MB-231 Breast Cancer Cells. 2020 , 14, 1178223420924634	1

650	Cellular Communication in Bone Homeostasis and the Related Anti-osteoporotic Drug Development. 2020 , 27, 1151-1169	7
649	The Menstrual Cycle and Risk of Breast Cancer: A Review. 2020 , 10, 21	14
648	Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society. 2020 , 157, 303-306	14
647	Obesity and cardiovascular disease in women. 2020 , 44, 1210-1226	20
646	17βEstradiol Inhibits PCSK9-Mediated LDLR Degradation Through GPER/PLC Activation in HepG2 Cells. 2019 , 10, 930	10
645	Underlying Breast Cancer Risk and Menopausal Hormone Therapy. 2020 , 105,	10
644	Hormone Therapy for Postmenopausal Women. 2020 , 382, 446-455	57
643	Breast Cancer: A Lifestyle Medicine Approach. 2020 , 14, 483-494	4
642	Hormonersatztherapie und vaskuläres Risiko. 2020 , 18, 16-19	
641	Methodological Challenges in Studying Testosterone Therapies for Hypoactive Sexual Desire Disorder in Women. 2020 , 17, 585-594	5
640	Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials. 2020 , 189, 972-981	4
639	[Hormone replacement therapy in peri- and postmenopause]. 2020 , 61, 558-564	1
638	The Women's Health Initiative: A Landmark Resource for Skeletal Research Since 1992. 2020 , 35, 845-860	2
637	Estrogen Signaling in Alzheimer's Disease: Molecular Insights and Therapeutic Targets for Alzheimer's Dementia. 2020 , 57, 2654-2670	41
636	The Saga of Testosterone for Menopausal Women at the Food and Drug Administration (FDA). 2020 , 17, 826-829	3
635	Objective and subjective vasomotor symptom outcomes in the CBT-Meno randomized controlled trial. 2020 , 23, 482-488	1
634	Hormone Replacement Therapy, Breast Cancer Risk Factors, and Breast Cancer Risk: A Nationwide Population-Based Cohort. 2020 , 29, 1341-1347	6
633	Estrogen and bones after menopause: a reappraisal of data and future perspectives. 2021 , 20, 13-21	4

- 632 Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50-59 Years of Age. **2021**, 190, 365-375 10
- 631 International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. **2021**, 18, 849-867 10
- 630 QingYan formula extracts protect against postmenopausal osteoporosis in ovariectomized rat model via active ER-dependent MEK/ERK and PI3K/Akt signal pathways. **2021**, 268, 113644 4
- 629 Osteoporosis Diagnosis and Management. **2021**, 6, 111-133
- 628 WITHDRAWN - Administrative Duplicate Publication: Risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis. **2021**, 27, NP2-NP10
- 627 Effects of royal jelly on bone metabolism in postmenopausal women: a randomized, controlled study. **2021**, 24, 164-170 1
- 626 Examining social capital and online social support links: a study in online health communities facing treatment uncertainty. **2021**, 18, 57-94 3
- 625 [Menopausal hormone therapy: internal-endocrine point of view]. **2021**, 146, 41-47
- 624 Estrogen and estrogen analogs for prevention and treatment of osteoporosis. **2021**, 1711-1719 3
- 623 The Present and Future of Screening in Breast Cancer Prevention. **2021**, 163-173
- 622 Hormones and dementia. **2021**, 233-267
- 621 Estrogen Signaling Based Current and Potential Therapies Against Obesity and Related Diseases. **2021**, 301-338
- 620 Surgical Prevention in Ovarian Cancer. **2021**, 194-206
- 619 Effects of Raloxifene Combined with Low-dose Conjugated Estrogen on the Endometrium in Menopausal Women at High Risk for Breast Cancer. **2021**, 76, e2380 1
- 618 Insights on neuroendocrine regulation of immune mediators in female reproductive aging and cancer. **2021**, 8, 127-148
- 617 Outcomes of open treatment of infrainguinal peripheral artery disease in women. **2021**, 223-231
- 616 Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. **2021**, 42, 967-984 34
- 615 Does Unopposed Peri-menopausal or Post-menopausal Estrogen Protect against Breast Cancer? A Systematic Review. 075-082

614	Prescribing of menopausal hormone therapy in Germany: Current status and changes between 2004 and 2016. 2021 , 30, 462-471	0
613	Hormone replacement therapy - where are we now?. 2021 , 24, 3-10	13
612	Precision hormone therapy: identification of positive responders. 2021 , 24, 350-358	4
611	Tissue selective effects of bazedoxifene on the musculoskeletal system in female mice. 2021 , 248, 181-191	0
610	Genetically Predicted C-Reactive Protein Associated With Postmenopausal Breast Cancer Risk: Interrelation With Estrogen and Cancer Molecular Subtypes Using Mendelian Randomization. 2020 , 10, 630994	2
609	Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts. 2021 , 12, 564781	6
608	Sex differences in coronary plaque changes assessed by serial computed tomography angiography. 2021 , 37, 2311-2321	1
607	Premature or early bilateral oophorectomy: a 2021 update. 2021 , 24, 466-473	8
606	Go Red for Women Strategically Focused Research Network: Summary of Findings and Network Outcomes. 2021 , 10, e019519	3
605	Do Outcomes between Women and Men Differ after Endovascular Thrombectomy? A Meta-analysis. 2021 , 42, 910-915	2
604	Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer. 2021 , 162,	1
603	Activation of G protein-coupled estrogen receptor 1 ameliorates proximal tubular injury and proteinuria in Dahl salt-sensitive female rats. 2021 , 320, R297-R306	0
602	Avoiding Cognitive Biases When Reading Research Studies. 2021 , 66, 141-142	
601	The Role of Osteoporosis as a Systemic Risk Factor for Periodontal Disease.	
600	Ten things to know about ten cardiovascular disease risk factors. 2021 , 5, 100149	19
599	Perils of prolonged ovarian suppression and hypoestrogenism in the treatment of breast cancer: Is the risk of treatment worse than the risk of recurrence?. 2021 , 525, 11181	2
598	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. 2021 , 24, 533-550	3
597	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. 2021 , 30, 474-491	7

596	Regenerative Medicine Approaches in Bioengineering Female Reproductive Tissues. 2021 , 28, 1573-1595	4
595	Self-selection for mammography screening according to use of hormone replacement therapy: A systematic literature review. 2021 , 71, 101812	1
594	Impact of menopausal hormone therapy on colorectal cancer risk-A systematic review. 2021 , 95, 390-397	2
593	Hepcidin-induced reduction in iron content and PGC-1 α expression negatively regulates osteoclast differentiation to play a protective role in postmenopausal osteoporosis. 2021 , 13, 11296-11314	7
592	Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor. 2021 , 19, 1729-1737	2
591	Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment. 2021 , 42, 720-752	6
590	The role of medications in successful aging. 2021 , 24, 505-512	0
589	Effect of resveratrol and mesenchymal stem cell monotherapy and combined treatment in management of osteoporosis in ovariectomized rats: Role of SIRT1/FOXO3a and Wnt/ β -catenin pathways. 2021 , 703, 108856	4
588	[Menopausal hormone therapy an cardiovascular risk. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. 2021 , 49, 438-447	0
587	[Benefit-risk balance of hormone replacement therapy: Cancers and mortality. Postmenopausal women management - CNGOF and GEMVi clinical practice guidelines]. 2021 , 49, 462-473	1
586	Osthole Ameliorates Estrogen Deficiency-Induced Cognitive Impairment in Female Mice. 2021 , 12, 641909	3
585	Bias in animal studies of estrogen effects on cardiovascular disease: A systematic review and meta-analysis. 2021 , 5, e12507	0
584	Korean red ginseng induces extrinsic and intrinsic apoptotic pathways in MCF-7 breast cancer cells and MCF-10A non-malignant breast cells. 2021 , 47, 2758-2766	1
583	Progesterone promotes immunomodulation and tumor development in the murine mammary gland. 2021 , 9,	2
582	Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. 2021 , 28, 610-618	5
581	Role of Sex Hormones in Human Body.	0
580	Sex and Response to Cardioprotective Conditioning Maneuvers. 2021 , 12, 667961	2
579	[Menopause and risk of thromboembolic events. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. 2021 , 49, 455-461	

578	The Importance of Gender to Understand Sex Differences in Cardiovascular Disease. 2021 , 37, 699-710	17
577	Menopausal hormone therapy for the management of osteoporosis. 2021 , 35, 101551	10
576	Selective estrogen receptor modulators and bone health. 2021 , 1-4	2
575	Human endometrium-derived stem cell improves cardiac function after myocardial ischemic injury by enhancing angiogenesis and myocardial metabolism. 2021 , 12, 344	0
574	Diagnosis, Screening and Treatment of Osteoporosis – Review. 2021 , 14, 567-575	2
573	Estrogen receptor- β signaling in post-natal mammary development and breast cancers. 2021 , 78, 5681-5705	3
572	A role for estrogen in skin ageing and dermal biomechanics. 2021 , 197, 111513	4
571	The influence of social support on cognitive health in older women: a Women’s Health Initiative study. 2021 , 1-17	2
570	Fracture recurrence in hip fracture with menopausal hormone therapy versus risedronate: a clinical trial. 2021 , 24, 408-414	1
569	Menopause: A Global Perspective and Clinical Guide for Practice. 2021 , 64, 528-554	1
568	Comparative venous thromboembolic safety of oral and transdermal postmenopausal hormone therapies among women Veterans. 2021 , 28, 1125-1129	1
567	The Overview: Recent Studies on Endometrial Cancer. 2021 , 3998-4002	
566	Estetrol and Mammary Gland: Friends or Foes?. 2021 , 26, 297-308	1
565	Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor- β activity on breast metabolic signaling. 2021 , 190, 53-67	1
564	Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team. 2021 , 190, 19-38	5
563	Molecular Mechanisms of Neuroimmune Crosstalk in the Pathogenesis of Stroke. 2021 , 22,	6
562	Use of Hormone Therapy in Postmenopausal Women with Alzheimer’s Disease: A Systematic Review. 2021 , 38, 769-791	2
561	Strategies for transdermal drug delivery against bone disorders: A preclinical and clinical update. 2021 , 336, 375-395	2

560	Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice. 2021 , 27, 1115-1150	5
559	Influence of cultural practices on breast cancer risks, stage at presentation and outcome in a multi-ethnic developing country. 2021 , 22, 806	0
558	Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. 2021 , 28, 973-997	18
557	Menopausal hormone therapy for women living with HIV. 2021 , 8, e591-e598	0
556	Estrogen Receptor and Vascular Aging. 2021 , 2,	2
555	Menopausal hormone therapy and risk of incident hypertension: role of the route of estrogen administration and progestogens in the E3N cohort. 2021 , 28, 1204-1208	2
554	Compounded Bioidentical Hormones: Myths and Realities. 2021 , 64, 793-802	1
553	Life After the Women's Health Initiative: Where Do We Stand?. 2021 , 36, 474-476	
552	Estimating 24-Hour Urinary Excretion of Sodium and Potassium Is More Reliable from 24-Hour Urine Than Spot Urine Sample in a Feeding Study of US Older Postmenopausal Women. 2021 , 5, nzab125	1
551	Osteoporosis associated with chronic kidney disease. 2021 , 1325-1380	0
550	Breast cancer risk factors by mode of detection among screened women in the Cancer Prevention Study-II. 2021 , 186, 791-805	3
549	Gender differences in the risk factors associated with atherosclerosis by carotid intima-media thickness, plaque score, and pulse wave velocity. 2021 , 36, 934-944	2
548	Epidemiologic methods in studies of osteoporosis. 2021 , 381-403	
547	Introduction: Past, Present, and Future of Heart Disease in Men and Women. 2021 , 3-6	
546	Women's Health Initiative Strong and Healthy Pragmatic Physical Activity Intervention Trial for Cardiovascular Disease Prevention: Design and Baseline Characteristics. 2021 , 76, 725-734	4
545	Estrogens, Estrogen Agonists/Antagonists, and Calcitonin. 408-411	2
544	Targeting of Neuropharmaceuticals by Chemical Delivery Systems. 463-500	3
543	Clinical Pharmacology of Selective Estrogen Receptor Modulators (SERMs). 2006 , 49-69	5

542	Reproductive Hormones and Stages of Life in Women: Moderators of Mood and Cardiovascular Health. 2010 , 585-601	1
541	Transgender Health Concerns. 2007 , 473-505	21
540	Women's health initiative studies of postmenopausal breast cancer. 2008 , 617, 151-60	5
539	Why hormones protect against large bowel cancer: old ideas, new evidence. 2008 , 617, 259-69	22
538	Biobehavioral Management of Hot Flashes in a 48-Year-Old Breast Cancer Survivor. 2008 , 177-185	1
537	Breast Cancer: Epidemiological Panorama and Opportunities for Prevention. 2013 , 15-27	1
536	Exogenous Hormones. 2010 , 89-117	1
535	Estrogens, Progestins, SERMs, and Osteoporosis. 2015 , 57-63	1
534	Cardiovascular Disease in Women. 2007 , 349-368	2
533	Current Therapies for Osteoporosis. 2007 , 189-210	1
532	Menopausal Hormone Therapy to Prevent Chronic Conditions. 2019 , 327-348	1
531	The Influence of Sex Steroids on Affairs of the Heart. 2014 , 225-231	2
530	Basic Study Design. 2015 , 89-121	3
529	Obesity-associated Breast Cancer: Analysis of risk factors. 2017 , 960, 571-606	76
528	A Novel Strategy to Improve Women's Health: Selective Estrogen Receptor Modulators. 2019 , 189-213	3
527	Patient-Oriented Research: Clinical Pathophysiology and Clinical Therapeutics. 2009 , 3-12	3
526	Oral Contraceptives, Hormone Replacement Therapy, and Hypertension. 2007 , 865-882	2
525	Interventions for Osteoporosis. 2007 , 351-375	1

524	Potentials of Estrogens in the Prevention of Osteoarthritis: What Do We Know and What Questions are Still Pending?. 2007 , 393-401	1
523	Stage of Reproductive Life, Atherosclerosis Progression and Estrogen Effects on Coronary Artery Atherosclerosis. 2007 , 509-528	2
522	Postmenopausal Hormone Therapy in the 21st Century: Reconciling Findings from Observational Studies and Randomized Clinical Trials. 2007 , 619-626	2
521	Reflections on Osteoporosis. 2008 , 47-69	7
520	DISORDERS OF CALCIUM METABOLISM AND BONE MINERALIZATION. 2009 , 587-609	1
519	Clinical Management of the Patient at Increased or High Risk. 2009 , 1381-1392	1
518	Physiology and Pathology of the Female Reproductive Axis. 2011 , 581-660	11
517	Metabolic Bone Disease. 2011 , 1305-1349	2
516	Primary and Secondary Prevention of Coronary Heart Disease. 2012 , 1010-1035	4
515	Sexuality and intimacy after cancer. 2011 , 590-616	2
514	Timing of cyclic estradiol treatment differentially affects cognition in aged female rhesus monkeys. 2018 , 132, 213-223	17
513	Exogenous Hormones. 2006 , 468-488	3
512	Summary of balancing risks and benefits. 2004 , 104, 128S-129S	6
511	Venous thromboembolic disease. 2004 , 104, 118S-127S	4
510	Executive summary. Hormone therapy. 2004 , 104, 1S-4S	37
509	Controversies Regarding Postmenopausal Hormone Replacement Therapy for Primary Cardiovascular Disease Prevention in Women. 2021 , 29, 296-304	1
508	The National Academies of Science, Engineering, and Medicine (NASEM) Report on Compounded Bioidentical Hormone Therapy. 2020 , 27, 1199-1201	3
507	The origin of breast cancer. 2007 , 14, 1060-8	12

506	Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. 2008 , 15, 67-73	45
505	Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. 2007 , 14, 978-84	20
504	The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women. 2010 , 17, 622-9	36
503	Early menopausal hormone use influences brain regions used for visual working memory. 2010 , 17, 692-9	47
502	Endothelial-mediated microcirculatory responses to an acute estradiol test are influenced by time since menopause, cumulative hormone exposure, and vasomotor symptoms. 2010 , 17, 749-57	4
501	Differential effects of 17beta-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency. 2010 , 17, 766-71	19
500	Effect of dienogest on estrogen-induced nitric oxide production in human umbilical vein endothelial cells and endothelium-dependent vasodilatation in postmenopausal women. 2010 , 17, 615-21	6
499	The Timing Hypothesis remains a valid explanation of differential cardioprotective effects of menopausal hormone treatment. 2011 , 18, 230-236	24
498	Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. 2013 , 20, 254-60	50
497	Effects of bazedoxifene alone and with conjugated equine estrogens on coronary and peripheral artery atherosclerosis in postmenopausal monkeys. 2013 , 20, 274-81	12
496	Differential effects of estradiol on carotid artery inflammation when administered early versus late after surgical menopause. 2013 , 20, 540-7	16
495	Conjugated equine estrogens and estradiol benzoate differentially modulate the natriuretic peptide system in spontaneously hypertensive rats. 2013 , 20, 554-60	5
494	Nuclear hormone receptors, metabolism, and aging: what goes around comes around. Transcription factors link lipid metabolism and aging-related processes. 2004 , 2004, re8	18
493	Harnessing hormonal signaling for cardioprotection. 2005 , 2005, re6	11
492	The association of CASC16 variants with breast Cancer risk in a northwest Chinese female population. 2020 , 26, 11	4
491	Effects of Rhizoma Drynariae Cataplasm on Fracture Healing in a Rat Model of Osteoporosis. 2019 , 25, 3133-3139	5
490	Estrogen Modulates Cartilage and Subchondral Bone Remodeling in an Ovariectomized Rat Model of Postmenopausal Osteoarthritis. 2019 , 25, 3146-3153	27
489	Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). 2006 , 29 Suppl, S1-105	190

488	Established risk factors account for most of the racial differences in cardiovascular disease mortality. 2007 , 2, e377	37
487	Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. 2008 , 3, e2790	68
486	Raloxifene and desmethylarrozifene block estrogen-induced malignant transformation of human breast epithelial cells. 2011 , 6, e27876	8
485	Improved culture-based isolation of differentiating endothelial progenitor cells from mouse bone marrow mononuclear cells. 2011 , 6, e28639	27
484	Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study. 2012 , 7, e34112	23
483	Menopausal hormone therapy is associated with having high blood pressure in postmenopausal women: observational cohort study. 2012 , 7, e40260	26
482	Pharmacological estrogen administration causes a FSH-independent osteo-anabolic effect requiring ER alpha in osteoblasts. 2012 , 7, e50301	18
481	Effect of hormone replacement therapy on cardiovascular outcomes: a meta-analysis of randomized controlled trials. 2013 , 8, e62329	19
480	Genome-wide association study of breast cancer in the Japanese population. 2013 , 8, e76463	30
479	Cyclopia extracts act as ER α antagonists and ER β agonists, in vitro and in vivo. 2013 , 8, e79223	9
478	Results of observational studies: analysis of findings from the Nurses' Health Study. 2014 , 9, e110403	15
477	Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70. 2015 , 10, e0138632	8
476	Treatment of Men for "Low Testosterone": A Systematic Review. 2016 , 11, e0162480	61
475	Adenosine A1 receptor activation increases myocardial protein S-nitrosothiols and elicits protection from ischemia-reperfusion injury in male and female hearts. 2017 , 12, e0177315	14
474	Genetic variants and traits related to insulin-like growth factor-I and insulin resistance and their interaction with lifestyles on postmenopausal colorectal cancer risk. 2017 , 12, e0186296	6
473	Clinical research quo vadis? Trends in reporting of clinical trials and observational study designs over two decades. 2015 , 7, 428-34	4
472	ER β agonist alters RNA splicing factor expression and has a longer window of antidepressant effectiveness than estradiol after long-term ovariectomy. 2019 , 44, 19	2
471	Effects of conjugated estrogen and bazedoxifene on hemostasis and thrombosis in mice. 2019 , 8, 788-795	1

470	Effects of raloxifene on brachial arterial endothelial function, carotid wall thickness, and arterial stiffness in osteoporotic postmenopausal women. 2010 , 51, 60-7	20
469	[Role of hormonal risk factors in oral cancer development]. 2009 , 150, 791-9	4
468	[Interactions of insulin and estrogen in the regulation of cell proliferation and carcinogenesis]. 2012 , 153, 125-36	4
467	Success Rate and Safety of Dental Implantology in Patients Treated With Antiresorptive Medication: A Systematic Review. 2021 , 47, 169-180	1
466	[Hormonal therapy of menopause: 2004 position of the Department of Female Endocrinology and Andrology of the Brazilian Society of Endocrinology and Metabolism]. 2005 , 49, 449-54	2
465	[Hormone therapy in menopause: when not to use]. 2007 , 51, 1058-63	1
464	[The influence of estrogen and progestogen replacement on growth hormone activity in women with hypopituitarism]. 2008 , 52, 901-16	3
463	[Peri-menopausal and post-menopausal experience among women with and without hormone replacement therapy]. 2004 , 20, 1682-9	6
462	Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women. 2007 , 62, 553-60	17
461	Estrogen modulates vascular smooth muscle cell function through downregulation of SIRT1. 2017 , 8, 110039-110051	13
460	Hormone replacement therapy decreases the risk of tinnitus in menopausal women: a nationwide study. 2018 , 9, 19807-19816	4
459	Colorectal tumor prevention by the progestin medroxyprogesterone acetate is critically dependent on postmenopausal status. 2018 , 9, 30561-30567	3
458	Management of age-related osteoporosis and prevention of associated fractures. 2006 , 2, 281-95	19
457	Prevalence, clinical significance, and management of peripheral arterial disease in women: is there a role for postmenopausal hormone therapy?. 2005 , 1, 111-7	7
456	Coronary artery disease in women: a review on prevention, pathophysiology, diagnosis, and treatment. 2006 , 2, 465-75	3
455	Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective. 2014 , 21, 417-36	82
454	Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?. 2019 , 17, 564-572	28
453	A review of the relationships between endogenous sex steroids and incident ischemic stroke and coronary heart disease events. 2015 , 11, 252-60	21

452	[The influence of age and the beginning of menopause on the lipid status, LDL oxidation, and CRP in healthy women]. 2007 , 135, 280-5	4
451	[Use of estrogen-replacement therapy in menopause--secondary prevention of osteoporosis]. 2007 , 64, 37-44	2
450	High-Density Lipoprotein Cholesterol. 2006 , 295-340	2
449	Is there a role for reproductive steroids in the etiology and treatment of affective disorders?. 2018 , 20, 187-196	14
448	The treatment of climacteric symptoms. 2012 , 109, 316-23; quiz 324	19
447	The Role of Estradiol in Traumatic Brain Injury: Mechanism and Treatment Potential. 2020 , 22,	5
446	Cancer treatment-related bone loss: a review and synthesis of the literature. 2008 , 15, S30-40	33
445	Hormone therapy in perimenopausal and postmenopausal women: examining the evidence on cardiovascular disease risks. 2007 , 33, 48-55	1
444	Soy isoflavones for the prevention of menopausal symptoms and bone loss--a safe and effective alternative to estrogen?. 2011 , 59, 504	2
443	Patterns of medication use for the treatment of menopausal symptoms before and after the women's health initiative; implications for decision-making practices of women and women's health professionals. 2011 , 03, 416-422	1
442	Climacteric Symptoms & Hormone Therapy. 2006 , 49, 11	3
441	Pharmacological treatment of osteoporosis. 2019 , 62, 542	3
440	Estrogen receptor is activated by korean red ginseng in vitro but not in vivo. 2012 , 36, 169-75	21
439	Hormone Replacement Therapy and Breast Cancer in Postmenopausal Women. 2011 , 17, 125	2
438	Effect of Black Cohosh on Genital Atrophy and Its Adverse Effect in Postmenopausal Women. 2012 , 18, 106	5
437	Changing Korean Menopausal Women's Awareness on Hormone Therapy: 7-years after Women's Health Initiative Study. 2012 , 18, 94	9
436	The 2020 Menopausal Hormone Therapy Guidelines. 2020 , 26, 69-98	10
435	Tissue-Selective Estrogen Complex and Breast. 2020 , 26, 99-103	3

434	The incidence rates of endometrial hyperplasia and endometrial cancer: a four-year population-based study. 2016 , 4, e2374	7
433	Sharing clinical decisions by discussing evidence with patients. 2005 , 9, 70-3	5
432	Importance of sex and gender in ischaemic stroke and carotid atherosclerotic disease. 2021 ,	3
431	Long term impact of the WHI studies on information-seeking and decision-making in menopause symptoms management: a longitudinal analysis of questions to a medicines call centre. 2021 , 21, 348	0
430	Androgen therapy for women after menopause. 2021 , 35, 101592	1
429	Sex differences in Alzheimer's disease: metabolic reprogramming and therapeutic intervention. 2021 , 32, 963-979	3
428	Menopause is more than Hot Flashes: What is Missing in Homeopathic Research? A Narrative Review. 2021 ,	1
427	What's new in... Hormone replacement therapy. 2001 , 29, i-iv	
426	Sexualhormone. 2004 , 835-856	1
425	. 2004 , 53, 261-264	
424	Coronary heart disease. 2004 , 104, 41S-48S	2
423	Breast cancer. 2004 , 104, 11S-16S	2
422	Ovarian, endometrial, and colorectal cancers. 2004 , 104, 77S-84S	1
421	Osteoporosis. 2004 , 104, 66S-76S	8
420	Stroke. 2004 , 104, 97S-105S	2
419	Hormone Therapy in Postmenopausal Women. 2005 , 48, 377	
418	Mortality Associated with Hormone Replacement Therapy in Younger and Older Women. 2006 , 060721075157061	
417	Hormone replacement therapy and atherosclerotic vascular disease. 2005 , 151-158	

416 Does Hormone Replacement Therapy Have a Future?. **2005**, 1, 5-8

415 The kaiser permanente interregional breast care leaders. **2005**, 9, 56-60

414 Habitual Caffeine Intake and the Risk of Hypertension in Women. **2006**, 2006, 24-26

413 KLIMAKTERIUM, MENOPAUSE UND POSTMENOPAUSE. **2006**, 271-318

412 Hormone Replacement Therapy. **2006**, 185-192

411 Estrogen Dose Response in Bone Density and Bone Histology. **2006**, 171-175

410 Andropause. **2006**, 749-758

409 Mammakarzinom der Frau. **2006**, 4215-4331

408 Pregnancy and Female Reproductive Disorders. **2006**, 1011-1019

407 Effects of Transdermal and Oral Hormone Replacement Therapy on Atherosclerosis, Skin, and Bone in Postmenopausal Women. **2006**, 56, 119-127

406 New Approaches to the Diagnosis and Treatment of Postmenopausal Osteoporosis. **2006**, 21, 91

1

405 Evidence-based approach in neurology practice and teaching. **2006**, 9, 11

404 Sexualsteroidoide und Karzinogenese des Mammakarzinoms. **2006**, 91-96

403 Genetic Markers in Cardiovascular Disease. **2006**, 587-608

402 Lessons Learned. **2006**, 14-38

401 The Effect of Hormone Replacement Therapy on Carotid Intima-Media Thickness in Healthy Postmenopausal Women. **2006**, 21, 14

400 Pregnancy and Female Reproductive Disorders. **2006**, 1011-1019

399 Women and Heart Disease. **2006**, 609-615

398 Management of early stage breast cancer in the elderly. **2006**, 2, 245-251

397 Lipid abnormalities. **2006**, 89-98

396 Hormone replacement therapy. **2006**, 139-149

395 Women and Coronary Heart Disease. **2006**, 689-720

394 Uniquely Women's Issues in Colorectal Cancer Screening. **2006**, 101, S625-S629

1

393 Body Weight, Menopausal Hormone Therapy, and Risk of Breast Cancer This work was supported by grant CA14089 from the National Cancer Institute and by grant BC044808 from the Department of Defense Congressionally Directed Breast Cancer Research Program.. **2007**, 569-578

392 The Role of Sex Steroids in Alzheimer's Disease: Prevention and Treatment. **2007**, 295-306

391 Sex Steroids and Hypertension. **2007**, 307-333

390 Menopause. **2007**, 589-600

389 Thrombotic Risk of Contraceptives and Other Hormonal Therapies. **2007**, 567-580

388 The Women's Health Initiative—Data and Discussion. **2007**, 611-618

387 Clinical Trials in Postmenopausal Hormone Therapy. **2007**, 863-874

386 Lipids and Lipoproteins and Effects of Hormone Therapy. **2007**, 461-469

385 Hormone Replacement Therapy in Menopause and Breast, Colorectal, and Lung Cancer: An Update. **2007**, 599-608

384 Reproduktion. **2007**, 503-520

383 Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial. **2007**, 2007, 478-479

382 MPA is more effective than venlafaxine for hot flashes. **2007**, 6, 115-116

381 Morbidity and Mortality Changes with Hormone Therapy. **2007**, 627-636

380 Breast and Ovarian Cancer. **2007**,

379 Evidence Based Medicine in Endocrinology. **2008**, 23, 379

378 Women and Coronary Heart Disease. **2008**, 71-96

377 Peri- und Postmenopause. **2008**, 91-117

376 [Gender specific medicine for elderly women]. **2008**, 45, 270-3

375 Primary Prevention of Breast Cancer, Screening for Early Detection of Breast Cancer, and Diagnostic Evaluation of Clinical and Mammographic Breast Abnormalities. **2008**, 27-55

374 Osteoporosis. **2008**, 47-69

373 Reproductive Ethics: Ethical Issues and Menopause. **2008**, 519-524

372 Sexualhormone. **2008**, 843-864

371 Menopausal Health After Breast Cancer. **2008**, 505-524

370 Menopause. **2008**, 29-46

369 Estrogen Therapy: Prevention and Treatment of Osteoporosis. **2008**, 1687-1703

o

368 Postmenopausal Pelvis. **2008**, 1017-1035

367 Menopausal Symptoms. **2009**, 227-248

366 Correspondence (letter to the editor): Causal Treatment for ADHD is Possible. **2008**, 105, 764-5

365 Effects of Sea Tangle Extract on Formation of Collagen and Collagen Cross-link in Ovariectomized Rats. **2008**, 18, 1578-1583

1

364 On the Role and Potential of High-Dimensional Biologic Data in Cancer Research. **2009**, 1-11

363 Sexualhormone. **2009**, 835-856

362 References. **2009**, 223-234

361 Selective Reporting and Clinical Trial Registry. **2009**, 30, 923

2

360 Endokrinpharmakologie. **2009**, 217-248

359 Case 42. Osteoporosis. **2009**,

358 Sexual Health in Women with Diabetes. **2009**, 145-165

357 REPRODUCTIVE HEALTH. **2009**, 631-640

356 Klinik der Perimenopause, der Postmenopause und des Seniums. **2009**, 521-559

1

355 HRT and anti-aging. **2009**, 24, 117-126

354 Premature Menopause. **2009**, 950-956

353 Menopause. **2009**, 834-838

352 Management of Menopause in the Breast Cancer Patient. **2009**, 1419-1430

351 Traitements Hormonaux Substitutifs de la Mhopause. **2009**, 819-822

350 NHG-Standaard Osteoporose. **2009**, 1173-1195

349 16 Coloncarcinoom. **2009**, 191-202

348 Exogenous hormones and their effects on the endometrium. **2009**, 325-341

347 Endogenous Hormones. **2010**, 73-87

346 Estrogens and Estrogen Agonists/Antagonists. **2010**, 351-358

345 Surgical Management of Inherited Susceptibility to Breast Cancer. **2010**, 61-78

344 Lifestyle Factors and Risk of Breast Cancer: A Review of Randomized Trial Findings. **2010**, 23-41

343 Impact of Hormone Replacement Therapy on Breast Cancer. **2010**, 101-108

342 Natural and Surgical Menopause. **2010**, 141-169

341 The Coronary Circulation. **2010**, 903-917

340 The Effects of Menopausal Hormone Therapy on Breast Cancer: Evidence from the Women's Health Initiative Randomized Placebo-Controlled Trials. **2010**, 197-207

339 Sexualhormone. **2010**, 867-888

338 M69 Osteoporose. **2010**, 255-296

337 Klimakterium -hormonelle Substitution. **2010**, 454-459

336 Aging and the Endocrine System. **2010**, 123-126

335 Menopause. **2010**, 1242-1246

334 Postmenopausal Hormone Replacement Therapy and Breast Cancer -Clinicopathologic Associations and Molecular Mechanisms. **2010**, 187-202

1

333 Endocrine and Metabolic Agents. 1

332 ¿Se justifica el uso de TRH en el envejecimiento activo?. **2010**, 10,

331 Drug-Induced Diabetes. 265-278

330 Menopause. 416-422

329 Gender Differences in Coronary Risk Factors and Risk Interventions. **2011**, 253-299

328 [Common molecular mechanism of osteoporosis and vascular diseases]. **2011**, 48, 146-8

327 Endocrinology and Aging. **2011**, 1219-1233

1

326 Chemoprevention of Colorectal Cancer. **2011**, 65-73

325 Menopause. **2011**, 405-421

324 Prevention of Ischemic Heart Disease in Women. **2011**, 398-414

323 Endocrinology. **2011**, 756-801

322 NHG-Standaard Osteoporose. **2011**, 717-739

321 Management of osteoporosis. **2011**, 1975-1988.e4

320 Menopause. **2011**, 760-770

319 Bones. **2011**, 218-235

318 Symptomatic changes in postmenopause with different methods of hormonal therapy. **2011**, 01, 20-24

317 Age-Related Changes in Bone and Soft Tissue. **2011**, 1201-1220

316 Chemoprevention. **2011**, 187-200

315 Sexualhormone. **2011**, 881-900

314 Preventive Health Care. **2011**, 73-99

313 Metabolic Bone Disorders of the Spine. **2011**, 1571-1595

312 Cardiovascular Aging. **2011**, 415-432

3

311 Cardiovascular risk factors in women and the role of sex hormones. **2011**, 10, 128-135

5

310 Breast Cancer Risk: Role of Somatic Breast Stem Cells. **2012**, 231-240

309 Risk-Benefit Analysis of Combination Versus Unopposed HRT in Post-Menopausal Women. **2011**, 1, 61-76

- 308 Evolution of Selective Estrogen and Androgen Receptor Modulators: Status of Current Therapy and New Drug Development. 1
- 307 Sexualhormone. **2012**, 903-922
- 306 Contraception orale, traitement hormonal de la mēopause, inducteurs de lâb̄vulation et risque de cancer du sein. **2012**, 183-190
- 305 Postmenopausal Hormone Therapy and Blood Pressure. **2012**, 347-372
- 304 Gynecology. **2012**, 455-467
- 303 La mēopause: physiologie et prise en charge th̄rapeutique. **2012**, 257-274
- 302 Progesterone Receptor Modulators Induce Apoptosis in Mammary Tumors and Uterine Leiomyomas. **2012**, 205-226
- 301 Cardiovascular Disease in Women. **2012**, 1757-1769
- 300 Women's Health. **2012**, 981-1028
- 299 Mortality Associated with Hormone Replacement Therapy in Postmenopausal Women. **2012**, 18, 133 2
- 298 Gynaecology and the Older Patient. 1259-1270
- 297 Bioidentical hormone therapy: Nova Scotia pharmacists' knowledge and beliefs. **2012**, 10, 159-67
- 296 The Role and Potential of Surrogate Outcomes in Clinical Trials: Have We Made Any Progress in the Past Decade?. **2013**, 3-19 1
- 295 Three cases of brain infarction with hormone replacement therapy. **2013**, 35, 301-305
- 294 Blutungs- und Gerinnungsst̄rungen. **2013**, 273-285
- 293 Menopause. **2013**, 1586-1608
- 292 Dietary Phytoestrogens in Preventing Osteoporosis in Postmenopausal Women: Italian Aspects. **2013**, 151-164
- 291 Sexualhormone. **2013**, 887-907

- 290 Endocrine prevention of breast cancer. **2013**, 39-49
- 289 Hormonersatztherapie. **2013**, 281-312
- 288 Impact of Medical Therapy on Cardiovascular Secondary Prevention. **2013**, 1075-1100
- 287 Monitoring Therapy for Osteoporosis. 227-238
- 286 Hormone Therapy for Osteoporosis. 108-122
- 285 What Is the Place of Hormone Replacement Therapy in Ovarian, Endometrial, and Breast Cancer?. **2014**, 237-246
- 284 Reproductive Changes in the Female Lifespan. **2014**, 25-31 2
- 283 Cancer Prevention, Screening, and Early Detection. **2014**, 322-359.e12 1
- 282 Cardiac Syndrome X and Microvascular Angina. **2014**, 1-25
- 281 Hormone replacement therapy. **2014**, 423-425
- 280 Sexualhormone. **2014**, 991-1013
- 279 Night Sweats. 175-188
- 278 Breast Cancer - Diagnosis and Treatment Prolonging Life: A Review. **2014**, 3, 196-206
- 277 Assessment of Health Related Quality of Life. **2015**, 279-295 1
- 276 The Women's Health Initiative: Lessons for Preventive Nutrition. **2015**, 335-369
- 275 Monitoring Committee Structure and Function. **2015**, 343-372
- 274 Spezifische Rehabilitation. **2015**, 303-369
- 273 Sexualhormone. **2015**, 1007-1028

- 272 Estrogen and Breast Cancer in Postmenopausal Women: A Critical Review. **2016**, 475-482
- 271 Estrogen and Cardiac Events with all-cause Mortality. A Critical Review. **2016**, 483-490
- 270 Overview. **2016**, 1284-1302.e3 1
- 269 Is there any relationship between different phenotypes of metabolic syndrome and cardiovascular mortality rate?. **2016**, 5, 185 1
- 268 Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease. **2016**, 1-15
- 267 Sexualhormone. **2016**, 705-718
- 266 28 De overgangsjaren en de postmenopauze. **2016**, 729-757
- 265 Microvascular Angina: Diagnosis, Prognosis and Treatment. **2016**, 65-93
- 264 Effects of Herbal Mixture Extracts Containing *Angelica gigas* Nakai and *Cuscuta chinensis* Lam. on Menopausal Symptoms in Ovariectomized Rats. **2016**, 45, 1083-1089 1
- 263 Sporadic Cancers. **2017**, 323-334
- 262 Peri- und Postmenopause. **2017**, 91-108
- 261 Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease. **2017**, 517-530
- 260 Five Decades of Hormone Therapy Research: The Long, the Short, and the Inconclusive. **2017**, 13-43 1
- 259 Pharmacotherapies for Menopause Management: Hormonal Options. **2017**, 67-85
- 258 Sexualhormone. **2017**, 723-737
- 257 Chapter 6: Randomized Controlled Trials. **2017**,
- 256 Tailoring cardiovascular risk assessment and prevention for women: One size does not fit all. **2017**, 2017, e201701 5
- 255 Risco do Aparecimento do Câncer de Mama em Mulheres Menopausadas com Síndrome Metabólica e o Papel da Dieta na Prevenção da Doença. 67-100 0

- 254 MENOPAUSAL HORMONE THERAPY WITH DYDROGESTERONE: ASPECTS OF EFFICACY AND SAFETY OF ULTRA-LOW DOSES. **2017**, 92-99 3
- 253 Timing of Cyclic Estradiol Treatment Differentially Affects Cognition in Aged Female Rhesus Monkeys.
- 252 Healthy Bones After Menopause: What Has to Be Done?. **2018**, 165-186
- 251 Sexualhormone. **2018**, 777-791
- 250 Data Monitoring: Structure for Clinical Trials and Sequential Monitoring Procedures. **2018**, 235-267
- 249 Estrogen receptor regulates hormone-induced growth arrest in a luminal A like breast cancer model.
- 248 Breast Cancer Prevention. **2019**, 543-606
- 247 Intervention-Prognostic Derivative Research. **2019**, 233-242
- 246 Sexualhormone. **2019**, 979-996 0
- 245 Clinical Research and Clinical Medicine at Present. **2019**, 15-29
- 244 Example: Research on "Hormone Replacement Therapy" **2019**, 169-192
- 243 La mñopause : physiologie et prise en charge thfapeutique. **2019**, 313-333
- 242 Pathologies artfielles. **2019**, 157-168
- 241 Non-experimental Intervention-Prognostic Studies. **2019**, 215-232
- 240 Les grandes tudes. **2019**, 323-326
- 239 Colorectal Cancer Prevention. **2019**, 473-509 1
- 238 Hormone Replacement Therapy and Postmenopausal Cardiovascular Events: A Meta-Analysis. **2019**, In Press, 0
- 237 Analysis of Adverse Events Associated with Low-dose Estrogen-Progestin Based on Data from the Japanese Adverse Drug Event Report Database and the Relief System for Sufferers from Adverse Drug Reactions. **2019**, 45, 115-124

236	Biological characteristics of osteoporosis drugs: the effect of osteoblast-osteoclast coupling. 2019 , 44, 1-7	2
235	Does hormone replacement therapy benefit post-menopausal women? â scoping review. 2019 , 13, 52-57	
234	Antidepressants for menopausal symptoms.	78
233	Effects of Estrogens and SERMs on Bone Metabolism: Clinical Aspects. 2020 , 239-257	
232	Risk Factors for Breast Cancer. 2022 , 17-29	
231	The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density. 2021 , 81, 1831-1858	7
230	Alteration of fecal microbial compositions and bacterial taxa in female osteoporotic patients.	1
229	Menopausal Hormone Therapy and Health Outcomes: Is Timing Everything?. 2021 , 67, 317-318	1
228	Concomitant Bilateral Salpingo-Oophorectomy at Hysterectomy: Differences by Race and Menopausal Status in the Veterans Affairs Health Care System, 2007-2014. 2020 , 29, 1513-1519	0
227	Postmenopausal Hormone Therapy and Its Association with Breast Cancer. 2020 , 11, 187-195	1
226	G Protein-Coupled Estrogen Receptor 1 (GPER) as a Novel Target for Schizophrenia Drug Treatment. 2020 , 1,	1
225	Encyclopedia of Behavioral Medicine. 2020 , 2351-2352	
224	Peri- und Postmenopause â Diagnostik und Therapie. 2020 , 347-360	
223	Menopause. 2020 , 1549-1569.e5	
222	Sexualhormone. 2020 , 833-848	
221	Prevalence of the Use of Oral Contraceptives and Hormone Replacement Therapy in Japan: the Japan Nurses' Health Study. 2020 ,	1
220	Gender Differences in Brain-Heart Connection. 2020 , 1-15	
219	Gender Differences in Brain-Heart Connection. 2020 , 937-951	1

- 218 Neuroprotective Effects of Estradiol plus Lithium Chloride via Anti-Apoptosis and Neurogenesis Pathway in and Parkinson's Disease Models. **2021**, 2021, 3064892 o
- 217 Risk-Benefit Analysis of Combination vs. Unopposed HRT in Post-Menopausal Women. 1424-1440
- 216 Antioxidant Vitamins and Cardiovascular Disease: Randomized Trials Fail to Fulfill the Promises of Observational Epidemiology. **2006**, 305-325
- 215 Osteoporose: Diagnostik âPrvention âTherapie. **2005**, 246-257
- 214 Hormontherapie nach gynkologischen Malignomen. **2005**, 225-229
- 213 Sexualhormone. 888-911
- 212 Blutungs- und Gerinnungsstfungen. **2006**, 245-254
- 211 Krebs und Hormone. **2006**, 537-547
- 210 Klimakterium, Postmenopause und Senium. **2006**, 61-103
- 209 SERMs and the Breast. 239-270
- 208 The Role of SERMs in the Management of Postmenopausal Women. 333-349
- 207 Cardiovascular Disease and SERMs. 207-238
- 206 Clinical Research Center-Based Investigations and Evidence-Based Medicine. **2006**, 155-163
- 205 Evidence-Based Case Studies in Osteoporosis. **2006**, 343-366
- 204 Integrative Pain Medicine Models. **2008**, 497-545
- 203 Reproductive Changes in the Female Lifespan. **2008**, 17-24
- 202 La position de la Soci'tfran'aise de shologie et de pathologie mammaire sur le traitement hormonal substitutif: valuation du risque et du bnfice ^travers une tude bibliographique. **2007**, 43-50
- 201 Hormone Replacement Therapy After Breast Cancer. **2006**, 879-902

200 Sexualhormone. **2007**, 893-917

199 Paradigm Shift in Causal Thinking in Epidemiology. **2006**, 127-133

198 Sexualhormone. **2008**, 845-867

197 The Synergy of Two Ovarian Hormone-induced Enzymes in Human Mammary Carcinogenesis. **2008**, 99-109

196 Menopausal transition: risks and their prevention. **2020**, 26-30

195 [Preventive activities in women's care]. **2020**, 52 Suppl 2, 125-148 2

194 Efficacy of progestin-only treatment for the management of menopausal symptoms: a systematic review. **2020**, 28, 217-224 3

193 Hormone replacement therapy is safe in women undergoing coronary artery bypass grafting. **2005**, 32, 507-14 4

192 Hormone replacement therapy after the menopause--where are we now?. **2005**, 55, 172-4 3

191 Platelet reactivity and genetics down on the pharm. **2006**, 117, 103-11; discussion 111-2 3

190 Clinical opinion: the biologic and pharmacologic principles for age-adjusted long-term estrogen therapy. **2006**, 8, 84 1

189 Clinical opinion: the biologic and pharmacologic principles of estrogen therapy for symptomatic menopause. **2006**, 8, 85 4

188 Should symptomatic menopausal women be offered hormone therapy?. **2006**, 8, 40 6

187 Validation of self-report of rheumatoid arthritis and systemic lupus erythematosus: The Women's Health Initiative. **2008**, 35, 811-8 56

186 Update on bazedoxifene: a novel selective estrogen receptor modulator. **2007**, 2, 299-303 11

185 In Perspective: Estrogen Therapy Proves to Safely and Effectively Reduce Total Mortality and Coronary Heart Disease in Recently Postmenopausal Women. **2008**, 17, 27-32 1

184 Stress incontinence. **2009**, 2009,

183 Heart disease and hormones. **2011**, 38, 137-41 5

182	Ovary-sparing hysterectomy: is it right for your patient?. 2009 , 58, 478-80	
181	Fracture prevention in postmenopausal women. 2011 , 2011,	3
180	Interviews With Two Women's Health Experts On the Use of Estrogen Therapies. 2012 , 37, 166-72	
179	Management of urinary incontinence. 2012 , 37, 345-361H	19
178	Soy consumption during menopause. 2012 , 4, 30-7	1
177	Estrogen-mimicking isoflavone genistein prevents bone loss in a rat model of obstructive sleep apnea-hypopnea syndrome. 2014 , 7, 1687-94	15
176	Treatment of the menopause: the swinging pendulum. 2010 , 2, 173-6	
175	Gynaecological aspects of the treatment and follow-up of transsexual men and women. 2010 , 2, 35-54	9
174	Recurrence of endometriosis after hysterectomy. 2014 , 6, 219-27	19
173	Relationship of elongated styloid process in digital panoramic radiography with carotid intima thickness and carotid atheroma in Doppler ultrasonography in osteoporotic females. 2015 , 16, 93-9	1
172	Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy - a systematic review and meta-analysis of controlled trials with direct randomization. 2017 , 17, 146-154	21
171	Matters of the heart: cardiovascular disease in U.S. women. 2013 , 110, 65-70	8
170	Expression of PGRMC1 in paraffin-embedded tissues of breast cancer. 2017 , 10, 9639-9643	2
169	The clinical impact of estrogen loss on cardiovascular disease in menopausal females. 2018 , 6,	3
168	Genetically determined elevated C-reactive protein associated with primary colorectal cancer risk: Mendelian randomization with lifestyle interactions. 2021 , 11, 1733-1753	1
167	Clinical Impact of Hormone Replacement Therapy on Atrial Fibrillation in Postmenopausal Women: A Nationwide Cohort Study. 2021 , 10,	1
166	High pre-diagnosis inflammation-related risk score associated with decreased ovarian cancer survival. 2021 ,	0
165	The sex steroid precursor dehydroepiandrosterone prevents nonalcoholic steatohepatitis by activating the AMPK pathway mediated by GPR30. 2021 , 48, 102187	4

164 Selective Estrogen Receptor Modulators (SERMs). **2022**, 399-411

163 Menopause and Hormone Replacement Therapy. **2021**, 203-211

162 Sexualhormone. **2021**, 745-760

161 Association between blood pressure levels and cognitive impairment in older women: a prospective analysis of the Women's Health Initiative Memory Study.. **2022**, 3, e42-e53 2

160 Update on hormone therapy for the management of postmenopausal women.. **2022**, 16, 1

159 Secondary Prevention, Not Secondary Importance: Embracing Survivorship Concerns and HRT After Cervical Cancer Radiation Therapy.. **2022**, 112, 414-416 0

158 The endocrinology of sarcopenia and frailty. **2022**, 46, 0

157 Differenzierter Einsatz von Gestagenen in der kombinierten Hormonersatztherapie â€ Einfluss auf das Mamma- und Endometriumkarzinomrisiko. **2022**, 20, 135

156 Sex differences in thrombosis as it affects acute ischemic stroke.. **2022**, 105647 0

155 A Comparison of Perceived Lifetime Breast Cancer Risk to Calculated Lifetime Risk Using the Gail Risk Assessment Tool.. **2022**,

154 Taking action to advance the study of race and ethnicity: the Women's Health Initiative (WHI).. **2022**, 8, 1 1

153 Ovarian Tissue Banking to Postpone Menopause. **2022**, 301-310

152 A Conversation with Ross Prentice. **2022**, 37,

151 Menopausal hormone therapy and risk of cardiovascular events in women with prediabetes or type 2 diabetes: A pooled analysis of 2917 postmenopausal women.. **2022**, 344, 13-19 1

150 Laparoscopic ovarian transposition in teenage and young women with locally advanced rectal cancer: respite amidst cancer chaos.. **2022**,

149 Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial.. **2022**, 3, e109-e118 2

148 Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk.. **2022**, 1-7 1

147 The impact of micronized progesterone on cardiovascular events - a systematic review.. **2022**, 1-10 2

- 146 Female Sex-Specific Cardiovascular Risk Factors and Heart Failure Practice Guidelines.. **2022**, 247, 63-63 ○
- 145 Peri- und Postmenopause. **2021**, 89-101
- 144 Accuracy of Cardiovascular Trial Outcome Ascertainment and Treatment Effect Estimates from Routine Health Data: A Systematic Review and Meta-Analysis. **2021**, 14, e007903 ○
- 143 Postmenopausal Osteoporosis. **2022**, 257-271 ○
- 142 Women's Health Initiative Strong and Healthy (<i>WHISH</i>): A Pragmatic Physical Activity Intervention Trial for Cardiovascular Disease Prevention.
- 141 The peri-menopause is a critical period for women. **2022**, 13, 19-24
- 140 What is the association between estrogen and breast cancer?. **2022**, 13, 50-56
- 139 Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms.. **2022**, 29, 304-308
- 138 Pregnancy and Reproductive Risk Factors for Cardiovascular Disease in Women.. **2022**, 130, 652-672 4
- 137 Ovarian function and menopause. **2022**, 1059-1072
- 136 Terapia ormonale sostitutiva e osteoporosi postmenopausale. **2022**, 23, 61-64
- 135 Bone and heart health in menopause.. **2022**, 1
- 134 Pediatric Device Trials are the Ideal way to Bring Devices to Market.. **2022**, 13, 231-234
- 133 Care reality of menopausal women in Germany: healthcare research using quantitative (SHI claims data) and qualitative (survey) data collection.. **2022**, 1 ○
- 132 Menopause-associated risk of cardiovascular disease.. **2022**, 1
- 131 Mathematical model for the estrogen paradox in breast cancer treatment.. **2022**, 84, 28
- 130 Endogenous and Exogenous Estrogen Exposures: How Women's Reproductive Health Can Drive Brain Aging and Inform Alzheimer's Prevention.. **2022**, 14, 831807 1
- 129 Optimizing menopausal hormone therapy: for treatment and prevention, menstrual regulation, and reduction of possible risks. **2022**, ○

128	The effect of micronized progesterone and medroxyprogesterone acetate in combination with transdermal estradiol on hemostatic biomarkers in postmenopausal women diagnosed with POI and early menopause: a randomized trial.. 2022 , 29, 580-589	1
127	Estradiol and Estrogen-like Alternative Therapies in Use: The Importance of the Selective and Non-Classical Actions.. 2022 , 10,	2
126	Fact or Fiction? The Role of Regulated Body-Identical Hormone Therapy for Menopausal Women.. 2022 ,	
125	Ten things to know about ten cardiovascular disease risk factors - 2022.. 2022 , 10, 100342	3
124	Sex Differences in Cardiovascular Diseases: A Matter of Estrogens, Ceramides, and Sphingosine 1-Phosphate.. 2022 , 23,	0
123	Isoflavones from Semen Sojae Preparatum Improve Atherosclerosis and Oxidative Stress by Modulating Nrf2 Signaling Pathway through Estrogen-Like Effects.. 2022 , 2022, 4242099	0
122	Obesity, Body Composition, and Sex Hormones: Implications for Cardiovascular Risk.. 2021 , 12, 2949-2993	0
121	Infertility and Risk of Heart Failure in the Women's Health Initiative.. 2022 , 79, 1594-1603	2
120	Serum follicle stimulating hormone and five-year change in adiposity in healthy postmenopausal women.. 2022 ,	0
119	Astragalin attenuates depression-like behaviors and memory deficits and promotes M2 microglia polarization by regulating IL-4R/JAK1/STAT6 signaling pathway in a murine model of perimenopausal depression.. 2022 , 1	0
118	Are we any WISER yet? Progress and contemporary need for smart trials to include women in coronary artery disease trials.. 2022 , 106762	1
117	Therapeutic Strategies and Potential Actions of Female Sex Steroid Hormones and Their Receptors in Colon Cancer Based on Preclinical Studies.. 2022 , 12,	0
116	The pathology of iatrogenic lesions. 207-254	
115	Anti-phospholipid antibody syndrome. 263-274	2
114	Bleeding disorders and thrombophilia. 283-300	
113	Female infertility and the evaluation of an infertile couple. 865-883	
112	Menopause. 985-1003	
111	Polycystic ovary syndrome. 1024-1046	1

- 110 Relationship between BMI trajectories and cardiometabolic outcomes in postmenopausal women - a growth mixture modelling approach.. **2022**,
- 109 2',3',4'-Trihydroxychalcone changes estrogen receptor β regulation of genes and breast cancer cell proliferation by a reprogramming mechanism.. **2022**, 28, 44 0
- 108 Obesity and breast cancer risk: the oncogenic implications of metabolic dysregulation.. **2022**, 0
- 107 The clinician's guide to prevention and treatment of osteoporosis.. **2022**, 11
- 106 17 β -Estradiol facilitates M2 macrophage skewing and ameliorates arrhythmias in ovariectomized female infarcted rats.. **2022**,
- 105 Steroid profiling in brain and plasma of adult zebra finches following traumatic brain injury. 0
- 104 Assessment of Estrogen Exposure from Transdermal Estradiol Gel Therapy with a Dried Urine Assay.. **2022**, 109038
- 103 Cancer Risk Factors and Prevention. **2022**, 21-50 1
- 102 Metabolic Bone Disease. **2017**, 893-903.e4
- 101 The Swinging Pendulum: Elective Oophorectomy at the Time of Hysterectomy.. **2022**, 139, 721-723
- 100 Treating menopause âMHT and beyond. 3
- 99 Evaluation of the Interaction of Sex Hormones and Cardiovascular Function and Health. 0
- 98 Menopausal Hormone Therapy Formulation and Breast Cancer Risk. **2022**, 139, 1103-1110 3
- 97 Heart rate variability as a function of menopausal status, menstrual cycle phase, and estradiol level. **2022**, 10, 0
- 96 The relationship between using estrogen and/or progesterone and the risk of mammary gland hyperplasia in women: a meta-analysis. 1-5 0
- 95 Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 7 million menopausal women over age 65: a retrospective observational study. 0
- 94 Estrogen for the Treatment and Prevention of Breast Cancer. **2022**, 28, 163-168 0
- 93 Menopause Hormone Therapy in the Management of Postmenopausal Osteoporosis. **2022**, 28, 204-207

92	Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease. 2022 , 28, 208-223	1
91	Menopausal Hormone Therapy and Breast Cancer. 2022 , 28, 169-175	0
90	Concerns About Compounded Bioidentical Menopausal Hormone Therapy. 2022 , 28, 241-245	
89	Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review.	2
88	Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea. 1-7	
87	Advances in Our Understanding of the Mechanism of Action of Drugs (including Traditional Chinese Medicines) for the Intervention and Treatment of Osteoporosis. 13,	0
86	Role of ABCA1 in Cardiovascular Disease. 2022 , 12, 1010	3
85	Hormone therapy and fracture rates among postmenopausal women: results from the Women's Interagency HIV Study. Publish Ahead of Print,	0
84	The Association Between Route of Post-menopausal Estrogen Administration and Blood Pressure and Arterial Stiffness in Community-Dwelling Women. 9,	0
83	Management of postmenopausal women: Collège National des Gynécologues et Obstétriciens Français (CNGOF) and Groupe d'Etude sur la Ménopause et le Vieillessement (GEMVi) Clinical Practice Guidelines. 2022 , 163, 62-81	0
82	Vulvovaginal atrophy – The impact on the quality of life and self-regard. Review of literature. 2022 , 125, 50-55	0
81	Commercial Hormone Replacement Therapy Jeopardized Proinflammatory Factors in Experimental Rat Models. 2022 , 10, 977-981	
80	Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. 2022 , 17,	1
79	The relationship between optimism, MCI, and dementia among postmenopausal women. 1-9	
78	History of infertility and pregnancy outcomes in Project Viva: a prospective study. 2022 , 22,	0
77	Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability – Results from the Women's Health Initiative hormone therapy trials.	1
76	Contributions of the Women's Health Initiative to Cardiovascular Research. 2022 , 80, 256-275	0
75	The interplay between diabetes mellitus and menopause: clinical implications.	1

74	Adherence to MIND Diet, Genetic Susceptibility, and Incident Dementia in Three US Cohorts. 2022 , 14, 2759	1
73	Ovarian steroid hormones: A long overlooked but critical contributor to brain aging and Alzheimer's disease. 14,	1
72	Uterus: A Unique Stem Cell Reservoir Able to Support Cardiac Repair via Crosstalk among Uterus, Heart, and Bone Marrow. 2022 , 11, 2182	
71	Knochengesundheit in der Postmenopause.	
70	Estrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer. 2005 , 11, 909s-917s	10
69	Dienogest Does Not Augment the Gene Expression of Adhesion Molecules, MCP-1, and Monocyte Adherence in Human Endothelial Cells.	
68	Einfluss einer Hormonersatztherapie in der Peri- und Postmenopause auf das Krebsrisiko. 2022 , 20, 178-185	
67	Biomaterials and advanced technologies for the evaluation and treatment of ovarian aging. 2022 , 20,	2
66	Persistent gap in menopause care 20 years after the WHI: a population-based study of menopause-related symptoms and their management. 2022 ,	
65	The Role of Soy Isoflavones in the Prevention of Bone Loss in Postmenopausal Women: A Systematic Review with Meta-Analysis of Randomized Controlled Trials. 2022 , 11, 4676	0
64	Optical coherence tomography evaluation of vaginal epithelial thickness during CO ₂ laser treatment: A pilot study.	0
63	Reassuring data regarding the use of hormone therapy at menopause and risk of breast cancer. Publish Ahead of Print,	
62	Estrogen therapy and breast cancer in randomized clinical trials: a narrative review. Publish Ahead of Print,	0
61	Sex hormones affect the pathogenesis and clinical characteristics of systemic lupus erythematosus. 9,	0
60	Dyslipidemia in midlife women: Approach and considerations during the menopausal transition. 2022 , 166, 14-20	1
59	Exemestane for Breast Cancer Prevention: A Feasible Strategy?. 2005 , 11, 918s-924s	0
58	Hormone Therapy and Risk of Breast Cancer: Where Are We Now?. 2022 , 28, 47	0
57	Molecular mechanism of action of estrogens, progestins, and androgens. 2023 , 123-159	0

56	Transdermal Absorption of Sclareol, an Active Ingredient in Clary Sage Oil: A Complementary and Alternative Medicine for Menopausal Symptoms. 2022 , 2, 304-312	0
55	Management of Menopause Symptoms and Quality of Life during the Menopause Transition. 2022 ,	0
54	Targeting the non-classical estrogen pathway in neurodegenerative diseases and brain injury disorders. 13,	1
53	Differences in Metabolomic Profiles Between Black and White Women and Risk of Coronary Heart Disease: an Observational Study of Women From Four US Cohorts. 2022 , 131, 601-615	1
52	Osteoporosis and Fragility Fractures: currently available pharmacological options and future directions. 2022 , 101780	2
51	Risk Factors for Ischemic Heart Disease in Women. 2022 , 163-191	0
50	Age at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study. 2022 , 43, 4148-4157	1
49	Biofunctional roles of estrogen in coronavirus disease 2019: Beyond a steroid hormone. 13,	0
48	Pulmonary embolism in menopausal hormone therapy: a population-based register study. 1-7	0
47	Chemoprevention of Cancer. 1-25	0
46	Identification of Candidate Genes in Breast Cancer Induced by Estrogen Plus Progestogens Using Bioinformatic Analysis. 2022 , 23, 11892	0
45	17 β -Estradiol Enhances 5-Fluorouracil Anti-Cancer Activities in Colon Cancer Cell Lines. 2022 , 10, 62	0
44	The association of hormone therapy with blood pressure control in postmenopausal women with hypertension: a secondary analysis of the Women's Health Initiative clinical trials. Publish Ahead of Print,	0
43	Menopausal Hormone Therapy for Prevention of Chronic Conditions. 2022 , 328, 1712	1
42	Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons. 2022 , 328, 1747	6
41	Updates in Transgender Breast Imaging. 2022 ,	0
40	Endometrial hyperplasia, estrogen therapy, and the prevention of endometrial cancer. 2023 , 104-124.e5	0
39	Sex differences in the inflammatory response to stroke.	0

- 38 Menopause, Hormone Therapy and Cardiovascular and Cerebrovascular Disease. **2008**, 37, 54-62 1
- 37 Actividades preventivas en la mujer. Actualizaci3n PAPPs 2022. **2022**, 54, 102471 0
- 36 The independent associations of anti-Müllerian hormone and estradiol levels over the menopause transition with lipids/lipoproteins: The study of women’s health across the nation. **2022**, 0
- 35 HORMONE EXPOSURE AND VENOUS THROMBOEMBOLISM IN COMMERCIALY-INSURED WOMEN 50 TO 64 YEARS OF AGE. 0
- 34 The unfolded protein response (UPR) pathway: the unsung hero in breast cancer management. 1
- 33 The effect of hormone replacement therapy on cognition and mood. 0
- 32 Pituitary adenomas and cerebrovascular disease: A review on pathophysiology, prevalence, and treatment. 13, 0
- 31 The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows. **2023**, 24, 764 2
- 30 Unraveling female reproductive senescence to enhance healthy longevity. **2023**, 33, 11-29 0
- 29 The osteoporosis treatment gap in Switzerland between 1998 and 2018. **2023**, 18, 0
- 28 Effects of steroid hormones on lipid metabolism in sexual dimorphism: A Mendelian randomization study. 13, 0
- 27 Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?. 2
- 26 Menopausal hormonal therapy and the risk of breast cancer in the light of new data. **2022**, 77-80 0
- 25 Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta. 0
- 24 The Use of Female Menopausal Hormonal Replacement Therapy To Prevent Cardiovascular Disease in Women and in Men: A Lack of Clinical Benefit and the Potential for Harm. **2023**, 31, 59-60 0
- 23 The Women’s Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context. Publish Ahead of Print, 0
- 22 Selective estrogen receptor modulators in post-menopausal osteoporosis. **2022**, 2, 93-96 0
- 21 Endokrinologie/hormonelle Gesundheit und gyn3kologische Infektionen in unterschiedlichen Lebensphasen. **2023**, 19-58 0

- 20 Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease (CVD). **2023**, 1-16
- 19 Vasomotor Symptoms During Menopause: A Practical Guide on Current Treatments and Future Perspectives. Volume 15, 273-287
- 18 Role of Phytoestrogen in Menopausal Women With Depressive Symptoms: A Consecutive Case Series Study. **2023**,
- 17 Sexualhormone. **2022**, 733-747
- 16 Plasma proteins related to inflammatory diet predict future cognitive impairment.
- 15 The characterization and therapeutic applications of ovarian theca cells: An update. **2023**, 317, 121479
- 14 Counselling of path_BRCA carriers who are considering risk-reducing oophorectomy. **2023**, 29, 42-52
- 13 Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?. **2023**, 147, 597-610
- 12 Frauengesundheit â€œFrauenmedizin. **2023**, e1-e39
- 11 The Current Strategy in Hormonal and Non-Hormonal Therapies in Menopauseâ€”A Comprehensive Review. **2023**, 13, 649
- 10 Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Personsâ€”Reply. **2023**, 329, 943
- 9 Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Persons. **2023**, 329, 942
- 8 New developments in the management of vulvovaginal atrophy: a comprehensive overview. **2023**, 24, 599-616
- 7 Perceptions, Benefits, and Use of Complementary and Integrative Therapies to Treat Menopausal Symptoms: A Pilot Study. **2023**, 4, 136-147
- 6 Relationship Between Vitamins and Diabetes. **2023**,
- 5 The Art of Hormone Replacement Therapy (HRT) in Menopause Management. 089719002311679
- 4 The effects of hormone replacement therapy on the microbiomes of postmenopausal women. 1-11
- 3 Rosetta Stone for Cancer Cure: Comparison of the Anticancer Capacity of Endogenous Estrogens, Synthetic Estrogens and Antiestrogens. 17,

- 2 Estrogen: Impact on cardiomyocytes and the heart. **2023**, 681-697 ○
- 1 Cardiovascular health and the menopause, metabolic health. **2023**, 101781 ○